

Cancer: New Registrations and Deaths 2004



MANATŪ HAUORA

NEW ZEALAND HEALTH INFORMATION SERVICE - 2007

Copyright

The copyright owner of this publication is the Ministry of Health, which is part of the New Zealand Crown. The New Zealand Health Information Service, a business unit of the Ministry of Health, permits the reproduction of material from this publication without prior notification, provided that all following conditions are met:

- the content is not distorted or changed
- the information is not sold
- the material is not used to promote or endorse any product or service
- the material is not used in an inappropriate or misleading context having regard to the nature of the material
- any relevant disclaimers, qualifications or caveats included in the publication are reproduced
- the New Zealand Health Information Service is acknowledged as the source.

Disclaimer

The purpose of this publication is to inform discussion and assist policy development. The opinions expressed in the publication do not necessarily reflect the official views of the Ministry of Health.

All care has been taken in the production of this publication; the data were deemed to be accurate at the time of publication, but may be subject to slight changes over time as more information is received. It is advisable to check the current status of figures given here with the New Zealand Health Information Service before quoting or using them in further analysis.

National collection, coding and collation of cancer registrations is a complex process. This is because the information in the Cancer Registry comes from laboratory reports, hospital information and mortality information, and cannot be finalised until data have become available from all sources. In addition, there are a number of steps required to ensure the final information is of good quality.

The Ministry of Health makes no warranty, expressed or implied, nor assumes any legal liability or responsibility for the accuracy, correctness, completeness or use of the information or data in this publication. Further, the Ministry of Health shall not be liable for any loss or damage arising directly or indirectly from the information or data presented in this publication.

The New Zealand Health Information Service welcomes comments and suggestions about this publication.

Acknowledgements

Many people have assisted in the production of this publication. In particular, the New Zealand Health Information Service thanks the peer reviewers for their valuable contribution.

Source

Cancer registration data for 2004 are sourced from the New Zealand Cancer Registry. Time-series cancer data are sourced from earlier editions of *Cancer: New Registrations and Deaths*. Mortality data are sourced from the Mortality Collection held by the New Zealand Health Information Service.

Citation:

New Zealand Health Information Service. 2007.
Cancer: New Registrations and Deaths 2004.
Wellington: Ministry of Health.

Published in 2007 by the

Ministry of Health

PO Box 5013

Wellington

New Zealand

ISBN 978-0-478-30785-6 (*print*)

ISBN 978-0-478-30787-0 (*online*)

This document is available on the New Zealand Health Information Service website:

<http://www.nzhis.govt.nz>

and the Ministry of Health website:

<http://www.moh.govt.nz>

Foreword

Cancer: New Registrations and Deaths 2004 updates the national cancer incidence and mortality data found in previous editions of this series. This publication provides an overview of cancer registrations (new cases of primary cancer diagnosed and reported to the New Zealand Cancer Registry) and deaths from cancer which were registered at the Births, Deaths and Marriages Registry in 2004. It shows the trends in cancer registrations and deaths and examines cancer registrations and deaths for major cancer sites by age, sex and ethnicity (comparing Māori and non-Māori populations).

Reducing the incidence and impact of cancer is a Priority Population Health Objective under the New Zealand Health Strategy. Hence, the national monitoring of cancer is particularly important.

Cancer remained the leading cause of death in New Zealand in 2004, accounting for 28.4 percent of all deaths in that year. Because cancer mainly emerges when people are older, ageing of the population means that the number of new cancer patients is increasing. This publication shows that registrations of new cancer patients increased by 21.2 percent between 1995 and 2004.

The passing of the Cancer Registry Act 1993 and Cancer Registration Regulations 1994 introduced fundamental changes to the collection of cancer data in New Zealand. Consequently, registrations from 1995 onward are not directly comparable with previous years. For this reason, this publication reports data from 1995 to 2004. Data relating to earlier years are available in previous publications or by contacting the New Zealand Health Information Service.

In the next (2005) edition of this publication, the New Zealand Health Information Service intends to move the population structure underlying the calculation of age-standardised rates from the Segi's World Population to the World Health Organization (WHO) population.

More information on cancer registrations and deaths can be found on the New Zealand Health Information Service website (www.nzhis.govt.nz).

This publication is one of a series produced by the New Zealand Health Information Service (see list below). Comments on it, and the others in the series are most welcome.

1. Cancer: New Registrations and Deaths
2. Mortality and Demographic Data
3. Selected Morbidity Data for Publicly Funded Hospitals
4. Selected Privately Funded Morbidity Data
5. Mental Health: Service Use in New Zealand
6. Report on Maternity: Maternal and Newborn Information
7. Fetal and Infant Deaths

Debra Keylard
Business Intelligence Manager
New Zealand Health Information Service

Jason Whakaari
Group Manager
New Zealand Health Information Service

August 2007

Contents

Foreword	3
Selected facts	8
Overview	10
Most common cancers and leading causes of cancer deaths	13
Common cancers and cancer deaths, all persons.....	13
Males.....	14
Females.....	16
Cancer registrations and deaths by age and sex, 2004	20
Child and youth cancers	21
Cancers in people aged from 25 to 44 years.....	21
Cancers in people aged from 45 to 64 years.....	21
Cancers in people from 65 to 74 years	22
Cancers in people aged 75 years and over.....	23
Cancer registrations and deaths by ethnicity	26
Selected sites: trends in registrations and deaths	30
Cancer of the trachea, bronchus and lung (ICD codes C33 and C34)	30
Female cancer of the breast (ICD code C50).....	31
Cancer of the colorectum and anus (ICD codes C18–C21)	32
Cancer of the prostate (ICD code C61)	34
Malignant melanoma of the skin (ICD code C43)	35
Cancer of the pancreas (ICD code C25).....	36
Cancer of the stomach (ICD code C16)	37
Cancer of the cervix uteri (ICD code C53).....	39
Non-Hodgkin lymphoma (ICD codes C82–C85 and C96).....	40
Other cancers	42
<i>Cancer of the ovary (ICD code C56)</i>	42
<i>Cancer of the bladder (ICD code C67)</i>	42
<i>Cancer of the kidney (ICD code C64)</i>	42
<i>Cancer of the brain (ICD code C71)</i>	42
Detailed statistical tables	43
Explanatory notes	101
Cancer registration data.....	101
<i>Scope of the National Cancer Register</i>	101
<i>Skin cancers</i>	101
<i>In-situ cancers</i>	101
<i>Disease coding</i>	101
<i>Multiple primary tumours</i>	102
Timeliness of data	102
Changes in legislation.....	102
Ethnicity.....	103
Rate calculations	103
Confidence intervals.....	105
Additional information available from the New Zealand Health Information Service..	105

References	106
-------------------------	------------

Appendices

Appendix 1: Full text of the Cancer Registry Act 1993	107
Appendix 2: Full text of the Cancer Registry Regulations 1994	110

Figures

Figure 1: Total numbers of cancer registrations, by sex, 1995–2004	11
Figure 2: Total numbers of cancer deaths, by sex, 1995–2004	11
Figure 3: Age-standardised rates for all cancer registrations, by sex, 1995–2004	12
Figure 4: Age-standardised rates for all cancer deaths, by sex, 1995–2004	12
Figure 5: Percentage distribution of cancer registrations by site for all persons, 2004	13
Figure 6: Percentage distribution of cancer deaths by site for all persons, 2004	14
Figure 7: Percentage distribution of cancer registrations by site for males, 2004	15
Figure 8: Percentage distribution of cancer deaths by site for males, 2004	15
Figure 9: Percentage distribution of cancer registrations by site for females, 2004	16
Figure 10: Percentage distribution of cancer deaths by site for females, 2004	17
Figure 11: Number of registrations and deaths for males by age, 2004	20
Figure 12: Number of registrations and deaths for females by age, 2004	20
Figure 13: Cancer of the trachea, bronchus and lung, registrations and deaths, 1995–2004	30
Figure 14: Cancer of the trachea, bronchus and lung, registrations and deaths by ethnicity, 2004	31
Figure 15: Female cancer of the breast, registrations and deaths, 1995–2004	31
Figure 16: Female cancer of the breast, registrations and deaths by ethnicity, 2004	32
Figure 17: Cancer of the colorectum and anus, registrations and deaths, 1995–2004	32
Figure 18: Cancer of the colorectum and anus, registrations and deaths by ethnicity, 2004	33
Figure 19: Cancer of the prostate, registrations and deaths, 1995–2004	34
Figure 20: Cancer of the prostate, registrations and deaths by ethnicity, 2004	34
Figure 21: Malignant melanoma of the skin, registrations and deaths, 1995–2004	35
Figure 22: Cancer of the pancreas, registrations and deaths, 1995–2004	36
Figure 23: Cancer of the pancreas, registrations and deaths by ethnicity, 2004	37
Figure 24: Cancer of the stomach, registrations and deaths, 1995–2004	37
Figure 25: Cancer of the stomach, registrations and deaths by ethnicity, 2004	38
Figure 26: Cancer of the cervix uteri, registrations and deaths, 1995–2004	39
Figure 27: Cancer of the cervix uteri, registrations and deaths by ethnicity, 2004	40
Figure 28: Non-Hodgkin lymphoma, registrations and deaths, 1995–2004	40
Figure 29: Non-Hodgkin lymphoma, registrations and deaths by ethnicity, 2004	41

Tables

Table 1: Cancer groups and most common cancers: registrations, deaths, and deaths to registrations ratios, 2004	18
Table 2: Selected cancer sites: age-standardised rates for registrations and deaths, by sex, 2004	19
Table 3: Cancer registrations and leading sites by age and sex, 2004	24
Table 4: Cancer deaths and leading sites by age and sex, 2004	25
Table 5: Selected cancer sites: registrations by Māori and non-Māori and sex, 2004	27
Table 6: Selected cancer sites: deaths from cancer by Māori and non-Māori and sex, 2004	29

Detailed statistical tables

Table A-1: Major causes of death by sex, numbers and percentages, 2004.....	43
Table A-2: Cancer registrations: site by sex and age, total registrations, 2004	44
Table A-3: Cancer registrations: site and sex by basis of diagnosis, 2004	52
Table A-4: Cancer registrations: selected sites by sex, age-standardised rates and numbers for total population, 1995–2004	60
Table A-5: Cancer registrations: site by ethnicity, total registrations, 2004.....	68
Table A-6: Selected cancer site: registrations and deaths of Pacific peoples by sex, 2004.....	71
Table A-7: Child and youth cancer registrations: site and histology by sex and age, numbers, 2004	72
Table A-8: Child and youth cancer registrations: histology by sex and age, numbers, 2004.....	83
Table A-9: Cancer mortality: site by age and sex, total population, 2004	91
Table A-10: Cancer mortality: site by ethnicity and sex, 2004	98

Explanatory notes tables

Table N-1: Segi's world population.....	103
Table N-2: Population data, 2004	104
Table N-3: Estimated Pacific peoples population data, 2004.....	104

Selected facts

Cancer registrations and deaths, 2004

- There were 19,223 new registrations for cancer, 21.2 percent more than in 1995.
- There were 8145 deaths from cancer, 9.7 percent more than in 1995.
- There were 10,143 male and 9080 female registrations.
- The male age-standardised registration rate (355.5 per 100,000 males) remained below the 1995 male rate (369.2).
- The female age-standardised registration rate (291.4 per 100,000 females) was higher than the 1995 female rate (284.9).

Most common cancers and leading causes of deaths from cancer

- The three most common sites for new cancer registrations were:
 - cancer of the colorectum and anus (2735 new cases)
 - prostate cancer (2693 cases)
 - breast cancer (2361 cases, including 22 males).
- The three leading sites for deaths from cancer were:
 - cancer of the trachea, bronchus and lung (1555 deaths)
 - cancer of the colorectum and anus (1173 deaths)
 - breast cancer (646 deaths, including 4 males).
- For males:
 - prostate cancer was the most commonly registered cancer (2693 cases, just under 27 percent of male registrations)
 - cancer of the trachea, bronchus and lung was the leading cause of death from cancer (929 deaths, just under 22 percent of male cancer deaths).
- For females:
 - breast cancer was the most commonly registered cancer (2339 cases, just under 26 percent of female registrations)
 - breast cancer was also the leading cause of cancer deaths among females (642 deaths, just over 16 percent of female cancer deaths).

Age and sex

- The age-specific rates for cancer registrations and cancer deaths increased with age.
- The most commonly registered cancer site varies with age and sex. The most commonly registered site for each sex and age group was:
 - leukaemia among children and youth (aged 0 to 24 years)
 - malignant melanoma of the skin for males, and breast cancer for females aged 25 to 44 years
 - prostate cancer for males, and breast cancer for females aged 45 to 74 years
 - prostate cancer for males, and cancer of the colorectum and anus among females aged 75 years and older.

Māori cancer statistics

- There were 1364 new cancer registrations (645 males and 719 females) among Māori.
- There were 767 deaths (372 males and 395 females) from cancer among Māori.
- The Māori age-standardised rates of cancer registrations were:
 - 348.4 per 100,000 for Māori males, slightly lower than the non-Māori male rate (356.0)
 - 323.5 per 100,000 for Māori females, somewhat higher than the non-Māori female rate (290.0).
- The Māori age-standardised rates for deaths from cancer were:
 - 211.9 per 100,000 for Māori males, higher than the non-Māori male rate (132.3)
 - 182.4 per 100,000 for Māori females, higher than the non-Māori female rate (101.2).
- Cancer of the trachea, bronchus and lung:
 - was the most commonly registered cancer among Māori males
 - had a Māori male age-standardised registration rate of 79.5 per 100,000 Māori males, more than twice the non-Māori male rate (32.7)
 - had a female age-standardised registration rate of 69.3 per 100,000 Māori females, more than three times the non-Māori female rate (19.7).
- Breast cancer was the most commonly registered site for Māori females, with an age-standardised rate of 81.5 per 100,000 Māori females, nearly the same as the non-Māori female rate (81.6).
- Cancer of the trachea, bronchus and lung:
 - was the leading cause of cancer deaths for both Māori and non-Māori males
 - had a Māori male age-standardised mortality rate of 68.0 per 100,000 Māori males, just under two-and-a-half times the non-Māori male rate (28.1)
 - was the leading cause of death among Māori females, but not among non-Māori females
 - had a Māori female age-standardised mortality rate of 59.6 per 100,000 Māori females, more than three-and-a-half times the non-Māori female rate (16.1).

Overview

Cancer: New Registrations and Deaths 2004 presents information about new cases of primary cancer diagnosed and reported to the New Zealand Cancer Registry in the 2004 calendar year. Cancer sites include cancers located in specific organs or tissues, as well as systemic cancers such as leukaemia and lymphoma. In-situ cancers are not included in the data presented here. The New Zealand Cancer Registry database records multiple primary cancers in the same person, of which only some are counted for incidence purposes according to the rules of the International Agency for Research on Cancer and the International Association of Cancer Registries (see Explanatory Notes).

The *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM) Third Edition* was used to classify the site or topography for the 2004 data used in this report. The *International Classification of Diseases for Oncology (ICD-O) Third Edition* was used to classify the morphology (histology type and behaviour) of tumours.

The Third Edition of ICD-O contains a revised morphology section. New classifications have been introduced and new codes assigned to accommodate them. This has resulted in changes to the coding of cancers diagnosed since 1 January 2003. For some tumour types, particularly haematological malignancies and ovarian cancer, these changes may affect incidence reporting. Thus, for particular cancer sites, registrations from 1 January 2003 may not be directly comparable with 2002 and earlier. Please see the Explanatory Notes for further details of these changes.

The information presented in this report reflects the New Zealand Cancer Registry data at one point in time (February 2007). Data in the Cancer Registry are subject to change over time as late reports about cancer registrations are received. As a result, data extracted at an earlier or later date may differ from those in this publication.


Data on deaths from cancer are sourced from the Mortality Collection held by the New Zealand Health Information Service. The Mortality Collection includes all deaths recorded in New Zealand for a particular year. Overseas deaths of cancer patients registered in New Zealand are not included in the collection.

There were 19,223 new registrations for cancer and 8145 deaths from cancer in New Zealand in 2004. Registrations have increased by 3.4 percent from 2003 and 21.2 percent from 1995. Deaths from cancer have also increased, but at lower rates (1.5 percent from 2003 and 9.7 percent from 1995).

In 2004, the age-standardised rate for new registrations was 319.6 per 100,000 population and the age-standardised rate of death from cancer was 120.8 per 100,000 population.

There were 10,143 male and 9080 female registrations. The number of male registrations has increased by 2.9 percent from 2003 and 18.8 percent from 1995. The number of female registrations has increased by 4.0 percent from 2003 and 23.9 percent from 1995.


Figure 1: Total numbers of cancer registrations, by sex, 1995–2004



Note: 1995 to 1999 mapped from ICD-9-CM Second Edition to ICD-10-AM Second Edition (codes C00–C96). 2000 to 2002 coded to ICD-10-AM Second Edition (codes C00–C96). From 2003 coded to ICD-10-AM Third Edition (codes C00–C96 and D45–D47).

In 2004, cancer remained the leading cause of death in New Zealand, accounting for 28.4 percent of deaths, slightly more than non-congenital heart diseases (27.4 percent) (see Table A-1). Cancer was the leading cause of death among males (29.9 percent of all deaths) and females (27.0 percent of all deaths), with 4246 males and 3899 females recorded as having died from cancer in 2004. Among males, the number of deaths from cancer decreased by 1.1 percent from 2003, but increased by 8.4 percent from 1995. Among females, the number of deaths from cancer increased by 4.4 percent from 2003 and 11.3 percent from 1995.


Figure 2: Total numbers of cancer deaths, by sex, 1995–2004



Note: 1995 to 1999 mapped from ICD-9-CM Second Edition to ICD-10-AM Second Edition (codes C00–C96). 2000 to 2002 coded to ICD-10-AM Second Edition (codes C00–C96). From 2003 coded to ICD-10-AM Third Edition (codes C00–C96 and D45–D47).

The age-standardised rate for cancer registrations among males was 355.5 per 100,000 males in 2004, nearly unchanged from the 2003 rate of 356.2, but still below the 1995 rate of 369.2. The female registration rate was 291.4 per 100,000 females in 2004, an increase from the 2003 rate of 287.4 in 2003 and the 1995 rate of 284.9.


Figure 3: Age-standardised rates for all cancer registrations, by sex, 1995–2004



Notes: rates per 100,000, age-standardised to Segi's world population. 1995 to 1999 mapped from ICD-9-CM Second Edition to ICD-10-AM Second Edition (codes C00–C96). 2000 to 2002 coded to ICD-10-AM Second Edition (codes C00–C96). From 2003 coded to ICD-10-AM Third Edition (codes C00–C96 and D45–D47).

Among men, the cancer mortality rate of 138.5 per 100,000 males represents a slight decrease from 2003 (143.2) and a substantial decrease from 166.7 in 1995. The female rate of 108.1 is a slight increase from the 2003 rate (106.3), but remains considerably lower than the 1995 rate of 127.5.

Figure 4: Age-standardised rates for all cancer deaths, by sex, 1995–2004



Notes: rates per 100,000, age-standardised to Segi's world population. 1995 to 1999 mapped from ICD-9-CM Second Edition to ICD-10-AM Second Edition (codes C00–C96). 2000 to 2002 coded to ICD-10-AM Second Edition (codes C00–C96). From 2003 coded to ICD-10-AM Third Edition (codes C00–C96 and D45–D47).


Age-standardised rates are a way of validly comparing groups that have different age structures (eg, one group may be older on average than the other), as well as comparing data from the same group where the age structure is changing over time (see Explanatory Notes).

Most common cancers and leading causes of cancer deaths

Common cancers and cancer deaths, all persons

Among all cancer registrations in 2004, the most common was cancer of the colorectum and anus (2735 new cases), followed closely by cancer of the prostate (2693 cases). Cancer of the colorectum and anus, prostate cancer, breast cancer (2361), malignant melanoma of the skin (1896) and cancer of the trachea, bronchus and lung (1819), together, accounted for 59.8 percent of all registered cancers in 2004.


Figure 5: Percentage distribution of cancer registrations by site for all persons, 2004



Note: percentages may not sum to 100 because of rounding.

Cancer of the trachea, bronchus and lung (1555 deaths) was the leading cause of death from cancer in 2004, followed by cancer of the colorectum and anus (1173 deaths). Together with cancer of the breast (646 deaths) and prostate cancer (583 deaths), they accounted for 48.6 percent of deaths from cancer in 2004.

Figure 6: Percentage distribution of cancer deaths by site for all persons, 2004



Note: percentages may not sum to 100 because of rounding.

Of all cancer registrations, prostate cancer had the highest age-standardised rate (44.6 registrations per 100,000 people), followed by cancer of the breast (42.6), cancer of the colorectum and anus (42.2), malignant melanoma of the skin (33.2) and cancer of the trachea, bronchus and lung (29.0). With the exception of malignant melanoma of the skin, these cancers also had the highest age-standardised death rates: cancer of the trachea, bronchus and lung (24.4 deaths per 100,000 people), cancer of the colorectum and anus (16.7), breast cancer (10.7) and prostate cancer (6.9) (see Table 2, page 19).

The deaths to registrations ratio (the number of deaths attributed to a particular cancer divided by the number of registrations) is a crude indicator of the likely prognosis of the cancer. The closer a value is to 1.0, the poorer the prognosis for that cancer.


The ratio of deaths to registrations was 0.42 overall and similar for males and females. On the basis of the deaths to registrations ratios, the specific cancer sites listed in Table 1 (see page 18) could be classified into three groups:

- those likely to have a better prognosis (a ratio of 0.3 or less)—testis, malignant melanoma of the skin, thyroid gland, the chronic myeloproliferative disorders and myelodysplastic syndromes, Hodgkin disease, corpus uteri, prostate, breast, other connective and soft tissue, and bladder
- those likely to have a fairly good prognosis (a ratio between 0.3 and 0.49)—kidney, colorectum and anus, leukaemia, non-Hodgkin lymphoma and cervix uteri
- those likely to have a poorer prognosis (a ratio of 0.50 or more)—ovary, oesophagus, stomach, brain, trachea, bronchus and lung, mesothelioma, pancreas, liver and intrahepatic bile ducts.

Males

Among males, the most commonly registered cancer was prostate cancer (2693 cases, 26.6 percent of male registrations), followed by cancer of the colorectum and anus (1370 cases), cancer of the trachea, bronchus and lung (1070 cases) and malignant melanoma of the skin (949 cases). Together, these four cancers accounted for 60 percent of all male cancers in 2004.

Figure 7: Percentage distribution of cancer registrations by site for males, 2004




Note: percentages may not sum to 100 because of rounding.

Prostate cancer had the highest age-standardised rate among males (94.6 registrations per 100,000 males). High rates were also recorded for cancer of the colorectum and anus (46.1), cancer of the trachea, bronchus and lung (36.0) and malignant melanoma of the skin (34.5).

Cancer of the trachea, bronchus and lung was the leading cause of death from cancer in males in 2004 (929 deaths, nearly 22 percent of male cancer deaths), followed by prostate cancer (583 deaths, slightly over 13 percent of male cancer deaths) and cancer of the colorectum and anus (570 deaths, slightly over 13 percent of male cancer deaths).

Figure 8: Percentage distribution of cancer deaths by site for males, 2004




Note: percentages may not sum to 100 because of rounding.

Cancer of the trachea, bronchus and lung had the highest age-standardised rate of death (30.8 deaths per 100,000 males), followed by cancer of the colorectum and anus (18.3) and prostate cancer (16.6).

Females

In females, breast cancer (2339 cases) was the most commonly registered cancer in 2004, and accounted for nearly 26 percent of all female registrations. Cancer of the colorectum and anus (1365 cases), malignant melanoma of the skin (947 cases) and cancer of the trachea, bronchus and lung (749 cases) were the next most common cancers. Together with breast cancer, they accounted for nearly 60 percent of female registrations. In 2004, there were 861 registrations of cancers of the female genital organs, primarily uterine cancer (cancer of the corpus uteri) (330 cases), ovarian cancer (277 cases) and cervical cancer (cancer of the cervix uteri) (154 cases).

Figure 9: Percentage distribution of cancer registrations by site for females, 2004




Note: percentages may not sum to 100 because of rounding.

Breast cancer had the highest age-standardised registration rate among females (81.7 cases per 100,000 females). Cancer of the colorectum and anus (38.9), malignant melanoma of the skin (32.4) and cancer of the trachea, bronchus and lung (23.2) also recorded high registration rates. Among cancers of the female genital organs, uterine cancer had the highest registration rate (11.5).

Cancer of the breast was the leading cause of death from cancer among females in 2004 (642 deaths or 16.4 percent of female cancer deaths), followed closely by cancer of the trachea, bronchus and lung (626 deaths) and cancer of the colorectum and anus (603 deaths). Together, these three cancers accounted for 48 percent of all female deaths from cancer in 2004. There were 353 deaths from cancers of the female genital organs, primarily from ovarian cancer (187 deaths), cervical cancer (71 deaths) and uterine cancer (64 deaths).

Figure 10: Percentage distribution of cancer deaths by site for females, 2004



Note: percentages may not sum to 100 because of rounding.

Cancer of the breast had the highest age-standardised death rate among females (20.2 deaths per 100,000 females), followed by cancer of the trachea, bronchus and lung (19.2) and cancer of the colorectum and anus (15.4). Among cancers affecting the female genital organs, ovarian cancer had the highest age-standardised death rate (5.4 deaths per 100,000 females).

Table 1: Cancer groups and most common cancers: registrations, deaths, and deaths to registrations ratios, 2004

Cancer site	Registrations			Deaths			Deaths to registrations ratios		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Lip, oral cavity and pharynx (C00–C14)	292	191	101	101	66	35	0.35	0.35	0.35
Other and unspecified parts of the tongue (C02)	41	26	15	17	9	8	0.41	0.35	0.53
Digestive organs (C15–C26)	4141	2171	1970	2418	1264	1154	0.58	0.58	0.59
Oesophagus (C15)	253	181	72	206	132	74	0.81	0.73	1.03
Stomach (C16)	368	211	157	301	186	115	0.82	0.88	0.73
Colorectum and anus (C18–C21)	2735	1370	1365	1173	570	603	0.43	0.42	0.44
Liver and intrahepatic bile ducts (C22)	164	121	43	176	119	57	1.07	0.98	1.33
Pancreas (C25)	360	176	184	355	172	183	0.99	0.98	0.99
Respiratory system and intrathoracic organs (C30–C39)	1924	1157	767	1609	968	641	0.84	0.84	0.84
Nasal cavity, middle ear, accessory sinuses and larynx (C30–C32)	85	74	11	43	34	9	0.51	0.46	0.82
Trachea, bronchus and lung (C33–C34)	1819	1070	749	1555	929	626	0.85	0.87	0.84
Bones, joints and articular cartilage (C40–C41)	46	24	22	21	8	13	0.46	0.33	0.59
Skin (C43–C44)	2001	1008	993	334	200	134	0.17	0.20	0.13
Malignant melanoma of skin (C43)	1896	949	947	249	152	97	0.13	0.16	0.10
Mesothelial and soft tissue (C45–C49)	223	142	81	128	92	36	0.57	0.65	0.44
Mesothelioma (C45)	82	75	7	77	71	6	0.94	0.95	0.86
Other connective and soft tissue (C49)	104	55	49	29	13	16	0.28	0.24	0.33
Breast (C50)	2361	22	2339	646	4	642	0.27	0.18	0.27
Female genital organs (C51–C58)	861	...	861	353	...	353	0.41	...	0.41
Cervix uteri (C53)	154	...	154	71	...	71	0.46	...	0.46
Corpus uteri (C54)	330	...	330	64	...	64	0.19	...	0.19
Ovary (C56)	277	...	277	187	...	187	0.68	...	0.68
Male genital organs (C60–C63)	2843	2843	...	591	591	...	0.21	0.21	...
Prostate (C61)	2693	2693	...	583	583	...	0.22	0.22	...
Testis (C62)	138	138	...	5	5	...	0.04	0.04	...
Urinary tract (C64–C68)	1099	761	338	363	245	118	0.33	0.32	0.35
Kidney, except renal pelvis (C64)	401	256	145	163	108	55	0.41	0.42	0.38
Bladder (C67)	626	467	159	180	124	56	0.29	0.27	0.35
Eye, brain and other parts of the central nervous system (C69–C72)	316	174	142	236	135	101	0.75	0.78	0.71
Brain (C71)	260	146	114	222	130	92	0.85	0.89	0.81
Thyroid and other endocrine glands (C73–C75)	202	63	139	38	14	24	0.19	0.22	0.17
Thyroid gland (C73)	191	55	136	29	10	19	0.15	0.18	0.14
Ill-defined, secondary or unspecified sites (C76–C80)	471	237	234	434	215	219	0.92	0.91	0.94
Lymphoid, haematopoietic and related tissue (C81–C96, D45–D47)	2443	1350	1093	873	444	429	0.36	0.33	0.39
Hodgkin lymphoma (C81)	80	50	30	15	9	6	0.19	0.18	0.20
Non-Hodgkin lymphoma (C82–C85, C96)	650	348	302	288	136	152	0.44	0.39	0.50
<i>Lymphomas (C81–C85, C96)</i>	730	398	332	303	145	158	0.42	0.36	0.48
Multiple myeloma and malignant plasma cell neoplasms (C90)	240	135	105	148	76	72	0.62	0.56	0.69
Leukaemia (C91–C95)	671	367	304	291	146	145	0.43	0.40	0.48
Chronic myeloproliferative disorders and myelodysplastic syndromes (D45–D47)	770	429	341	122	73	49	0.16	0.17	0.14
All sites	19,223	10,143	9080	8145	4246	3899	0.42	0.42	0.43

... = not applicable

Table 2: Selected cancer sites: age-standardised rates for registrations and deaths, by sex, 2004

Cancer site	Registrations			Deaths		
	Total	Males	Females	Total	Males	Females
Oesophagus (C15)	3.7	6.0	1.8	3.0	4.5	1.7
Stomach (C16)	5.8	7.5	4.2	4.7	6.4	3.1
Colorectum and anus (C18–C21)	42.2	46.1	38.9	16.7	18.3	15.4
Liver and intrahepatic bile ducts (C22)	2.7	4.2	1.4	2.7	4.1	1.5
Pancreas (C25)	5.5	6.3	4.7	5.1	5.8	4.4
Trachea, bronchus and lung (C33–C34)	29.0	36.0	23.2	24.4	30.8	19.2
Malignant melanoma of skin (C43)	33.2	34.5	32.4	3.8	5.2	2.6
Breast (C50)	42.6	0.8	81.7	10.7	--	20.2
Cervix uteri (C53)	3.0	...	5.9	1.3	...	2.4
Corpus uteri (C54)	5.9	...	11.5	1.0	...	2.0
Ovary (C56)	4.7	...	9.0	2.9	...	5.4
Prostate (C61)	44.6	94.6	...	6.9	16.6	...
Testis (C62)	3.2	6.6	...	--	--	...
Kidney, except renal pelvis (C64)	7.2	9.5	5.1	2.6	3.7	1.6
Bladder (C67)	9.1	15.0	4.1	2.3	3.8	1.1
Brain (C71)	5.0	5.8	4.2	3.9	4.8	3.1
Thyroid gland (C73)	3.8	2.3	5.3	0.5	0.4	0.5
Non-Hodgkin lymphoma (C82–C85, C96)	11.0	12.7	9.5	4.2	4.6	4.0
Multiple myeloma and malignant plasma cell neoplasms (C90)	3.8	4.6	3.2	2.1	2.5	1.8
Leukaemia (C91–C95)	11.7	13.2	10.6	4.5	4.9	4.2
Chronic myeloproliferative disorders and myelodysplastic syndromes (D45–D47)	11.0	13.6	9.0	1.3	2.2	0.8
All sites	319.6	355.5	291.4	120.8	138.5	108.1

Rates per 100,000, age-standardised to Segi's world population.

... = not applicable


-- = amount too small to be calculated

Cancer registrations and deaths by age and sex, 2004

Cancer is a disease that tends to emerge in people later in life. The age-specific rates for cancer registration in 2004 for all cancer sites were 20.1 per 100,000 people aged under 25, 373.5 per 100,000 people aged from 25 to 64 years, and 2277.2 per 100,000 people aged 65 years and over.


Of the 10,143 male registrations in 2004, 32.3 percent were in the 75 years and over age group, 29.8 percent in the 65–74 years age group and 31.0 percent in the 45–64 years age group. Of the 4246 male deaths from cancer recorded in 2004, 44.8 percent were in the 75 years and over age group, 28.4 percent in the 65–74 years age group and 23.4 percent in the 45–64 years age group.

Figure 11: Number of registrations and deaths for males by age, 2004



Of the 9080 female registrations for cancer in 2004, 30.2 percent were for women aged 75 years or over, 22.3 percent aged 65–74 years and 35.3 percent aged 45–64 years. Of the 3899 female cancer deaths, 45.5 percent were of women aged 75 years or over, 22.6 percent aged 65–74 years and 26.1 percent aged 45–64 years.

Figure 12: Number of registrations and deaths for females by age, 2004



Child and youth cancers

In 2004, cancer amongst children and youth (people aged under 25) accounted for 1.5 percent of all cancer registrations, and 0.5 percent of all cancer deaths.

There were 296 registrations for cancer of people aged under 25 years (152 males and 144 females), of which 124 were under the age of 15 (57 males and 67 females).

The most common type of cancer for males and females under 15 years of age was leukaemia (17 male and 26 female registrations). For males aged 15 to 24 years, cancer of the testis was the most commonly registered cancer in 2004 (24 cases). For females aged 15 to 24 years, malignant melanoma of the skin (12 cases), leukaemia (11 cases) and cancer of the thyroid gland (10 cases) were the most commonly registered cancer sites.

There were 42 deaths (20 male, 22 female) of people aged under 25 years. Of these, 20 were under the age of 15 years (9 male, 11 female). The most common cause of cancer death in males and females aged under 25 years was leukaemia (5 male and 8 female). Cancer of the bone and articular cartilage also accounted for 6 female deaths.

Cancers in people aged from 25 to 44 years

This age group accounted for 7.9 percent of all cancer registrations, and 4.1 percent of all cancer deaths in 2004.

There were 1513 registrations for cancer of people aged 25 to 44 years (555 males and 958 females).

Among males aged 25 to 44 years, malignant melanoma of the skin (122 registrations) was the leading cancer site, followed by cancer of the testis (80 registrations) and cancer of the colorectum and anus (40 registrations).

Cancer of the breast was the most commonly registered cancer (326 registrations) for females aged 25 to 44 years, followed by malignant melanoma of the skin (185 registrations).

There were 330 deaths from cancer of people aged from 25 to 44 years (126 males and 204 females).

Among males aged from 25 to 44 years, cancer of the brain and malignant melanoma of the skin accounted for 17 deaths each, while cancer of the trachea, bronchus and lung accounted for 15 deaths.

Among females aged from 25 to 44 years, cancer of the breast was the leading cause of cancer death (76 deaths).

Cancers in people aged from 45 to 64 years

This age group accounted for 33.0 percent of all cancer registrations, and 24.7 percent of all cancer deaths in 2004.

There were 6350 registrations for cancer of people aged from 45 to 64 years (3141 males and 3209 females). The age-specific registration rates for males and females in this age group are nearly the same (677.6 per 100,000 males and 677.7 per 100,000 females aged from 45 to 64 years), and considerably higher than the comparable age-specific rates for the 25–44 year old age group.

Among males aged from 45 to 64 years, cancer of the prostate (912 registrations) was the leading cancer site, followed by malignant melanoma of the skin (373 registrations), cancer of the colorectum and anus (367 registrations) and cancer of the trachea, bronchus and lung (308 registrations).

Cancer of the breast was the most commonly registered cancer (1173 registrations) for females aged from 45 to 64 years, followed by malignant melanoma of the skin (358 registrations) and cancer of the colorectum and anus (348 registrations).

There were 2010 deaths from cancer of people aged from 45 to 64 years (992 males and 1018 females). The age-specific rates for cancer deaths for males and females in this age group are nearly the same (214.0 per 100,000 males and 215.0 per 100,000 females, aged 45 to 64 years), and considerably higher than the comparable rates for the 25–44 year old age group.

Among males aged from 45 to 64 years, cancer of the trachea, bronchus and lung was the leading cause of cancer death (237 deaths), followed by cancer of the colorectum and anus (129 deaths).

Among females aged from 45 to 64 years, cancer of the breast was the leading cause of cancer death (235 deaths), followed by cancer of the trachea, bronchus and lung (201 deaths).

Cancers in people from 65 to 74 years

This age group accounted for 26.2 percent of all cancer registrations, and 25.6 percent of all cancer deaths in 2004.

There were 5045 registrations for cancer of people aged from 65 to 74 years (3022 males and 2023 females). The age-specific registration rate for males was higher than the rate for females in this age group (2412.6 per 100,000 males and 1499.3 per 100,000 females aged from 65 to 74 years). Both male and female age-specific registration rates for this age group were considerably higher than the comparable rates for the 45–64 year old age group.

Among males aged from 65 to 74 years, cancer of the prostate (965 registrations) was the leading cancer site, followed by cancer of the colorectum and anus (453 registrations), cancer of the trachea, bronchus and lung (361 registrations) and malignant melanoma of the skin (206 registrations).

Cancer of the breast was the most commonly registered cancer (422 registrations) for females aged from 65 to 74 years, followed by cancer of the colorectum and anus (386 registrations), cancer of the trachea, bronchus and lung (222 registrations) and malignant melanoma of the skin (180 registrations).

There were 2088 deaths from cancer of people aged from 65 to 74 years (1206 males and 882 females). The age-specific rate for cancer deaths for males was higher than the rate for females in this age group (962.8 per 100,000 males and 653.7 per 100,000 females aged from 65 to 74 years). Both male and female age-specific cancer death rates for this age group were considerably higher than the comparable rates for the 45–64 year old age group.

Among males aged from 65 to 74 years, cancer of the trachea, bronchus and lung was the leading cause of cancer death (324 deaths), followed by cancer of the colorectum and anus (176 deaths) and prostate cancer (137 deaths).

Among females aged from 65 to 74 years, cancer of the trachea, bronchus and lung was the leading cause of cancer death (194 deaths), followed by cancer of the breast (138 deaths) and cancer of the colorectum and anus (130 deaths).

Cancers in people aged 75 years and over

This age group accounted for 31.3 percent of all cancer registrations, and 45.1 percent of all cancer deaths in 2004.

There were 6019 registrations for cancer of people aged 75 and over (3273 males and 2746 females). The age-specific registration rate for males was higher than the rate for females in this age group (3647.2 per 100,000 males and 2020.3 per 100,000 females aged 75 and over). Both male and female age-specific registration rates for this age group were considerably higher than the comparable rates for the 65–74 year old age group.

Among males aged 75 and over, cancer of the prostate (808 registrations) was the leading cancer site, followed by cancer of the colorectum and anus (509 registrations) and cancer of the trachea, bronchus and lung (382 registrations).

Cancer of the colorectum and anus was the most commonly registered cancer (574 registrations) for females aged 75 and over, followed by cancer of the breast (417 registrations) and cancer of the trachea, bronchus and lung (245 registrations).

There were 3675 deaths from cancer of people aged 75 and over (1902 males and 1773 females). The age-specific rate for cancer deaths for males was higher than the rate for females in this age group (2119.5 per 100,000 males and 1304.4 per 100,000 females aged 75 and over). Both male and female age-specific cancer death rates for this age group were considerably higher than the comparable rates for the 65–74 year old age group.

Among males aged 75 and over, prostate cancer was the leading cause of cancer death (411 deaths), followed by cancer of the trachea, bronchus and lung (353 deaths) and cancer of the colorectum and anus (254 deaths).

Among females aged 75 and over, cancer of the colorectum and anus was the leading cause of cancer death (325 deaths), followed by cancer of the trachea, bronchus and lung (215 deaths) and breast cancer (192 deaths).

Table 3: Cancer registrations and leading sites by age and sex, 2004

Age groups (years)	Males			Females		
	Site	No.	All sites rate [†]	Site	No.	All sites rate [†]
0–14	Leukaemia	17		Leukaemia	26	
	Brain	6		Brain	8	
	Non-Hodgkin lymphoma	6		Kidney, except renal pelvis	7	
	Kidney, except renal pelvis	5		Bone and articular cartilage of limbs	6	
	Myeloproliferative and myelodysplastic	4		Non-Hodgkin lymphoma	3	
	All other sites	19		Myeloproliferative and myelodysplastic	3	
	<i>All sites</i>	57	12.5	All other sites	14	
				<i>All sites</i>	67	15.6
15–24	Testis	24		Malignant melanoma of skin	12	
	Malignant melanoma of skin	10		Leukaemia	11	
	Leukaemia	7		Thyroid gland	10	
	Brain	6		Non-Hodgkin lymphoma	5	
	Other connective and soft tissue	6		Myeloproliferative and myelodysplastic	5	
	All other sites	42		Colorectum and anus	5	
	<i>All sites</i>	95	31.7	All other sites	29	
				<i>All sites</i>	77	26.8
25–44	Malignant melanoma of skin	122		Breast	326	
	Testis	80		Malignant melanoma of skin	185	
	Colorectum and anus	40		Cervix uteri	58	
	Non-Hodgkin lymphoma	39		Colorectum and anus	52	
	Brain	31		Thyroid gland	51	
	All other sites	243		All other sites	286	
	<i>All sites</i>	555	98.2	<i>All sites</i>	958	159.0
45–64	Prostate	912		Breast	1173	
	Malignant melanoma of skin	373		Malignant melanoma of skin	358	
	Colorectum and anus	367		Colorectum and anus	348	
	Trachea, bronchus and lung	308		Trachea, bronchus and lung	254	
	Non-Hodgkin lymphoma	127		Corpus uteri	166	
	All other sites	1054		All other sites	910	
	<i>All sites</i>	3141	677.6	<i>All sites</i>	3209	677.7
65–74	Prostate	965		Breast	422	
	Colorectum and anus	453		Colorectum and anus	386	
	Trachea, bronchus and lung	361		Trachea, bronchus and lung	222	
	Malignant melanoma of skin	206		Malignant melanoma of skin	180	
	Bladder	139		Corpus uteri	81	
	All other sites	898		All other sites	732	
	<i>All sites</i>	3022	2412.6	<i>All sites</i>	2023	1499.3
75 +	Prostate	808		Colorectum and anus	574	
	Colorectum and anus	509		Breast	417	
	Trachea, bronchus and lung	382		Trachea, bronchus and lung	245	
	Malignant melanoma of skin	238		Malignant melanoma of skin	211	
	Myeloproliferative and myelodysplastic	215		Myeloproliferative and myelodysplastic	173	
	All other sites	1121		All other sites	1126	
	<i>All sites</i>	3273	3647.2	<i>All sites</i>	2746	2020.3

* = in identifying leading sites, ill-defined, secondary and unspecified sites are not included

† = rate is the age-specific rate for the relevant age and sex group

Table 4: Cancer deaths and leading sites by age and sex, 2004

Age groups (years)	Males			Females		
	Leading sites*		All sites rate†	Leading sites*		All sites rate†
	Site	No.		Site	No.	
0–14						
	Adrenal gland	3		Leukaemia	5	
	Brain	2		Bone and articular cartilage of limbs	3	
	Leukaemia	2		Brain	2	
	Retroperitoneum and peritoneum	1		Adrenal gland	1	
	Other connective and soft tissue	1		All other sites	0	
	All other sites	0				
	<i>All sites</i>	9	2.0	<i>All sites</i>	11	2.6
15–24						
	Leukaemia	3		Leukaemia	3	
	Bone and articular cartilage of limbs	2		Bone and articular cartilage of limbs	3	
	Testis	2		Bone and articular cartilage of other and unspecified	2	
	Other connective and soft tissue	1		Breast	1	
	Stomach	1		Hodgkin disease	1	
	Colorectum and anus	1		Non-Hodgkin lymphoma	1	
	Accessory sinuses	1		All other sites	0	
	All other sites	0				
	<i>All sites</i>	11	3.7	<i>All sites</i>	11	3.8
25–44						
	Brain	17		Breast	76	
	Malignant melanoma of skin	17		Trachea, bronchus and lung	16	
	Trachea, bronchus and lung	15		Brain	15	
	Stomach	11		Colorectum and anus	15	
	Colorectum and anus	10		Cervix uteri	14	
	All other sites	56		Ovary	14	
				All other sites	54	
	<i>All sites</i>	126	22.3	<i>All sites</i>	204	33.9
45–64						
	Trachea, bronchus and lung	237		Breast	235	
	Colorectum and anus	129		Trachea, bronchus and lung	201	
	Stomach	57		Colorectum and anus	133	
	Brain	50		Ovary	56	
	Pancreas	50		Non-Hodgkin lymphoma	37	
	All other sites	469		All other sites	356	
	<i>All sites</i>	992	214.0	<i>All sites</i>	1018	215.0
65–74						
	Trachea, bronchus and lung	324		Trachea, bronchus and lung	194	
	Colorectum and anus	176		Breast	138	
	Prostate	137		Colorectum and anus	130	
	Pancreas	55		Ovary	45	
	Stomach	50		Pancreas	40	
	All other sites†	464		All other sites†	335	
	<i>All sites</i>	1206	962.8	<i>All sites</i>	882	653.7
75 +						
	Prostate	411		Colorectum and anus	325	
	Trachea, bronchus and lung	353		Trachea, bronchus and lung	215	
	Colorectum and anus	254		Breast	192	
	Bladder	75		Pancreas	107	
	Stomach	67		Non-Hodgkin lymphoma	77	
	All other sites†	742		All other sites†	857	
	<i>All sites</i>	1902	2119.5	<i>All sites</i>	1773	1304.4

* = in identifying leading sites, ill-defined, secondary and unspecified sites are not included

† = rate is the age-specific rate for the relevant age and sex group

‡ = includes a value for malignant neoplasm without specification of site (C80) greater than the lowest leading site value

Cancer registrations and deaths by ethnicity

When looking at cancer registrations and deaths by ethnicity, it is important to note three points.

First, ethnic data is based on prioritised self-identification. Individuals may select up to three ethnic groups to which they feel they belong. Any person who selects Māori as one of their three ethnicities is recorded as being of Māori ethnicity.

Second, the ethnicity reported in this publication is that recorded on the National Cancer Register, sourced from hospital discharge information and the National Health Index, and that recorded by the New Zealand Health Information Service Mortality Collection.

Third, ethnicity was not reported in 758 cases (3.9 percent of registrations). In a high proportion of cases where ethnicity was not recorded, it was because the diagnosis of cancer was made in the private health care sector. Particular sites, such as prostate cancer (277 cases, 10.3 percent of prostate cancer registrations), malignant melanoma of the skin (214 cases, 11.3 percent of melanoma registrations) and breast cancer (77 cases, 3.3 percent of breast cancer registrations) had comparatively high numbers of registrations where ethnicity was not recorded in 2004. There was only one death from cancer without a specified ethnicity. Registrations and deaths recorded without an ethnic identification have been included in the non-Māori and the non-Māori, non-Pacific peoples groups.

In 2004, there were 1364 registrations (645 males and 719 females) of cancer for Māori and 491 registrations (232 males and 259 females) for Pacific peoples in New Zealand. Māori registrations accounted for 7.1 percent of all registrations, 6.4 percent of male and 7.9 percent of female registrations. Registrations of Pacific peoples accounted for 2.6 percent of all registrations, 2.3 percent of male and 2.9 percent of female registrations.

In 2004, there were 767 deaths (372 males and 395 females) from cancer for Māori. These deaths accounted for 9.4 percent of all deaths from cancer, 8.8 percent of male deaths and 10.1 percent of female deaths. There were 263 deaths (149 males and 114 females) for Pacific peoples in New Zealand. Deaths for Pacific peoples accounted for 3.2 percent of all deaths, 3.5 percent of male and 2.9 percent of female deaths.

The Māori age-standardised rate of cancer registrations (332.8 per 100,000 Māori population) was slightly higher than the non-Māori rate (319.1 per 100,000 non-Māori population) in 2004. The age-standardised rate for Pacific peoples of 286.1 per 100,000 Pacific population was lower than the rate for non-Māori, non-Pacific peoples (312.5 per 100,000).

While the male Māori age-standardised rate for cancer registrations (348.4 per 100,000 Māori males) was slightly lower than the non-Māori male rate (356.0 per 100,000 non-Māori males), the female Māori registration rate (323.5) was higher than the non-Māori female rate (290.0).

The male registration rate for Pacific peoples (319.1 per 100,000 male Pacific peoples) was slightly lower than that for non-Māori, non-Pacific peoples (352.1 per 100,000 male non-Māori, non-Pacific peoples), as was the female rate (265.5 per 100,000 female Pacific peoples, compared with 280.3 per 100,000 female non-Māori, non-Pacific peoples).

The age-standardised rate for Māori deaths from cancer (193.9 per 100,000 Māori population) was higher than the non-Māori rate (114.3 per 100,000 non-Māori population). Similarly, the age-standardised cancer death rate for Pacific peoples (168.0 per 100,000 Pacific population) was higher than the rate for non-Māori, non-Pacific peoples (112.7 per 100,000).

Both the male and female age-standardised rates for deaths from cancer were higher for Māori than non-Māori and for Pacific peoples than non-Māori, non-Pacific peoples.

The male Māori rate of 212.4 cancer deaths per 100,000 Māori males was 1.6 times higher than the non-Māori rate of 132.3 per 100,000 non-Māori males. The female Māori rate of 182.4 per 100,000 Māori females was 1.8 times higher than the non-Māori rate of 101.2.

For Pacific peoples, the male age-standardised rate for deaths from cancer was 219.8 per 100,000 Pacific males, compared with 129.8 per 100,000 for non-Māori, non-Pacific peoples. The female equivalent was 130.1 per 100,000 Pacific females, compared with 100.4 per 100,000 for non-Māori, non-Pacific peoples.

Table 5: Selected cancer sites: registrations by Māori and non-Māori and sex, 2004

Cancer site	Males				Females			
	No.	Rate*	No.	Rate*	No.	Rate*	No.	Rate*
Oesophagus (C15)	10	6.0	171	6.0	5	--	67	1.7
Stomach (C16)	33	16.1	178	6.5	27	12.4	130	3.5
Colorectum and anus (C18–C21)	43	22.7	1327	47.5	47	22.8	1318	40.0
Liver and intrahepatic bile ducts (C22)	21	9.8	100	3.7	4	--	39	1.4
Pancreas (C25)	20	10.2	156	5.9	15	7.9	169	4.5
Trachea, bronchus and lung (C33–C34)	141	79.5	929	32.7	138	69.3	611	19.7
Malignant melanoma of skin (C43)	5	--	944	37.4	12	5.0	935	35.6
Breast (C50)	0	--	22	0.8	196	81.5	2143	81.6
Cervix uteri (C53)	27	10.5	127	5.5
Corpus uteri (C54)	30	13.3	300	11.3
Ovary (C56)	26	12.2	251	8.7
Prostate (C61)	123	76.5	2570	96.3
Testis (C62)	25	8.0	113	6.2
Kidney, except renal pelvis (C64)	21	11.7	235	9.4	7	2.8	138	5.3
Bladder (C67)	16	8.5	451	15.3	8	3.6	151	4.1
Brain (C71)	6	2.6	140	6.2	7	2.8	107	4.4
Thyroid gland (C73)	7	3.3	48	2.3	16	5.1	120	5.3
Non-Hodgkin lymphoma (C82–C85, C96)	19	9.1	329	13.1	10	4.6	292	10.0
Multiple myeloma and malignant plasma cell neoplasms (C90)	14	8.5	121	4.3	11	5.3	94	3.0
Leukaemia (C91–C95)	20	10.6	347	13.6	27	11.7	277	10.6
Chronic myeloproliferative disorders and myelodysplastic syndromes (D45–D47)	36	18.2	393	13.0	31	14.8	310	8.4
All other sites	85	...	924	...	75	...	782	...
All sites	645	348.4	9498	356.0	719	323.5	8361	290.0

Notes: The non-Māori numbers and age-standardised rates include registrations and deaths with unspecified ethnicity and registrations and deaths for Pacific peoples who did not also identify themselves as Māori. The non-Māori numbers should therefore be interpreted with caution.

Māori and non-Māori age-standardised rates are not comparable with age-standardised rates in 1995 and earlier publications, owing to changes in population data definitions.

Rates based on small numbers, particularly for those categories with fewer than 20, are unstable and subject to random fluctuation from year to year.

* = rates per 100,000, age-standardised to Segi's world population

... = not applicable

-- = rate suppressed as there are five or fewer cases in this category

Māori males had a different registration profile from non-Māori males. While prostate cancer was the most commonly registered site among non-Māori males, cancer of the trachea, bronchus and lung was the most common among Māori males, accounting for almost 22 percent of Māori male registrations, compared with 10 percent among non-Māori males. The Māori male age-standardised rate for cancer of the trachea, bronchus and lung (79.5 per 100,000) was nearly two-and-a-half times that of the non-Māori male rate (32.7). Prostate cancer was the second most common site for registered cancers among Māori males (19 percent of Māori male registrations) and the most common among non-Māori males (27 percent of non-Māori male registrations). The Māori age-standardised rate for prostate cancer (76.5 per 100,000 Māori males) was substantially less than the non-Māori rate (96.3).

Māori males had noticeably higher rates of cancer of the stomach (16.1 registrations per 100,000 Māori males, two-and-a-half times the non-Māori rate) followed by cancer of the liver and intrahepatic bile ducts (9.8 per 100,000, nearly three times the non-Māori rate) and multiple myeloma (8.5 per 100,000, twice the non-Māori rate). The last of these figures should be treated with caution because the number of Māori cases was low (14 cases).

Māori males had a noticeably lower age-standardised registration rate for cancer of the colorectum and anus (22.7 per 100,000 Māori males, nearly half the non-Māori male rate). Malignant melanoma of the skin, which accounted for 10 percent of registrations among non-Māori males, made up only 1 percent of Māori male registrations.

As for non-Māori females, cancer of the breast was the leading site for registrations for Māori females in 2004, accounting for similar proportions of registrations (27 percent of Māori female and 26 percent of non-Māori female registrations). The age-standardised rates were also similar (81.5 per 100,000 Māori and 81.6 per 100,000 non-Māori females).

As with Māori males, cancer of the trachea, bronchus and lung accounted for a greater proportion of Māori female registrations (19 percent) than non-Māori female registrations (7 percent). The Māori female age-standardised rate of 69.3 per 100,000 Māori females was three-and-a-half times the non-Māori female rate (19.7).

Cancer of the colorectum and anus was far less common among Māori females (7 percent) than non-Māori females (16 percent). The Māori age-standardised registration rate (22.8 per 100,000 Māori females) was just over half of the non-Māori rate (40.0 per 100,000 non-Māori females).

Malignant melanoma of the skin, which accounted for 11 percent of registrations among non-Māori females, made up only 2 percent of Māori female registrations, and the Māori female age-standardised rate of 5.0 per 100,000 was around one-seventh of the non-Māori female rate of 35.6, although the Māori rate should be treated with caution because of the small number of cases.

Māori females also had higher age-standardised rates than non-Māori females for cervical cancer (10.5 per 100,000 compared with 5.5) and stomach cancer (12.4 compared with 3.5).

While cancer of the trachea, bronchus and lung was the leading cause of cancer death for both Māori and non-Māori males, it accounted for a greater proportion of Māori cancer deaths (32 percent of Māori male deaths compared with 21 percent of non-Māori male deaths). The age-standardised rate of death from this cancer was nearly two-and-a-half times higher among Māori males (68.0 per 100,000) than non-Māori males (28.1).

Prostate cancer and cancer of the colorectum and anus accounted for a lower proportion of Māori than non-Māori male cancer deaths, although the age-standardised mortality rates were similar for both Māori and non-Māori for both types of cancer.

Age-standardised mortality rates were higher for Māori males than non-Māori males for prostate cancer (26.8 cancer deaths per 100,000 Māori males, over one-and-a-half times the non-Māori rate),

cancer of the stomach (18.0 for Māori males, over three times the non-Māori rate) and cancer of the liver and intrahepatic bile ducts (11.4 for Māori males, over three times the non-Māori rate).

As with Māori males, cancer of the trachea, bronchus and lung was the leading cause of death among Māori females, accounting for 30 percent of Māori female deaths from cancer. Among non-Māori females, this cancer accounted for 14 percent of cancer deaths. The age-standardised mortality rate for Māori females (59.6 per 100,000 Māori females) was nearly four times the non-Māori rate (16.1).

Breast cancer accounted for a higher proportion of deaths (approximately 20 percent) among Māori females compared with non-Māori females (16 percent). The Māori female mortality rate (32.7 per 100,000) was nearly twice the non-Māori female rate (18.7).

Māori females had higher rates of death than non-Māori females from cervical and uterine cancer, but these differences should be treated with caution because the actual numbers of Māori deaths were small for each of these cancers.

Table 6: Selected cancer sites: deaths from cancer by Māori and non-Māori and sex, 2004

Cancer site	Males				Females			
	No.	Rate*	No.	Rate*	No.	Rate*	No.	Rate*
Oesophagus (C15)	10	5.8	122	4.4	7	3.3	67	1.6
Stomach (C16)	32	18.0	154	5.5	21	9.8	94	2.5
Colorectum and anus (C18–C21)	25	13.0	545	18.4	29	12.8	574	15.2
Liver and intrahepatic bile ducts (C22)	24	11.4	95	3.4	2	--	55	1.5
Pancreas (C25)	15	7.5	157	5.6	9	4.5	174	4.4
Trachea, bronchus and lung (C33–C34)	117	68.0	812	28.1	120	59.6	506	16.1
Malignant melanoma of skin (C43)	4	--	148	5.4	2	--	95	2.7
Breast (C50) (female only)	81	32.7	561	18.7
Cervix uteri (C53)	15	5.5	56	2.0
Corpus uteri (C54)	9	4.5	55	1.8
Ovary (C56)	18	8.5	169	5.1
Prostate (C61)	37	26.8	546	16.1
Testis (C62)	2	--	3	--
Kidney, except renal pelvis (C64)	11	6.6	97	3.5	2	--	53	1.6
Bladder (C67)	3	--	121	3.9	4	--	52	1.0
Brain (C71)	7	3.0	123	4.8	11	4.4	81	3.0
Non-Hodgkin lymphoma (C82–C85, C96)	12	6.2	124	4.4	12	6.2	140	3.8
Multiple myeloma and malignant plasma cell neoplasms (C90)	4	--	72	2.4	4	--	68	1.7
Leukaemia (C91–C95)	7	3.0	139	5.0	7	2.8	138	4.2
Chronic myeloproliferative disorders and myelodysplastic syndromes (D45–D47)	3	--	70	2.1	0	...	49	0.8
Other sites	59	...	546	...	42	...	517	...
All sites	372	212.4	3874	132.3	395	182.4	3504	101.2

Notes: The non-Māori numbers and age-standardised rates include registrations and deaths with unspecified ethnicity and registrations and deaths for Pacific peoples who did not also identify themselves as Māori. The non-Māori numbers should therefore be interpreted with caution.

Māori and non-Māori age-standardised rates are not comparable with age-standardised rates in 1995 and earlier publications, owing to changes in population data definitions.

Rates based on small numbers, particularly for those categories with fewer than 20, are unstable and subject to random fluctuation from year to year.

* = rates per 100,000, age-standardised to Segi's world population


... = not applicable

-- = rate suppressed as there are five or fewer cases in this category

Selected sites: trends in registrations and deaths

Cancer of the trachea, bronchus and lung (ICD codes C33 and C34)

Figure 13: Cancer of the trachea, bronchus and lung, registrations and deaths, 1995–2004



Note: rates per 100,000, age-standardised to Segi's world population

2004	Male		Female	
	Number	Rate*	Number	Rate*
New registrations	1070	36.0	749	23.2
Deaths	929	30.8	626	19.2

* = rate per 100,000, age-standardised to Segi's world population


In 2004, cancer of the trachea, bronchus and lung was the third most common site for cancer registrations for males (accounting for 10.5 percent of male registrations) and the fourth most common site for females (accounting for 8.2 percent of female registrations). It was the most common cause of cancer death for males (accounting for 21.9 percent of male deaths from cancer) and the second most common for females (accounting for 16.1 percent of female cancer deaths). The deaths to registrations ratio for both males and females were both relatively high at 0.87 and 0.84 respectively.

The age-standardised registration rate for males was 36.0 per 100,000 males, while for females the rate was 23.2 per 100,000 females. Since 1995, the rate of male registration has decreased by 13 percent, while during the same period the female rate increased by 17 percent.

The age-standardised mortality rate for males was 30.8 per 100,000 male population, while for females it was 19.2 per 100,000 female population.

Māori had notably higher age-standardised registration and mortality rates than non-Māori. Both the male Māori registration and death rates were nearly two-and-a-half times the comparable non-Māori male rates. The Māori female age-standardised registration rate was three-and-a-half times the non-Māori rate, and the Māori female death rate nearly four times the non-Māori rate.


Figure 14: Cancer of the trachea, bronchus and lung, registrations and deaths by ethnicity, 2004



Note: rates per 100,000, age-standardised to Segi's world population.

Female cancer of the breast (ICD code C50)

Figure 15: Female cancer of the breast, registrations and deaths, 1995–2004



Note: rates per 100,000, age-standardised to Segi's world population.

2004	Number	Rate*
New registrations	2339	81.5
Deaths	642	20.2

* = rate per 100,000 female population, age-standardised to Segi's world population


In 2004, breast cancer was the most commonly registered cancer site for females (accounting for 25.8 percent of female registrations) and the leading cause of cancer death among females (accounting for 16.4 percent of female cancer deaths). It had a comparatively low deaths to registrations ratio of 0.27.

The 2004 age-standardised registration rate for cancer of the breast of 81.5 per 100,000 female population was 5 percent greater than the 1995 rate, but 9 percent less than the peak in 2000.

The 2004 age-standardised mortality rate (20.2 per 100,000 female population) was 19 percent lower than in 1995.

While the age-standardised registration rates for Māori and non-Māori females were nearly the same, the Māori female age-standardised mortality rate (32.7 per 100,000) was higher than the non-Māori rate (18.7 per 100,000).


Figure 16: Female cancer of the breast, registrations and deaths by ethnicity, 2004



Note: rates per 100,000, age-standardised to Segi's world population.

Cancer of the colorectum and anus (ICD codes C18–C21)

Figure 17: Cancer of the colorectum and anus, registrations and deaths, 1995–2004



Note: rates per 100,000, age-standardised to Segi's world population.

2004	Male		Female	
	Number	Rate*	Number	Rate*
New registrations	1370	46.1	1365	38.9
Deaths	570	18.3	603	15.4

* = rate per 100,000, age-standardised to Segi's world population


In 2004, cancer of the colorectum and anus was the second most common site of cancer registration for both males (accounting for 13.5 percent of male registrations) and females (accounting for 15.0 percent of female registrations). It was the third most common cause of cancer death for both males (accounting for 13.4 percent of male deaths from cancer) and females (accounting for 15.5 percent of female cancer deaths). The deaths to registrations ratios for males and females were similar—0.42 for males and 0.44 for females.

The 2004 age-standardised registration rate of cancer of the colorectum and anus for males was 12 percent less than the male rate in 1995. The 2004 female age-standardised registration rate was 8 percent less than the female rate in 1995.

Both male and female Māori age-standardised registration rates for cancer of the colorectum and anus were substantially lower than the comparable non-Māori rates.

Both male and female Māori age-standardised mortality rates were somewhat lower than the comparable non-Māori rates.


Figure 18: Cancer of the colorectum and anus, registrations and deaths by ethnicity, 2004



Note: rates per 100,000, age-standardised to Segi's world population.

Cancer of the prostate (ICD code C61)

Figure 19: Cancer of the prostate, registrations and deaths, 1995–2004



Note: rates per 100,000, age-standardised to Segi's world population.

2004	Number	Rate*
New registrations	2693	94.6
Deaths	583	16.6

* = rate per 100,000 male population, age-standardised to Segi's world population


Prostate cancer was the most common site among males for cancer registrations in 2004, accounting for 26.6 percent of male registrations, and the second most common cause of male cancer death, accounting for 13.7 percent of male cancer deaths. The deaths to registrations ratio was 0.22.

The age-standardised rate for registrations of 94.6 per 100,000 male population is only slightly less than the 1995 rate of 101.0 per 100,000 males.

The age-standardised mortality rate remained relatively stable from 1995 to 2002, at around 18 to 20 per 100,000 males. The 2004 rate of 16.6 represents a slight decline from 2002.

While the age-standardised registration rate of prostate cancer for Māori males was lower than the non-Māori rate, the Māori mortality rate was higher.


Figure 20: Cancer of the prostate, registrations and deaths by ethnicity, 2004



Note: rates per 100,000, age-standardised to Segi's world population.

Malignant melanoma of the skin (ICD code C43)

Figure 21: Malignant melanoma of the skin, registrations and deaths, 1995–2004



Note: rates per 100,000, age-standardised to Segi's world population.

2004	Male		Female	
	Number	Rate*	Number	Rate*
New registrations	949	34.5	947	32.4
Deaths	152	5.2	97	2.6

* = rate per 100,000, age-standardised to Segi's world population

In 2004, melanoma of the skin was the fourth most commonly registered cancer site for males (9.4 percent of male registrations) and the third for females (10.4 percent of female registrations). Melanoma of the skin was the sixth most common cause of death among males (3.6 percent of male cancer deaths) and the ninth most common cause of female cancer deaths (2.5 percent of female cancer deaths). Melanoma of the skin had relatively low deaths to registrations ratios of 0.16 for males and 0.10 for females.


Compared with 1995, both male and female age-standardised registration rates for melanoma of the skin have declined by around 14 percent. However, these rates have remained relatively stable since 1996, and the 2004 rates for males and females continue that stability.

Both the male and female age-standardised mortality rates have been stable since 1995, with the male rates in the range of 5 to 6 deaths per 100,000 males and the female rates in the range of 2.5 to 3.5. The 2004 male and female mortality rates continue that stability.

Age-standardised rates for melanoma of the skin for Māori are not a useful comparative tool because there are too few cases to provide reliable rates. For Māori, there were 17 cases registered (5 males and 12 females) and 6 deaths recorded (4 males and 2 females) in 2004.

Cancer of the pancreas (ICD code C25)

Figure 22: Cancer of the pancreas, registrations and deaths, 1995–2004



Note: rates per 100,000, age-standardised to Segi's world population.

2004	Male		Female	
	Number	Rate*	Number	Rate*
New registrations	176	6.3	184	4.7
Deaths	172	5.8	183	4.4

* = rate per 100,000, age-standardised to Segi's world population

Cancer of the pancreas was the 12th most common site for male and 10th most common site for female registrations in 2004. It accounted for 1.7 percent of male and 2.0 percent of female registrations.

It was the fifth most common site for male cancer deaths, accounting for 4.1 percent of male cancer deaths. It was also the fifth most common cause of cancer death among females and accounted for 4.7 percent of female cancer deaths. Cancer of the pancreas had relatively high deaths to registrations ratios of 0.98 for males and 0.99 for females.

The 2004 male age-standardised registration rate was higher than the 1995 rate (5.8 per 100,000 males). The 2004 female rate was slightly less than the 1995 rate (5.2 per 100,000 females).


The age-standardised mortality rates for males have fluctuated from 4.9 per 100,000 males (in 2001) to 6.6 (in 1998). The 2004 age-standardised mortality rate for males (5.8) lies within this range. The rates for females have fluctuated from 3.7 per 100,000 females (in 2003) to 5.3 (in 1996 and 1998). The 2004 age-standardised mortality rate for females (4.4) lies within this range.

For Māori males, the age-standardised rate of registrations for cancer of the pancreas (10.2 per 100,000) was higher than the non-Māori male rate (5.9 per 100,000). Similarly, the female Māori age-standardised rate (7.9) was higher than the non-Māori female rate (4.5).

The age-standardised mortality rate for Māori males (7.5 per 100,000 Māori males) was somewhat higher than the non-Māori male rate (5.6 per 100,000 non-Māori males). The female age-standardised mortality rates were similar for Māori and non-Māori (4.5 per 100,000 Māori females and 4.4 per 100,000 non-Māori females).

It should be noted that the age-standardised registration and mortality rates for Māori were based on a small number of cases (20 or fewer) and should be treated with caution.

Figure 23: Cancer of the pancreas, registrations and deaths by ethnicity, 2004




Note: rates per 100,000, age-standardised to Segi's world population.

Age-standardised rates for Māori registrations and deaths were based on small numbers and should be treated with caution.

Cancer of the stomach (ICD code C16)

Figure 24: Cancer of the stomach, registrations and deaths, 1995–2004



Note: rates per 100,000, age-standardised to Segi's world population.

2004	Male		Female	
	Number	Rate*	Number	Rate*
New registrations	211	7.5	157	4.2
Deaths	186	6.4	115	3.1

* = rate per 100,000, age-standardised to Segi's world population

In 2004, cancer of the stomach was the 10th most common site for male registrations (accounting for 2.1 percent of male registrations), but the fourth most common cause of cancer deaths among males (accounting for 4.4 percent of male cancer deaths). It was the 12th most common site for female registrations (accounting for 1.7 percent of female registrations) and the eighth most common cause of cancer deaths among females (accounting for 3.0 percent of female cancer deaths). Cancer of the stomach had relatively high deaths to registrations ratios of 0.88 for males and 0.73 for females.


The 2004 male age-standardised registration rate was lower than the 1995 rate (9.7 per 100,000 males) and the lowest during the period from 1995. The 2004 female age-standardised registration rate was nearly the same as the 1995 rate (4.3 per 100,000 females).

The 2004 male age-standardised mortality rate was nearly the same as the 1995 male rate (6.2 per 100,000 males). The 2004 female mortality rate was similar to the 1995 female rate (3.5 per 100,000 females).

The age-standardised rate of registration of cancer of the stomach for Māori males (16.1 per 100,000 Māori males) was considerably higher than the non-Māori male rate (6.5 per 100,000 non-Māori males). Similarly, the Māori female age-standardised mortality rate (12.4 per 100,000 Māori females) was considerably higher than the non-Māori female rate (3.5 per 100,000 non-Māori females).

The age-standardised mortality rate for Māori males (18.0 per 100,000 Māori males) was considerably higher than the non-Māori male rate (5.5 per 100,000 non-Māori males). The female age-standardised mortality rate for Māori (9.8 per 100,000) was also considerably higher than the non-Māori female rate (2.5 per 100,000).


Figure 25: Cancer of the stomach, registrations and deaths by ethnicity, 2004



Note: rates per 100,000, age-standardised to Segi's world population.

Cancer of the cervix uteri (ICD code C53)

Figure 26: Cancer of the cervix uteri, registrations and deaths, 1995–2004



Note: rates per 100,000, age-standardised to Segi's world population.

2004	Number	Rate*
New registrations	154	5.9
Deaths	71	2.4

* = rate per 100,000, age-standardised to Segi's world population

In 2004, cancer of the cervix uteri was the 13th most common cancer registered for females, accounting for 1.7 percent of female registrations. It was the 13th most common site for female cancer deaths and accounted for 1.8 percent of female cancer deaths. In 2004, the deaths to registrations ratio was 0.46.


The 2004 age-standardised registration rate was 42 percent less than the 1995 rate (10.2 per 100,000 females).

The age-standardised mortality rate for cancer of the cervix uteri has declined from 4.0 per 100,000 females in 1995 to 2.4 per 100,000 females in 2004.

Māori females had an age-standardised registration rate of 10.5 per 100,000 Māori females, which was higher than the non-Māori rate of 5.5 per 100,000 non-Māori females.

Māori females had an age-standardised mortality rate of 5.5 per 100,000 Māori females, which was higher than the non-Māori rate of 2.0 per 100,000 non-Māori females. However, the age-standardised mortality rates for Māori were based on a small number of cases (15) and should be treated with caution.


Figure 27: Cancer of the cervix uteri, registrations and deaths by ethnicity, 2004



Note: rates per 100,000, age-standardised to Segi's world population.
 * = rate based on a small number of cases

Non-Hodgkin lymphoma (ICD codes C82–C85 and C96)

Figure 28: Non-Hodgkin lymphoma, registrations and deaths, 1995–2004



Note: rates per 100,000, age-standardised to Segi's world population.

2004	Male		Female	
	Number	Rate*	Number	Rate*
New registrations	348	12.7	302	9.5
Deaths	136	4.6	152	4.0

* = rate per 100,000, age-standardised to Segi's world population

In 2004, non-Hodgkin lymphoma was the eighth most common site for cancer registrations for both males and females, accounting for 3.4 percent of male and 3.3 percent of female registrations. It was the eighth most common site for cancer deaths for males, accounting for 3.2 percent of male cancer

deaths. It was the sixth most common site of cancer deaths for females, accounting 3.9 percent of female cancer deaths. The deaths to registrations ratios were 0.39 for males and 0.50 for females.


The 2004 male age-standardised registration rate was the same as the 1995 male rate. The 2004 female age-standardised rate was also similar to the 1995 female rate (9.2 per 100,000 females).

The 2004 male mortality rate for non-Hodgkin lymphoma was similar to the 1995 male rate (5.2 per 100,000). The 2004 mortality rate for females was the same as the 1995 female rate.

The Māori male age-standardised registration rate (9.1 per 100,000 Māori males) was lower than the non-Māori male rate (13.1 per 100,000 non-Māori males). The Māori female age-standardised registration rate of (4.6 per 100,000 Māori females) was less than the non-Māori female rate (10.0 per 100,000 non-Māori females).

The Māori male age-standardised mortality rate (6.2 per 100,000 Māori males) was higher than the non-Māori male rate (4.4 per 100,000 non-Māori males). The female Māori age-standardised mortality rate (6.2 per 100,000 Māori females) was also higher than the non-Māori female rate (3.8 per 100,000). It should be noted that the age-standardised mortality rates for Māori were based on a small number of cases (fewer than 20) and should be treated with caution.

Figure 29: Non-Hodgkin lymphoma, registrations and deaths by ethnicity, 2004



Note: rates per 100,000, age-standardised to Segi's world population.

* = rate based on a small number of cases

Other cancers

Cancer of the ovary (ICD code C56)

There were 277 registrations of, and 187 deaths from, cancer of the ovary in 2004. This was the ninth highest number of registrations for females and the fourth highest number of female cancer deaths. The age-standardised registration rate for cancer of the ovary was 9.0 per 100,000 female population, while the age-standardised mortality rate was 5.4 per 100,000 female population. The deaths to registrations ratio in 2004 for cancer of the ovary was 0.68.

Māori females had an age-standardised registration rate of 12.2 per 100,000 Māori females, which was higher than the non-Māori rate of 8.7 per 100,000 non-Māori females. There were 18 Māori deaths from cancer of the ovary, with an age-standardised mortality rate of 8.5 per 100,000 Māori females. This compares with a non-Māori age-standardised mortality rate of 5.1 per 100,000 non-Māori females. The age-standardised mortality rates for Māori, however, are based on a small number of cases and should be treated with caution.

The introduction of the third edition of ICD-O from 1 January 2003 has resulted in a slight reduction in the number of cases recorded for ovarian cancer from 2003 onwards compared with previous years. Ovarian tumours of borderline malignancy were considered malignant in the second edition of ICD-O, but are considered to be of uncertain behaviour in the third edition and have been excluded from incidence reporting since 2003. Please see the Explanatory Notes for further details of these changes.

Cancer of the bladder (ICD code C67)

In 2004, there were 626 registrations for cancer of the bladder (467 male and 159 female). There were 180 deaths from cancer of the bladder (124 male and 56 female), with a deaths to registrations ratio of 0.27 for males and 0.35 for females.

The age-standardised registration rate for males (15.0 per 100,000 males) was more than three times higher than the female rate (4.1 per 100,000 females).

The age-standardised registration rate for Māori males with cancer of the bladder (8.5 per 100,000 Māori males) was lower than the non-Māori male rate (15.3 per 100,000 non-Māori males). Māori females had an age-standardised rate of 3.6 per 100,000 Māori females, lower than the non-Māori rate of 4.1 per 100,000 non-Māori females.

There were 7 Māori deaths from cancer of the bladder (3 males and 4 females) in 2004.

Cancer of the kidney (ICD code C64)

There were 401 registrations for cancer of the kidney in 2004 (256 male and 145 female). The male age-standardised registration rate was 9.5 per 100,000 males, while the female rate was 5.1 per 100,000 females. There were 163 deaths from cancer of the kidney (108 male and 55 female). The age-standardised mortality rate for males was 3.7 per 100,000 males and for females 1.6 per 100,000 females. The deaths to registrations ratios were 0.42 for males and 0.38 for females.

There were 28 Māori registrations for cancer of the kidney (21 males and 7 females) and 13 Māori deaths (11 males and 2 females).

Cancer of the brain (ICD code C71)

There were 260 registrations for cancer of the brain in 2004 (146 male and 114 female). The male age-standardised registration rate was 5.8 per 100,000 males, while the female rate was 4.2 per 100,000 females. There were 222 deaths from cancer of the brain (130 males and 92 females). The age-standardised mortality rate for males was 4.8 per 100,000 males, while for females it was 3.1 per 100,000 females. The deaths to registrations ratios were relatively high at 0.89 for males and 0.81 for females.

There were 13 Māori (6 male and 7 female) registrations for, and 18 (7 male and 11 female) deaths from, cancer of the brain.

Detailed statistical tables

Table A-1: Major causes of death by sex, numbers and percentages, 2004

	Total		Male		Female	
	No.	%	No.	%	No.	%
Cancer, malignant disease (C00–C96, D45–D47)	8145	28.4	4246	29.9	3899	27.0
<i>Colorectal cancer (C18–C21)</i>	1173	4.1	570	4.0	603	4.2
<i>Trachea, bronchus and lung cancer (C33–C34)</i>	1555	5.4	929	6.5	626	4.3
Breast cancer (C50)	646	2.3	4	0.0	642	4.4
<i>Prostate cancer (C61)</i>	583	2.0	583	4.1
Diseases of the heart (except congenital) (I05–I09, I11, I13, I20–I25, I30–I52)	7837	27.4	4012	28.3	3825	26.5
<i>Ischaemic heart disease (I20–I25)</i>	6313	22.0	3366	23.7	2947	20.4
<i>Other forms of heart disease (I05–I09, I11, I13, I30–I52)</i>	1524	5.3	646	4.5	878	6.1
Cerebrovascular disease (I60–I69)	2806	9.8	1050	7.4	1756	12.2
Chronic lower respiratory diseases (J40–J47)	1854	6.5	944	6.6	910	6.3
Transport accidents (V01–V99)	520	1.8	366	2.6	154	1.1
Other unintentional injuries (excluding transport accidents) (W00–X59)	590	2.1	319	2.2	271	1.9
Intentional self-harm (X60–X84)	488	1.7	379	2.7	109	0.8
Pneumonia and influenza (J10–J18)	465	1.6	165	1.2	300	2.1
Sudden Infant Death Syndrome (R95)	42	0.1	23	0.2	19	0.1
Perinatal conditions (P00–P96)	150	0.5	76	0.5	74	0.5
Diabetes mellitus (E10–E14)	843	2.9	438	3.1	405	2.8
Diseases of arteries, arterioles and capillaries (I70–I79)	508	1.8	277	2.0	231	1.6
Central nervous system disorders (G00–G46)	891	3.1	369	2.6	522	3.6
All other causes	3497	12.2	1537	10.8	1960	13.6
Total	28,636	100.0	14,201	100.0	14,435	100.0

... = not applicable

Table A-2: Cancer registrations: site by sex and age, total registrations, 2004

	Age in years at registration																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
All sites																			
Total:	19,223	52	33	39	65	107	147	308	404	654	944	1389	1802	2215	2475	2570	2581	1925	1513
Male:	10,143	27	13	17	34	61	65	104	146	240	340	593	953	1255	1446	1576	1590	1041	642
Female:	9080	25	20	22	31	46	82	204	258	414	604	796	849	960	1029	994	991	884	871
C00 Lip																			
Total:	36	0	0	0	0	0	1	3	5	3	1	3	5	6	2	3	2	1	1
Male:	31	0	0	0	0	0	1	3	4	3	1	3	3	6	2	2	2	1	0
Female:	5	0	0	0	0	0	0	0	1	0	0	0	2	0	0	1	0	0	1
C01 Base of tongue																			
Total:	21	0	0	0	0	0	0	1	0	0	5	2	2	4	5	0	1	1	0
Male:	15	0	0	0	0	0	0	0	0	0	3	1	1	4	4	0	1	1	0
Female:	6	0	0	0	0	0	0	1	0	0	2	1	1	0	1	0	0	0	0
C02 Other and unspecified parts of tongue																			
Total:	41	0	0	0	0	0	0	2	0	1	5	4	3	8	2	3	2	8	3
Male:	26	0	0	0	0	0	0	2	0	0	3	4	2	7	1	1	2	4	0
Female:	15	0	0	0	0	0	0	0	0	1	2	0	1	1	1	2	0	4	3
C03 Gum																			
Total:	10	0	0	0	0	0	0	0	0	0	0	0	0	2	5	1	0	0	2
Male:	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
Female:	8	0	0	0	0	0	0	0	0	0	0	0	0	1	5	0	0	0	2
C04 Floor of mouth																			
Total:	24	0	0	0	0	0	0	0	0	1	1	2	3	9	1	4	1	1	1
Male:	18	0	0	0	0	0	0	0	0	0	1	2	3	8	0	3	0	0	1
Female:	6	0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	1	1	0
C05 Palate																			
Total:	12	0	0	0	1	0	0	0	0	0	2	2	2	2	0	1	1	0	1
Male:	6	0	0	0	0	0	0	0	0	0	2	1	1	0	0	1	1	0	0
Female:	6	0	0	0	1	0	0	0	0	0	0	1	1	2	0	0	0	0	1
C06 Other and unspecified parts of mouth																			
Total:	16	0	1	0	0	0	0	0	0	1	0	3	1	3	2	2	2	1	0
Male:	9	0	1	0	0	0	0	0	0	0	0	2	1	2	1	1	1	0	0
Female:	7	0	0	0	0	0	0	0	0	1	0	1	0	1	1	1	1	1	0
C07 Parotid gland																			
Total:	29	0	0	0	1	1	0	0	2	2	0	4	2	2	4	1	4	3	3
Male:	14	0	0	0	0	0	0	0	1	2	0	1	0	1	3	1	2	2	1
Female:	15	0	0	0	1	1	0	0	1	0	0	3	2	1	1	0	2	1	2
C08 Other and unspecified major salivary glands																			
Total:	6	0	0	0	0	0	0	0	0	1	0	0	1	0	0	3	1	0	0
Male:	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Female:	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	3	1	0	0
C09 Tonsil																			
Total:	44	0	0	0	0	0	1	1	1	3	6	6	9	8	2	4	1	1	1
Male:	31	0	0	0	0	0	1	1	0	2	4	6	6	5	2	1	1	1	1
Female:	13	0	0	0	0	0	0	0	1	1	2	0	3	3	0	3	0	0	0

Table A-2: (continued) Cancer registrations: site by sex and age, total registrations, 2004

	Age in years at registration																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C10 Oropharynx																			
Total:	9	0	0	0	0	0	0	0	0	1	0	1	1	0	1	1	2	1	1
Male:	5	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	2	0	0
Female:	4	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	1	1
C11 Nasopharynx																			
Total:	22	0	0	1	1	0	0	2	2	2	3	2	2	2	2	1	2	0	0
Male:	13	0	0	0	1	0	0	1	0	2	3	0	1	1	2	1	1	0	0
Female:	9	0	0	1	0	0	0	1	2	0	0	2	1	1	0	0	1	0	0
C12 Pyriform sinus																			
Total:	6	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0	0	0
Male:	5	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	0	0	0
Female:	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C13 Hypopharynx																			
Total:	7	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0	2	1	0
Male:	6	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	1	0
Female:	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
C14 Other and ill-defined sites in the lip, oral cavity and pharynx																			
Total:	9	0	0	0	0	0	0	0	0	0	0	0	0	2	2	3	1	1	0
Male:	9	0	0	0	0	0	0	0	0	0	0	0	0	2	2	3	1	1	0
C15 Oesophagus																			
Total:	253	0	0	0	0	0	0	0	3	3	5	7	22	35	26	35	40	43	34
Male:	181	0	0	0	0	0	0	0	3	3	4	2	16	31	21	22	30	26	23
Female:	72	0	0	0	0	0	0	0	0	0	1	5	6	4	5	13	10	17	11
C16 Stomach																			
Total:	368	0	0	0	1	4	4	6	5	12	17	29	27	38	43	37	47	49	49
Male:	211	0	0	0	0	3	4	3	2	6	8	19	19	23	32	24	30	22	16
Female:	157	0	0	0	1	1	0	3	3	6	9	10	8	15	11	13	17	27	33
C17 Small intestine																			
Total:	70	0	0	0	0	0	0	1	2	1	2	4	12	8	13	5	9	8	5
Male:	41	0	0	0	0	0	0	0	0	1	1	4	8	7	6	4	5	3	2
Female:	29	0	0	0	0	0	0	1	2	0	1	0	4	1	7	1	4	5	3
C18 Colon																			
Total:	1812	0	0	0	0	5	5	5	17	25	38	61	112	177	270	312	333	252	200
Male:	830	0	0	0	0	1	2	2	4	11	16	33	43	90	138	159	165	106	60
Female:	982	0	0	0	0	4	3	3	13	14	22	28	69	87	132	153	168	146	140
C19 Rectosigmoid junction																			
Total:	205	0	0	0	0	1	0	1	5	4	9	14	18	40	22	29	31	18	13
Male:	110	0	0	0	0	0	0	1	3	4	4	7	8	17	12	14	21	10	9
Female:	95	0	0	0	0	1	0	0	2	0	5	7	10	23	10	15	10	8	4
C20 Rectum																			
Total:	671	0	0	0	0	0	2	5	11	9	26	41	72	83	99	96	94	81	52
Male:	414	0	0	0	0	0	1	3	5	4	15	26	51	51	64	59	62	52	21
Female:	257	0	0	0	0	0	1	2	6	5	11	15	21	32	35	37	32	29	31

Table A-2: (continued) Cancer registrations: site by sex and age, total registrations, 2004

	Age in years at registration																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C21 Anus and anal canal																			
Total:	47	0	0	0	0	0	0	0	0	3	5	6	8	5	7	4	4	2	3
Male:	16	0	0	0	0	0	0	0	0	0	3	1	2	0	4	3	3	0	0
Female:	31	0	0	0	0	0	0	0	0	3	2	5	6	5	3	1	1	2	3
C22 Liver and intrahepatic bile ducts																			
Total:	164	1	0	1	0	1	1	0	1	7	9	15	13	18	21	25	25	17	9
Male:	121	0	0	0	0	1	0	0	1	6	6	11	11	15	17	17	19	12	5
Female:	43	1	0	1	0	0	1	0	0	1	3	4	2	3	4	8	6	5	4
C23 Gallbladder																			
Total:	58	0	0	0	0	0	0	0	1	1	2	2	5	5	8	8	12	5	9
Male:	16	0	0	0	0	0	0	0	0	0	0	0	3	1	2	2	6	2	0
Female:	42	0	0	0	0	0	0	0	1	1	2	2	2	4	6	6	6	3	9
C24 Other and unspecified parts of biliary tract																			
Total:	60	0	0	0	0	0	0	0	0	2	1	4	7	4	9	8	10	11	4
Male:	26	0	0	0	0	0	0	0	0	1	0	1	4	1	4	4	5	5	1
Female:	34	0	0	0	0	0	0	0	0	1	1	3	3	3	5	4	5	6	3
C25 Pancreas																			
Total:	360	0	0	0	0	1	0	2	2	11	11	17	22	35	45	72	56	36	50
Male:	176	0	0	0	0	1	0	2	1	8	8	10	12	20	27	42	20	12	13
Female:	184	0	0	0	0	0	0	0	1	3	3	7	10	15	18	30	36	24	37
C26 Other and ill-defined digestive organs																			
Total:	73	0	0	0	0	0	0	0	0	0	2	1	3	4	8	10	10	10	25
Male:	29	0	0	0	0	0	0	0	0	0	1	1	1	1	7	4	4	4	6
Female:	44	0	0	0	0	0	0	0	0	0	1	0	2	3	1	6	6	6	19
C30 Nasal cavity and middle ear																			
Total:	10	0	0	0	0	0	0	0	0	0	3	1	1	0	2	1	1	1	0
Male:	9	0	0	0	0	0	0	0	0	0	3	1	1	0	2	1	0	1	0
Female:	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C31 Accessory sinuses																			
Total:	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1
Male:	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Female:	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
C32 Larynx																			
Total:	72	0	0	0	0	0	0	0	1	1	4	3	10	11	8	15	6	8	5
Male:	64	0	0	0	0	0	0	0	1	0	3	3	10	10	8	14	6	6	3
Female:	8	0	0	0	0	0	0	0	0	1	1	0	0	1	0	1	0	2	2
C33 Trachea																			
Total:	3	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0
Male:	3	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0
C34 Bronchus and lung																			
Total:	1816	0	0	0	0	1	1	7	9	29	43	105	163	249	271	312	297	221	108
Male:	1067	0	0	0	0	0	0	1	5	13	25	63	93	125	166	195	190	129	62
Female:	749	0	0	0	0	1	1	6	4	16	18	42	70	124	105	117	107	92	46

Table A-2: (continued) Cancer registrations: site by sex and age, total registrations, 2004

	Age in years at registration																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C37 Thymus																			
Total:	6	0	0	0	0	1	0	0	2	1	1	0	0	0	0	1	0	0	0
Male:	3	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0
Female:	3	0	0	0	0	0	0	0	2	0	0	0	0	0	0	1	0	0	0
C38 Heart, mediastinum and pleura																			
Total:	13	0	0	1	0	0	0	2	1	1	0	1	1	0	2	2	0	2	0
Male:	9	0	0	1	0	0	0	2	1	0	0	0	1	0	2	2	0	0	0
Female:	4	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	2	0
C39 Other and ill-defined sites in the respiratory system and intrathoracic organs																			
Total:	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Male:	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C40 Bone and articular cartilage of limbs																			
Total:	25	0	3	4	6	2	0	2	1	0	2	1	0	1	0	0	2	0	1
Male:	10	0	0	1	4	1	0	1	0	0	2	1	0	0	0	0	0	0	0
Female:	15	0	3	3	2	1	0	1	1	0	0	0	1	0	0	2	0	1	1
C41 Bone and articular cartilage of other and unspecified sites																			
Total:	21	1	0	0	5	2	2	3	0	0	0	0	0	2	3	1	1	1	0
Male:	14	1	0	0	3	1	2	0	0	0	0	0	0	2	2	1	1	1	0
Female:	7	0	0	0	2	1	0	3	0	0	0	0	0	0	1	0	0	0	0
C43 Malignant melanoma of skin																			
Total:	1896	0	0	1	7	15	35	82	81	109	151	181	210	189	197	189	190	156	103
Male:	949	0	0	0	2	8	12	22	36	52	61	83	109	120	97	109	110	85	43
Female:	947	0	0	1	5	7	23	60	45	57	90	98	101	69	100	80	80	71	60
C44 Other malignant neoplasms of skin																			
Total:	105	0	0	0	1	1	1	5	1	2	5	7	7	6	7	11	25	9	17
Male:	59	0	0	0	0	1	0	1	1	2	3	5	3	3	4	9	18	6	3
Female:	46	0	0	0	1	0	1	4	0	0	2	2	4	3	3	2	7	3	14
C45 Mesothelioma																			
Total:	82	0	0	0	0	1	0	0	0	0	0	5	7	12	15	18	14	6	4
Male:	75	0	0	0	0	1	0	0	0	0	0	4	6	12	15	15	13	5	4
Female:	7	0	0	0	0	0	0	0	0	0	0	1	1	0	0	3	1	1	0
C46 Kaposi's sarcoma																			
Total:	6	0	0	0	0	0	0	1	1	2	0	1	0	0	0	1	0	0	0
Male:	6	0	0	0	0	0	0	1	1	2	0	1	0	0	0	1	0	0	0
C47 Peripheral nerves and autonomic nervous system																			
Total:	7	0	1	1	0	0	0	2	1	0	0	0	1	1	0	0	0	0	0
Male:	2	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0
Female:	5	0	1	1	0	0	0	2	0	0	0	0	1	0	0	0	0	0	0
C48 Retroperitoneum and peritoneum																			
Total:	24	0	0	0	0	0	0	0	1	1	2	1	4	5	2	4	2	0	2
Male:	4	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1	0	0
Female:	20	0	0	0	0	0	0	0	1	1	1	1	4	4	2	3	1	0	2
C49 Other connective and soft tissue																			
Total:	104	1	1	1	4	5	1	3	4	4	8	7	5	11	12	10	11	4	12
Male:	55	1	1	1	2	4	1	2	0	2	3	5	3	6	7	7	6	0	4
Female:	49	0	0	0	2	1	0	1	4	2	5	2	2	5	5	3	5	4	8

Table A-2: (continued) Cancer registrations: site by sex and age, total registrations, 2004

	Age in years at registration																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C50 Breast																			
Total:	2361	0	0	0	0	1	8	41	90	188	277	343	274	286	253	175	157	122	146
Male:	22	0	0	0	0	0	0	0	0	1	0	0	3	4	3	3	4	2	2
Female:	2339	0	0	0	0	1	8	41	90	187	277	343	271	282	250	172	153	120	144
C51 Vulva																			
Total:	53	0	1	0	0	0	0	2	1	6	2	4	3	4	0	4	6	10	10
Female:	53	0	1	0	0	0	0	2	1	6	2	4	3	4	0	4	6	10	10
C52 Vagina																			
Total:	10	0	0	0	0	0	0	0	0	0	2	1	0	1	2	1	0	2	1
Female:	10	0	0	0	0	0	0	0	0	0	2	1	0	1	2	1	0	2	1
C53 Cervix uteri																			
Total:	154	0	0	0	1	2	11	20	9	18	17	17	16	11	7	8	8	3	6
Female:	154	0	0	0	1	2	11	20	9	18	17	17	16	11	7	8	8	3	6
C54 Corpus uteri																			
Total:	330	0	0	0	0	0	0	4	9	11	26	29	59	52	48	33	31	16	12
Female:	330	0	0	0	0	0	0	4	9	11	26	29	59	52	48	33	31	16	12
C55 Uterus, part unspecified																			
Total:	11	0	0	0	0	0	0	0	0	1	0	0	0	0	2	0	3	1	4
Female:	11	0	0	0	0	0	0	0	0	1	0	0	0	0	2	0	3	1	4
C56 Ovary																			
Total:	277	0	0	1	0	2	4	6	4	12	15	24	27	31	39	34	27	29	22
Female:	277	0	0	1	0	2	4	6	4	12	15	24	27	31	39	34	27	29	22
C57 Other and unspecified female genital organs																			
Total:	19	0	0	0	0	0	1	0	0	1	0	6	5	3	1	0	1	1	0
Female:	19	0	0	0	0	0	1	0	0	1	0	6	5	3	1	0	1	1	0
C58 Placenta																			
Total:	7	0	0	0	0	1	1	3	1	1	0	0	0	0	0	0	0	0	0
Female:	7	0	0	0	0	1	1	3	1	1	0	0	0	0	0	0	0	0	0
C60 Penis																			
Total:	10	0	0	0	0	0	0	0	0	0	0	1	0	1	3	2	2	1	0
Male:	10	0	0	0	0	0	0	0	0	0	0	1	0	1	3	2	2	1	0
C61 Prostate																			
Total:	2693	0	0	0	0	0	0	0	0	8	31	125	315	441	501	464	412	243	153
Male:	2693	0	0	0	0	0	0	0	0	8	31	125	315	441	501	464	412	243	153
C62 Testis																			
Total:	138	1	1	0	7	17	23	19	19	19	14	8	6	0	0	3	0	0	1
Male:	138	1	1	0	7	17	23	19	19	19	14	8	6	0	0	3	0	0	1
C63 Other and unspecified male genital organs																			
Total:	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Male:	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
C64 Kidney, except renal pelvis																			
Total:	401	8	2	2	0	2	3	5	8	17	22	30	44	56	50	59	46	32	15
Male:	256	3	1	1	0	1	1	3	8	9	12	18	32	36	37	40	29	18	7
Female:	145	5	1	1	0	1	2	2	0	8	10	12	12	20	13	19	17	14	8

Table A-2: (continued) Cancer registrations: site by sex and age, total registrations, 2004

	Age in years at registration																		
	Total	0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80–	85+
C65 Renal pelvis																			
Total:	33	0	0	0	0	0	0	0	0	0	0	2	4	3	6	4	4	7	3
Male:	15	0	0	0	0	0	0	0	0	0	0	0	3	1	3	4	1	2	1
Female:	18	0	0	0	0	0	0	0	0	0	0	2	1	2	3	0	3	5	2
C66 Ureter																			
Total:	18	0	0	0	0	0	0	0	0	0	0	1	0	1	2	4	5	5	0
Male:	10	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2	4	2	0
Female:	8	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1	3	0
C67 Bladder																			
Total:	626	0	0	0	0	0	0	6	3	17	17	26	39	48	68	114	139	88	61
Male:	467	0	0	0	0	0	0	3	0	12	12	19	32	41	55	84	102	63	44
Female:	159	0	0	0	0	0	0	3	3	5	5	7	7	7	13	30	37	25	17
C68 Other and unspecified urinary organs																			
Total:	21	0	0	0	0	0	0	0	0	0	0	1	1	2	4	3	4	5	1
Male:	13	0	0	0	0	0	0	0	0	0	0	1	1	2	2	2	1	4	0
Female:	8	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	3	1	1
C69 Eye and adnexa																			
Total:	46	5	1	0	1	0	1	0	1	2	2	4	3	5	6	7	3	2	3
Male:	25	4	0	0	1	0	0	0	1	2	2	2	1	3	3	4	1	1	0
Female:	21	1	1	0	0	0	1	0	0	0	0	2	2	2	3	3	2	1	3
C70 Meninges																			
Total:	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Female:	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
C71 Brain																			
Total:	260	3	5	6	1	7	8	9	16	19	14	21	22	27	31	18	29	16	8
Male:	146	2	2	2	1	5	3	6	10	12	8	10	13	16	17	12	16	8	3
Female:	114	1	3	4	0	2	5	3	6	7	6	11	9	11	14	6	13	8	5
C72 Spinal cord, cranial nerves and other parts of central nervous system																			
Total:	8	2	0	0	0	0	1	1	0	1	0	0	1	0	0	2	0	0	0
Male:	3	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Female:	5	1	0	0	0	0	1	1	0	1	0	0	1	0	0	0	0	0	0
C73 Thyroid gland																			
Total:	191	1	0	1	4	11	7	13	21	22	21	14	18	14	18	6	13	3	4
Male:	55	1	0	0	0	5	2	1	2	7	5	4	5	8	7	1	6	0	1
Female:	136	0	0	1	4	6	5	12	19	15	16	10	13	6	11	5	7	3	3
C74 Adrenal gland																			
Total:	6	2	0	1	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0
Male:	4	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Female:	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
C75 Other endocrine glands and related structures																			
Total:	5	0	0	2	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0
Male:	4	0	0	1	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0
Female:	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Table A-2: (continued) Cancer registrations: site by sex and age, total registrations, 2004

	Age in years at registration																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C76 Other and ill-defined sites																			
Total:	16	0	0	0	0	0	0	0	0	0	1	0	3	0	0	0	2	4	6
Male:	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2
Female:	12	0	0	0	0	0	0	0	0	0	1	0	3	0	0	0	2	2	4
C77 Secondary and unspecified lymph nodes																			
Total:	57	0	0	0	0	1	0	0	1	2	4	5	3	5	3	11	7	8	7
Male:	38	0	0	0	0	1	0	0	0	2	4	4	3	1	2	7	6	5	3
Female:	19	0	0	0	0	0	0	0	1	0	0	1	0	4	1	4	1	3	4
C78 Secondary respiratory and digestive organs																			
Total:	280	0	0	0	0	1	0	2	3	3	5	10	12	23	31	47	56	48	39
Male:	136	0	0	0	0	1	0	1	1	1	2	3	6	13	10	30	33	19	16
Female:	144	0	0	0	0	0	0	1	2	2	3	7	6	10	21	17	23	29	23
C79 Secondary other sites																			
Total:	95	0	0	0	0	0	0	0	0	3	2	6	3	5	16	11	18	15	16
Male:	49	0	0	0	0	0	0	0	0	3	1	1	1	4	8	7	9	9	6
Female:	46	0	0	0	0	0	0	0	0	0	1	5	2	1	8	4	9	6	10
C80 Malignant neoplasm without specification of site																			
Total:	23	0	0	0	0	0	0	0	0	0	0	0	1	2	2	1	3	6	8
Male:	10	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	3	2
Female:	13	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2	3	6
C81 Hodgkin lymphoma																			
Total:	80	0	0	1	3	4	10	12	9	6	5	3	5	4	5	1	7	4	1
Male:	50	0	0	0	2	2	3	6	6	5	4	3	5	2	1	0	7	3	1
Female:	30	0	0	1	1	2	7	6	3	1	1	0	0	2	4	1	0	1	0
C82 Follicular [nodular] non-Hodgkin lymphoma																			
Total:	124	0	0	0	0	0	2	1	6	2	12	16	16	15	18	15	10	7	4
Male:	70	0	0	0	0	0	0	1	3	1	6	11	11	8	11	10	4	3	1
Female:	54	0	0	0	0	0	2	0	3	1	6	5	5	7	7	5	6	4	3
C83 Diffuse non-Hodgkin lymphoma																			
Total:	336	1	3	2	4	3	3	2	11	9	16	32	39	33	34	37	53	37	17
Male:	184	1	1	2	2	2	2	2	7	7	10	17	21	20	16	18	25	23	8
Female:	152	0	2	0	2	1	1	0	4	2	6	15	18	13	18	19	28	14	9
C84 Peripheral and cutaneous T-cell lymphomas																			
Total:	56	0	0	3	2	0	3	2	1	2	1	9	5	4	7	5	5	4	3
Male:	34	0	0	2	0	0	3	2	1	2	1	3	3	1	5	4	5	1	1
Female:	22	0	0	1	2	0	0	0	0	0	0	6	2	3	2	1	0	3	2
C85 Other and unspecified types of non-Hodgkin lymphoma																			
Total:	131	0	0	0	1	0	1	2	5	5	4	7	6	12	17	19	19	17	16
Male:	59	0	0	0	1	0	1	0	4	3	2	6	1	6	8	5	12	4	6
Female:	72	0	0	0	0	0	0	2	1	2	2	1	5	6	9	14	7	13	10
C88 Malignant immunoproliferative diseases																			
Total:	32	0	0	0	0	0	0	0	0	0	0	1	1	7	3	8	6	2	4
Male:	21	0	0	0	0	0	0	0	0	0	0	1	1	2	2	4	5	2	4
Female:	11	0	0	0	0	0	0	0	0	0	0	0	0	5	1	4	1	0	0

Table A-2: (continued) Cancer registrations: site by sex and age, total registrations, 2004

	Age in years at registration																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C90 Multiple myeloma and malignant plasma cell neoplasms																			
Total:	240	0	0	0	0	0	0	1	1	6	13	15	20	28	32	39	30	31	24
Male:	135	0	0	0	0	0	0	1	0	4	9	5	11	13	17	27	21	16	11
Female:	105	0	0	0	0	0	0	0	1	2	4	10	9	15	15	12	9	15	13
C91 Lymphoid leukaemia																			
Total:	393	16	10	3	6	1	0	2	4	6	16	30	29	33	52	56	58	33	38
Male:	230	6	4	1	2	0	0	2	2	3	12	20	18	22	27	31	41	22	17
Female:	163	10	6	2	4	1	0	0	2	3	4	10	11	11	25	25	17	11	21
C92 Myeloid leukaemia																			
Total:	198	3	1	2	5	6	2	9	8	8	11	13	12	19	20	18	24	17	20
Male:	95	2	1	2	4	1	1	4	5	4	4	5	7	5	10	9	12	9	10
Female:	103	1	0	0	1	5	1	5	3	4	7	8	5	14	10	9	12	8	10
C93 Monocytic leukaemia																			
Total:	10	2	0	1	0	0	1	0	0	0	0	0	1	1	1	0	0	2	1
Male:	5	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	0	1	0
Female:	5	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
C94 Other leukaemias of specified cell type																			
Total:	52	3	0	0	0	0	0	0	0	1	1	2	1	0	4	7	8	18	7
Male:	28	1	0	0	0	0	0	0	0	0	1	1	1	0	2	4	5	10	3
Female:	24	2	0	0	0	0	0	0	0	1	0	1	0	0	2	3	3	8	4
C95 Leukaemia of unspecified cell type																			
Total:	18	1	1	0	0	0	1	1	0	0	0	1	3	1	1	1	3	1	3
Male:	9	0	0	0	0	0	0	1	0	0	0	1	2	1	1	0	1	0	2
Female:	9	1	1	0	0	0	1	0	0	0	0	0	1	0	0	1	2	1	1
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue																			
Total:	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0
Male:	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Female:	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0
D45 Polycythaemia vera																			
Total:	207	1	1	2	1	2	2	5	8	9	13	20	16	19	22	29	26	17	14
Male:	113	1	0	1	1	1	1	3	4	4	8	10	11	10	13	17	17	6	5
Female:	94	0	1	1	0	1	1	2	4	5	5	10	5	9	9	12	9	11	9
D46 Myelodysplastic syndromes																			
Total:	384	0	1	2	1	2	0	2	1	0	2	7	12	17	28	50	83	78	98
Male:	231	0	1	1	0	1	0	0	0	0	1	3	8	11	15	33	62	48	47
Female:	153	0	0	1	1	1	0	2	1	0	1	4	4	6	13	17	21	30	51
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue																			
Total:	179	0	0	0	0	3	0	1	4	6	7	7	13	12	17	37	24	30	18
Male:	85	0	0	0	0	1	0	0	3	5	4	5	6	5	8	18	11	12	7
Female:	94	0	0	0	0	2	0	1	1	1	3	2	7	7	9	19	13	18	11

Table A-3: Cancer registrations: site and sex by basis of diagnosis, 2004

	Total	Clinical	Radiological	Histological	Autopsy	Death certificate only
All sites						
Total:	19,223	21	1267	17,365	79	491
Male:	10,143	10	725	9121	51	236
Female:	9080	11	542	8244	28	255
C00 Lip						
Total:	36	0	0	36	0	0
Male:	31	0	0	31	0	0
Female:	5	0	0	5	0	0
C01 Base of tongue						
Total:	21	0	0	21	0	0
Male:	15	0	0	15	0	0
Female:	6	0	0	6	0	0
C02 Other and unspecified parts of tongue						
Total:	41	0	0	41	0	0
Male:	26	0	0	26	0	0
Female:	15	0	0	15	0	0
C03 Gum						
Total:	10	0	0	10	0	0
Male:	2	0	0	2	0	0
Female:	8	0	0	8	0	0
C04 Floor of mouth						
Total:	24	0	0	24	0	0
Male:	18	0	0	18	0	0
Female:	6	0	0	6	0	0
C05 Palate						
Total:	12	0	0	12	0	0
Male:	6	0	0	6	0	0
Female:	6	0	0	6	0	0
C06 Other and unspecified parts of mouth						
Total:	16	0	0	16	0	0
Male:	9	0	0	9	0	0
Female:	7	0	0	7	0	0
C07 Parotid gland						
Total:	29	0	0	29	0	0
Male:	14	0	0	14	0	0
Female:	15	0	0	15	0	0
C08 Other and unspecified major salivary glands						
Total:	6	0	1	5	0	0
Male:	1	0	0	1	0	0
Female:	5	0	1	4	0	0
C09 Tonsil						
Total:	44	0	1	42	0	1
Male:	31	0	1	29	0	1
Female:	13	0	0	13	0	0

Table A-3: (continued) Cancer registrations: site and sex by basis of diagnosis, 2004

	Total	Clinical	Radiological	Histological	Autopsy	Death certificate only
C10 Oropharynx						
Total:	9	0	0	9	0	0
Male:	5	0	0	5	0	0
Female:	4	0	0	4	0	0
C11 Nasopharynx						
Total:	22	0	0	22	0	0
Male:	13	0	0	13	0	0
Female:	9	0	0	9	0	0
C12 Pyriform sinus						
Total:	6	0	0	6	0	0
Male:	5	0	0	5	0	0
Female:	1	0	0	1	0	0
C13 Hypopharynx						
Total:	7	0	1	6	0	0
Male:	6	0	1	5	0	0
Female:	1	0	0	1	0	0
C14 Other and ill-defined sites in the lip, oral cavity and pharynx						
Total:	9	0	0	7	1	1
Male:	9	0	0	7	1	1
C15 Oesophagus						
Total:	253	0	23	222	0	8
Male:	181	0	18	156	0	7
Female:	72	0	5	66	0	1
C16 Stomach						
Total:	368	0	19	336	5	8
Male:	211	0	8	201	1	1
Female:	157	0	11	135	4	7
C17 Small intestine						
Total:	70	0	3	67	0	0
Male:	41	0	1	40	0	0
Female:	29	0	2	27	0	0
C18 Colon						
Total:	1812	6	87	1684	4	31
Male:	830	4	41	776	1	8
Female:	982	2	46	908	3	23
C19 Rectosigmoid junction						
Total:	205	0	6	198	1	0
Male:	110	0	3	106	1	0
Female:	95	0	3	92	0	0
C20 Rectum						
Total:	671	1	19	641	0	10
Male:	414	1	14	396	0	3
Female:	257	0	5	245	0	7
C21 Anus and anal canal						
Total:	47	0	2	45	0	0
Male:	16	0	0	16	0	0
Female:	31	0	2	29	0	0

Table A-3: (continued) Cancer registrations: site and sex by basis of diagnosis, 2004

	Total	Clinical	Radiological	Histological	Autopsy	Death certificate only
C22 Liver and intrahepatic bile ducts						
Total:	164	1	76	69	2	16
Male:	121	1	55	52	2	11
Female:	43	0	21	17	0	5
C23 Gallbladder						
Total:	58	0	17	39	1	1
Male:	16	0	6	9	1	0
Female:	42	0	11	30	0	1
C24 Other and unspecified parts of biliary tract						
Total:	60	0	19	38	0	3
Male:	26	0	8	17	0	1
Female:	34	0	11	21	0	2
C25 Pancreas						
Total:	360	0	166	155	5	34
Male:	176	0	71	88	4	13
Female:	184	0	95	67	1	21
C26 Other and ill-defined digestive organs						
Total:	73	0	9	25	1	38
Male:	29	0	3	13	0	13
Female:	44	0	6	12	1	25
C30 Nasal cavity and middle ear						
Total:	10	0	1	9	0	0
Male:	9	0	1	8	0	0
Female:	1	0	0	1	0	0
C31 Accessory sinuses						
Total:	3	0	1	2	0	0
Male:	1	0	0	1	0	0
Female:	2	0	1	1	0	0
C32 Larynx						
Total:	72	0	4	65	0	3
Male:	64	0	4	59	0	1
Female:	8	0	0	6	0	2
C33 Trachea						
Total:	3	0	0	3	0	0
Male:	3	0	0	3	0	0
C34 Bronchus and lung						
Total:	1816	3	300	1383	17	113
Male:	1067	0	162	826	13	66
Female:	749	3	138	557	4	47
C37 Thymus						
Total:	6	0	0	6	0	0
Male:	3	0	0	3	0	0
Female:	3	0	0	3	0	0
C38 Heart, mediastinum and pleura						
Total:	13	0	2	11	0	0
Male:	9	0	0	9	0	0
Female:	4	0	2	2	0	0

Table A-3: (continued) Cancer registrations: site and sex by basis of diagnosis, 2004

	Total	Clinical	Radiological	Histological	Autopsy	Death certificate only
C39 Other and ill-defined sites in the respiratory system and intrathoracic organs						
Total:	1	0	0	1	0	0
Male:	1	0	0	1	0	0
C40 Bone and articular cartilage of limbs						
Total:	25	0	0	25	0	0
Male:	10	0	0	10	0	0
Female:	15	0	0	15	0	0
C41 Bone and articular cartilage of other and unspecified sites						
Total:	21	0	1	19	1	0
Male:	14	0	1	13	0	0
Female:	7	0	0	6	1	0
C43 Malignant melanoma of skin						
Total:	1896	1	5	1887	0	3
Male:	949	1	3	944	0	1
Female:	947	0	2	943	0	2
C44 Other malignant neoplasms of skin						
Total:	105	0	0	105	0	0
Male:	59	0	0	59	0	0
Female:	46	0	0	46	0	0
C45 Mesothelioma						
Total:	82	0	8	74	0	0
Male:	75	0	8	67	0	0
Female:	7	0	0	7	0	0
C46 Kaposi's sarcoma						
Total:	6	0	2	4	0	0
Male:	6	0	2	4	0	0
C47 Peripheral nerves and autonomic nervous system						
Total:	7	0	0	7	0	0
Male:	2	0	0	2	0	0
Female:	5	0	0	5	0	0
C48 Retroperitoneum and peritoneum						
Total:	24	0	3	21	0	0
Male:	4	0	1	3	0	0
Female:	20	0	2	18	0	0
C49 Other connective and soft tissue						
Total:	104	0	2	101	0	1
Male:	55	0	1	54	0	0
Female:	49	0	1	47	0	1
C50 Breast						
Total:	2361	3	24	2309	0	25
Male:	22	0	1	21	0	0
Female:	2339	3	23	2288	0	25
C51 Vulva						
Total:	53	0	0	52	0	1
Female:	53	0	0	52	0	1

Table A-3: (continued) Cancer registrations: site and sex by basis of diagnosis, 2004

	Total	Clinical	Radiological	Histological	Autopsy	Death certificate only
C52 Vagina						
Total:	10	0	0	10	0	0
Female:	10	0	0	10	0	0
C53 Cervix uteri						
Total:	154	2	2	148	1	1
Female:	154	2	2	148	1	1
C54 Corpus uteri						
Total:	330	0	1	326	0	3
Female:	330	0	1	326	0	3
C55 Uterus, part unspecified						
Total:	11	0	3	3	0	5
Female:	11	0	3	3	0	5
C56 Ovary						
Total:	277	0	26	238	2	11
Female:	277	0	26	238	2	11
C57 Other and unspecified female genital organs						
Total:	19	0	0	19	0	0
Female:	19	0	0	19	0	0
C58 Placenta						
Total:	7	0	1	6	0	0
Female:	7	0	1	6	0	0
C60 Penis						
Total:	10	0	1	9	0	0
Male:	10	0	1	9	0	0
C61 Prostate						
Total:	2693	0	137	2499	5	52
Male:	2693	0	137	2499	5	52
C62 Testis						
Total:	138	1	2	134	0	1
Male:	138	1	2	134	0	1
C63 Other and unspecified male genital organs						
Total:	2	0	0	2	0	0
Male:	2	0	0	2	0	0
C64 Kidney, except renal pelvis						
Total:	401	2	66	306	11	16
Male:	256	2	45	192	8	9
Female:	145	0	21	114	3	7
C65 Renal pelvis						
Total:	33	0	0	33	0	0
Male:	15	0	0	15	0	0
Female:	18	0	0	18	0	0
C66 Ureter						
Total:	18	0	0	18	0	0
Male:	10	0	0	10	0	0
Female:	8	0	0	8	0	0

Table A-3: (continued) Cancer registrations: site and sex by basis of diagnosis, 2004

	Total	Clinical	Radiological	Histological	Autopsy	Death certificate only
C67 Bladder						
Total:	626	0	14	600	3	9
Male:	467	0	12	446	2	7
Female:	159	0	2	154	1	2
C68 Other and unspecified urinary organs						
Total:	21	0	0	21	0	0
Male:	13	0	0	13	0	0
Female:	8	0	0	8	0	0
C69 Eye and adnexa						
Total:	46	0	5	41	0	0
Male:	25	0	3	22	0	0
Female:	21	0	2	19	0	0
C70 Meninges						
Total:	2	0	0	2	0	0
Female:	2	0	0	2	0	0
C71 Brain						
Total:	260	0	49	201	2	8
Male:	146	0	29	113	1	3
Female:	114	0	20	88	1	5
C72 Spinal cord, cranial nerves and other parts of central nervous system						
Total:	8	0	2	6	0	0
Male:	3	0	1	2	0	0
Female:	5	0	1	4	0	0
C73 Thyroid gland						
Total:	191	0	1	186	4	0
Male:	55	0	0	53	2	0
Female:	136	0	1	133	2	0
C74 Adrenal gland						
Total:	6	0	0	5	0	1
Male:	4	0	0	3	0	1
Female:	2	0	0	2	0	0
C75 Other endocrine glands and related structures						
Total:	5	0	0	5	0	0
Male:	4	0	0	4	0	0
Female:	1	0	0	1	0	0
C76 Other and ill-defined sites						
Total:	16	0	5	5	0	6
Male:	4	0	1	1	0	2
Female:	12	0	4	4	0	4
C77 Secondary and unspecified lymph nodes						
Total:	57	0	1	55	0	1
Male:	38	0	1	37	0	0
Female:	19	0	0	18	0	1
C78 Secondary respiratory and digestive organs						
Total:	280	1	103	147	3	26
Male:	136	0	53	68	3	12
Female:	144	1	50	79	0	14

Table A-3: (continued) Cancer registrations: site and sex by basis of diagnosis, 2004

	Total	Clinical	Radiological	Histological	Autopsy	Death certificate only
C79 Secondary other sites						
Total:	95	0	36	53	0	6
Male:	49	0	19	28	0	2
Female:	46	0	17	25	0	4
C80 Malignant neoplasm without specification of site						
Total:	23	0	3	0	0	20
Male:	10	0	1	0	0	9
Female:	13	0	2	0	0	11
C81 Hodgkin lymphoma						
Total:	80	0	0	80	0	0
Male:	50	0	0	50	0	0
Female:	30	0	0	30	0	0
C82 Follicular [nodular] non-Hodgkin lymphoma						
Total:	124	0	0	124	0	0
Male:	70	0	0	70	0	0
Female:	54	0	0	54	0	0
C83 Diffuse non-Hodgkin lymphoma						
Total:	336	0	0	329	4	3
Male:	184	0	0	179	3	2
Female:	152	0	0	150	1	1
C84 Peripheral and cutaneous T-cell lymphomas						
Total:	56	0	0	55	1	0
Male:	34	0	0	33	1	0
Female:	22	0	0	22	0	0
C85 Other and unspecified types of non-Hodgkin lymphoma						
Total:	131	0	1	124	3	3
Male:	59	0	1	56	1	1
Female:	72	0	0	68	2	2
C88 Malignant immunoproliferative diseases						
Total:	32	0	0	32	0	0
Male:	21	0	0	21	0	0
Female:	11	0	0	11	0	0
C90 Multiple myeloma and malignant plasma cell neoplasms						
Total:	240	0	1	228	0	11
Male:	135	0	1	129	0	5
Female:	105	0	0	99	0	6
C91 Lymphoid leukaemia						
Total:	393	0	0	386	1	6
Male:	230	0	0	228	0	2
Female:	163	0	0	158	1	4
C92 Myeloid leukaemia						
Total:	198	0	0	196	0	2
Male:	95	0	0	95	0	0
Female:	103	0	0	101	0	2

Table A-3: (continued) Cancer registrations: site and sex by basis of diagnosis, 2004

	Total	Clinical	Radiological	Histological	Autopsy	Death certificate only
C93 Monocytic leukaemia						
Total:	10	0	0	10	0	0
Male:	5	0	0	5	0	0
Female:	5	0	0	5	0	0
C94 Other leukaemias of specified cell type						
Total:	52	0	1	51	0	0
Male:	28	0	1	27	0	0
Female:	24	0	0	24	0	0
C95 Leukaemia of unspecified cell type						
Total:	18	0	0	15	1	2
Male:	9	0	0	7	1	1
Female:	9	0	0	8	0	1
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue						
Total:	3	0	0	3	0	0
Male:	1	0	0	1	0	0
Female:	2	0	0	2	0	0
D45 Polycythaemia vera						
Total:	207	0	2	205	0	0
Male:	113	0	1	112	0	0
Female:	94	0	1	93	0	0
D46 Myelodysplastic syndromes						
Total:	384	0	2	381	0	1
Male:	231	0	2	229	0	0
Female:	153	0	0	152	0	1
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue						
Total:	179	0	0	179	0	0
Male:	85	0	0	85	0	0
Female:	94	0	0	94	0	0

Table A-4: Cancer registrations: selected sites by sex, age-standardised rates and numbers for total population, 1995–2004

Cancer site (ICD)	Year	Male				Female			
		Number	Age-standardised rate*	95% confidence interval		Number	Age-standardised rate*	95% confidence interval	
				Lower limit	Upper limit			Lower limit	Upper limit
All sites									
	1995	8538	369.2	377.0	377.0	7327	284.9	291.4	291.4
	1996	8553	362.0	369.7	369.7	7504	286.9	293.4	293.4
	1997	8423	347.7	355.1	355.1	7617	283.8	290.2	290.2
	1998	8842	357.0	364.4	364.4	7689	279.6	285.8	285.8
	1999	8927	354.1	361.4	361.4	7863	286.3	292.6	292.6
	2000	9468	370.4	377.9	377.9	8232	295.1	301.5	301.5
	2001	9563	362.3	369.6	369.6	8350	289.5	295.7	295.7
	2002	9399	348.2	355.2	355.2	8544	287.0	293.0	293.0
	2003	9856	356.2	363.3	363.3	8730	287.4	293.4	293.4
	2004	10,143	355.5	362.5	362.5	9080	291.4	297.4	297.4
Lip (C00)									
	1995	29	1.2	1.6	1.6	11	0.4	0.6	0.6
	1996	22	0.9	1.3	1.3	16	0.6	0.9	0.9
	1997	33	1.5	2.0	2.0	24	0.7	1.0	1.0
	1998	45	1.8	2.3	2.3	18	0.5	0.7	0.7
	1999	30	1.3	1.8	1.8	30	1.0	1.4	1.4
	2000	22	0.9	1.3	1.3	9	0.3	--	--
	2001	32	1.3	1.7	1.7	12	0.3	0.5	0.5
	2002	17	0.7	1.0	1.0	9	0.3	--	--
	2003	35	1.3	1.8	1.8	16	0.4	0.6	0.6
	2004	31	1.2	1.7	1.7	5	0.2	--	--
Tongue (C01+C02)									
	1995	48	2.3	3.0	3.0	16	0.6	0.9	0.9
	1996	32	1.4	1.9	1.9	9	0.2	--	--
	1997	37	1.6	2.1	2.1	29	0.9	1.2	1.2
	1998	34	1.5	2.0	2.0	23	0.9	1.3	1.3
	1999	31	1.4	1.9	1.9	24	0.9	1.3	1.3
	2000	45	1.8	2.3	2.3	15	0.5	0.8	0.8
	2001	30	1.2	1.6	1.6	18	0.7	1.0	1.0
	2002	33	1.3	1.7	1.7	20	0.6	0.9	0.9
	2003	43	1.8	2.3	2.3	28	0.8	1.1	1.1
	2004	41	1.6	2.0	2.0	21	0.6	0.9	0.9
Major salivary glands (C07+C08)									
	1995	19	0.8	1.2	1.2	14	0.5	0.8	0.8
	1996	16	0.7	1.0	1.0	12	0.5	0.8	0.8
	1997	20	0.9	1.3	1.3	12	0.4	0.6	0.6
	1998	24	1.0	1.4	1.4	13	0.5	0.8	0.8
	1999	29	1.2	1.6	1.6	11	0.5	0.8	0.8
	2000	24	1.0	1.4	1.4	12	0.5	0.8	0.8
	2001	18	0.7	1.0	1.0	16	0.6	0.9	0.9
	2002	14	0.6	0.9	0.9	19	0.7	1.0	1.0
	2003	13	0.5	0.7	0.7	20	0.7	1.0	1.0
	2004	15	0.5	0.8	0.8	20	0.7	0.9	0.9

Table A-4: (continued) Cancer registrations: selected sites by sex, age-standardised rates and numbers for total population, 1995–2004

Cancer site (ICD)	Year	Male				Female			
		Number	Age-standardised rate*	95% confidence interval		Number	Age-standardised rate*	95% confidence interval	
				Lower limit	Upper limit			Lower limit	Upper limit
Oesophagus (C15)									
	1995	143	6.1	7.1	7.1	64	1.9	2.4	2.4
	1996	127	5.1	6.0	6.0	71	2.2	2.7	2.7
	1997	139	5.6	6.5	6.5	69	1.8	2.2	2.2
	1998	109	4.2	5.0	5.0	57	1.5	1.9	1.9
	1999	147	5.7	6.6	6.6	76	2.1	2.6	2.6
	2000	146	5.5	6.4	6.4	79	2.0	2.4	2.4
	2001	143	5.2	6.1	6.1	75	1.9	2.3	2.3
	2002	154	5.4	6.3	6.3	82	2.2	2.6	2.6
	2003	159	5.6	6.5	6.5	98	2.5	3.0	3.0
	2004	181	6.0	6.9	6.9	72	1.8	2.2	2.2
Stomach (C16)									
	1995	232	9.7	10.9	10.9	135	4.3	5.0	5.0
	1996	251	10.5	11.8	11.8	151	4.6	5.3	5.3
	1997	241	9.9	11.1	11.1	160	4.6	5.3	5.3
	1998	249	9.9	11.1	11.1	162	5.1	5.9	5.9
	1999	252	9.7	10.9	10.9	135	4.1	4.8	4.8
	2000	216	8.1	9.2	9.2	143	4.5	5.2	5.2
	2001	229	8.1	9.1	9.1	149	4.4	5.1	5.1
	2002	264	9.5	10.7	10.7	144	4.4	5.1	5.1
	2003	251	8.7	9.8	9.8	140	3.9	4.6	4.6
	2004	211	7.5	8.5	8.5	157	4.2	4.9	4.9
Colon (C18)									
	1995	726	31.2	33.5	33.5	840	29.2	31.2	31.2
	1996	756	31.8	34.1	34.1	866	29.2	31.1	31.1
	1997	719	29.4	31.5	31.5	811	27.2	29.1	29.1
	1998	765	30.8	33.0	33.0	856	28.1	30.0	30.0
	1999	819	32.0	34.2	34.2	881	28.0	29.8	29.8
	2000	740	27.7	29.7	29.7	904	27.9	29.7	29.7
	2001	807	29.5	31.5	31.5	941	27.5	29.3	29.3
	2002	812	29.2	31.2	31.2	907	26.2	27.9	27.9
	2003	809	27.9	29.8	29.8	949	26.5	28.1	28.1
	2004	830	27.5	29.4	29.4	982	26.9	28.5	28.5
Rectum, rectosigmoid junction and anus (C19–C21)									
	1995	476	20.9	22.8	22.8	361	13.0	14.3	14.3
	1996	491	21.5	23.4	23.4	321	11.6	12.9	12.9
	1997	474	20.1	21.9	21.9	326	11.5	12.5	12.5
	1998	473	19.7	21.5	21.5	339	11.7	12.9	12.9
	1999	489	19.8	21.6	21.6	365	12.0	13.2	13.2
	2000	503	19.7	21.4	21.4	365	12.9	14.2	14.2
	2001	517	19.4	21.1	21.1	359	11.8	13.0	13.0
	2002	514	19.1	20.7	20.7	355	11.2	12.4	12.4
	2003	557	20.2	21.9	21.9	385	11.8	12.9	12.9
	2004	540	18.6	20.2	20.2	383	12.0	13.2	13.2

Table A-4: (continued) Cancer registrations: selected sites by sex, age-standardised rates and numbers for total population, 1995–2004

Cancer site (ICD)	Year	Male			Female				
		Number	Age-standardised rate*	95% confidence interval Lower limit Upper limit	Number	Age-standardised rate*	95% confidence interval Lower limit Upper limit		
Colorectum and anus (C18–C21)									
	1995	1202	52.1	55.0	55.0	1201	42.2	44.6	44.6
	1996	1247	53.3	56.3	56.3	1187	40.8	43.1	43.1
	1997	1193	49.5	52.3	52.3	1137	38.7	40.9	40.9
	1998	1238	50.5	53.3	53.3	1195	39.8	42.1	42.1
	1999	1308	51.8	54.6	54.6	1246	40.0	42.2	42.2
	2000	1243	47.4	50.0	50.0	1269	40.7	42.9	42.9
	2001	1324	48.9	51.5	51.5	1300	39.3	41.4	41.4
	2002	1326	48.2	50.8	50.8	1262	37.4	39.5	39.5
	2003	1366	48.2	50.7	50.7	1334	38.2	40.3	40.3
	2004	1370	46.1	48.6	48.6	1365	38.9	41.0	41.0
Pancreas (C25)									
	1995	138	5.8	6.8	6.8	160	5.2	6.0	6.0
	1996	145	6.0	7.0	7.0	174	5.7	6.5	6.5
	1997	151	6.3	7.3	7.3	160	4.7	5.4	5.4
	1998	170	6.8	7.8	7.8	161	5.0	5.8	5.8
	1999	162	6.3	7.3	7.3	129	3.9	4.6	4.6
	2000	159	5.8	6.7	6.7	167	5.0	5.8	5.8
	2001	159	6.0	6.9	6.9	147	4.0	4.6	4.6
	2002	159	5.8	6.6	6.6	167	4.4	5.0	5.0
	2003	174	6.1	7.0	7.0	173	4.4	5.1	5.1
	2004	176	6.3	7.2	7.2	184	4.7	5.4	5.4
Trachea, bronchus and lung (C33+C34)									
	1995	967	41.3	43.9	43.9	535	19.9	21.6	21.6
	1996	967	40.4	42.9	42.9	576	21.6	23.4	23.4
	1997	936	37.6	40.0	40.0	602	22.2	24.0	24.0
	1998	935	37.5	39.9	39.9	541	19.3	20.9	20.9
	1999	941	36.0	38.3	38.3	585	20.3	21.9	21.9
	2000	949	35.5	37.8	37.8	650	22.3	24.0	24.0
	2001	882	31.9	34.0	34.0	647	21.5	23.1	23.1
	2002	931	32.7	34.8	34.8	688	21.6	23.2	23.2
	2003	1032	35.2	37.4	37.4	771	25.5	27.3	27.3
	2004	1070	36.0	38.2	38.2	749	23.2	24.9	24.9
Melanoma of the skin (C43)									
	1995	879	40.2	42.9	42.9	880	37.7	40.2	40.2
	1996	785	35.0	37.4	37.4	800	32.6	34.9	34.9
	1997	745	32.2	34.5	34.5	736	29.2	31.3	31.3
	1998	779	32.1	34.4	34.4	727	28.1	30.1	30.1
	1999	783	32.6	34.9	34.9	719	27.9	29.9	29.9
	2000	818	33.6	35.9	35.9	842	32.2	34.4	34.4
	2001	869	34.8	37.2	37.2	888	32.7	34.8	34.8
	2002	933	36.3	38.7	38.7	909	33.6	35.8	35.8
	2003	962	36.0	38.3	38.3	892	32.1	34.3	34.3
	2004	949	34.5	36.7	36.7	947	32.4	34.5	34.5

Table A-4: (continued) Cancer registrations: selected sites by sex, age-standardised rates and numbers for total population, 1995–2004

Cancer site (ICD)	Year	Male				Female			
		Number	Age-standardised rate*	95% confidence interval		Number	Age-standardised rate*	95% confidence interval	
				Lower limit	Upper limit			Lower limit	Upper limit
Breast (C50)									
	1995	1865	77.4	80.9	80.9
	1996	1906	78.4	81.9	81.9
	1997	1990	80.2	83.7	83.7
	1998	12	0.4	0.6	0.6	2071	81.1	84.6	84.6
	1999	16	0.6	0.9	0.9	2235	87.6	91.2	91.2
	2000	12	0.5	0.8	0.8	2306	89.4	93.0	93.0
	2001	17	0.6	0.9	0.9	2310	86.6	90.2	90.2
	2002	15	0.5	0.7	0.7	2364	86.0	89.4	89.4
	2003	12	0.4	0.7	0.7	2325	81.5	84.8	84.8
	2004	22	0.8	1.1	1.1	2339	81.7	85.0	85.0
Cervix uteri (C53)									
	1995	232	10.2	11.5	11.5
	1996	219	9.8	11.1	11.1
	1997	218	8.9	10.1	10.1
	1998	210	8.5	9.6	9.6
	1999	222	9.2	10.4	10.4
	2000	205	8.5	9.7	9.7
	2001	189	7.9	9.0	9.0
	2002	180	6.8	7.8	7.8
	2003	177	7.0	8.1	8.1
	2004	154	5.9	6.8	6.8
Corpus uteri and uterus part unspecified (C54+C55)									
	1995	234	9.6	10.8	10.8
	1996	277	11.3	12.6	12.6
	1997	272	10.7	12.0	12.0
	1998	279	10.8	12.1	12.1
	1999	316	11.8	13.1	13.1
	2000	281	10.6	11.8	11.8
	2001	311	11.5	12.7	12.7
	2002	314	11.2	12.4	12.4
	2003	325	8.3	9.2	9.2
	2004	341	11.7	13.0	13.0
Ovary and other uterine adenexa (C56+C57)									
	1995	291	11.9	13.3	13.3
	1996	288	11.7	13.1	13.1
	1997	268	10.6	11.9	11.9
	1998	289	11.5	12.8	12.8
	1999	308	12.0	13.3	13.3
	2000	301	11.2	12.5	12.5
	2001	316	11.7	13.0	13.0
	2002	325	11.5	12.7	12.7
	2003	264	9.1	10.2	10.2
	2004	296	9.7	10.7	10.7

Table A-4: (continued) Cancer registrations: selected sites by sex, age-standardised rates and numbers for total population, 1995–2004

Cancer site (ICD)	Year	Male				Female			
		Number	Age-standardised rate*	95% confidence interval		Number	Age-standardised rate*	95% confidence interval	
				Lower limit	Upper limit			Lower limit	Upper limit
Prostate (C61)									
	1995	2481	101.0	105.0	105.0
	1996	2439	97.7	101.6	101.6
	1997	2336	91.4	95.1	95.1
	1998	2494	96.2	100.0	100.0
	1999	2590	98.2	102.0	102.0
	2000	3045	117.1	121.3	121.3
	2001	3046	113.8	117.9	117.9
	2002	2656	96.9	100.6	100.6
	2003	2696	97.9	101.6	101.6
	2004	2693	94.6	98.2	98.2
Testis (C62)									
	1995	115	5.7	6.7	6.7
	1996	123	6.0	7.1	7.1
	1997	138	6.8	7.9	7.9
	1998	126	6.1	7.2	7.2
	1999	125	6.3	7.4	7.4
	2000	143	7.2	8.4	8.4
	2001	132	6.4	7.5	7.5
	2002	167	7.8	9.0	9.0
	2003	136	6.5	7.6	7.6
	2004	138	6.6	7.7	7.7
Penis and other male genital organs (C60+C63)									
	1995	15	0.6	0.9	0.9
	1996	10	0.5	--	--
	1997	11	0.4	0.6	0.6
	1998	16	0.6	0.9	0.9
	1999	12	0.5	0.8	0.8
	2000	16	0.7	1.0	1.0
	2001	19	0.7	1.1	1.1
	2002	18	0.7	1.0	1.0
	2003	9	0.3	--	--
	2004	12	0.4	0.6	0.6
Bladder (C67)									
	1995	366	15.5	17.1	17.1	140	4.5	5.2	5.2
	1996	401	16.0	17.6	17.6	137	4.2	4.9	4.9
	1997	374	14.6	16.1	16.1	137	4.0	4.7	4.7
	1998	431	16.5	18.1	18.1	152	4.5	5.2	5.2
	1999	410	15.7	17.2	17.2	149	4.3	5.0	5.0
	2000	407	14.7	16.1	16.1	169	5.1	5.9	5.9
	2001	436	15.1	16.5	16.5	150	4.2	4.9	4.9
	2002	432	14.7	16.1	16.1	158	3.9	4.5	4.5
	2003	449	14.9	16.2	16.2	150	4.4	5.1	5.1
	2004	467	15.0	16.3	16.3	159	4.1	4.8	4.8

Table A-4: (continued) Cancer registrations: selected sites by sex, age-standardised rates and numbers for total population, 1995–2004

Cancer site (ICD)	Year	Male				Female			
		Number	Age-standardised rate*	95% confidence interval		Number	Age-standardised rate*	95% confidence interval	
				Lower limit	Upper limit			Lower limit	Upper limit
Kidney and other unspecified urinary organs (C64+C65+C66+C68)									
	1995	185	8.5	9.7	9.7	121	4.7	5.5	5.5
	1996	202	9.0	10.2	10.2	126	4.8	5.6	5.6
	1997	233	9.8	11.1	11.1	158	5.9	6.8	6.8
	1998	214	9.1	10.3	10.3	118	4.1	4.8	4.8
	1999	237	9.5	10.7	10.7	147	5.5	6.4	6.4
	2000	227	9.0	10.2	10.2	124	4.3	5.1	5.1
	2001	247	9.4	10.6	10.6	149	5.5	6.4	6.4
	2002	236	8.9	10.1	10.1	149	5.1	6.0	6.0
	2003	260	9.4	10.6	10.6	155	5.3	6.2	6.2
	2004	294	10.7	12.0	12.0	179	5.9	6.8	6.8
Eye and adnexa (C69)									
	1995	20	1.0	1.4	1.4	21	1.0	1.4	1.4
	1996	31	1.5	2.0	2.0	26	1.2	1.7	1.7
	1997	34	1.5	2.0	2.0	27	1.2	1.7	1.7
	1998	39	1.5	2.0	2.0	24	1.0	1.4	1.4
	1999	22	1.1	1.6	1.6	23	1.0	1.4	1.4
	2000	31	1.4	1.9	1.9	23	0.9	1.3	1.3
	2001	28	1.0	1.4	1.4	31	1.2	1.6	1.6
	2002	19	0.8	1.2	1.2	24	1.0	1.5	1.5
	2003	30	1.3	1.7	1.7	24	1.0	1.4	1.4
	2004	25	1.2	1.6	1.6	21	0.8	1.1	1.1
Brain (C71)									
	1995	102	5.0	6.0	6.0	104	4.6	5.5	5.5
	1996	160	7.9	9.1	9.1	116	5.1	6.0	6.0
	1997	142	6.9	8.0	8.0	95	4.0	4.8	4.8
	1998	151	7.1	8.2	8.2	100	4.1	4.9	4.9
	1999	141	6.4	7.5	7.5	96	4.0	4.8	4.8
	2000	155	7.0	8.1	8.1	98	4.0	4.8	4.8
	2001	146	6.4	7.5	7.5	108	4.6	5.5	5.5
	2002	179	7.4	8.5	8.5	101	3.9	4.7	4.7
	2003	134	5.7	6.6	6.6	113	4.4	5.2	5.2
	2004	146	5.8	6.7	6.7	114	4.2	5.0	5.0
Other and unspecified parts of the nervous system (C70+C72)									
	1995	7	0.4	--	--	8	0.4	--	--
	1996	5	0.3	--	--	5	0.3	--	--
	1997	7	0.3	--	--	8	0.5	--	--
	1998	5	0.3	--	--	5	0.2	--	--
	1999	3	0.2	--	--	7	0.4	--	--
	2000	6	0.4	--	--	12	0.6	0.9	0.9
	2001	3	0.1	--	--	8	0.4	--	--
	2002	6	0.4	--	--	3	0.1	--	--
	2003	7	0.3	--	--	10	0.4	--	--
	2004	3	0.2	--	--	7	0.3	--	--

Table A-4: (continued) Cancer registrations: selected sites by sex, age-standardised rates and numbers for total population, 1995–2004

Cancer site (ICD)	Year	Male				Female			
		Number	Age-standardised rate*	95% confidence interval		Number	Age-standardised rate*	95% confidence interval	
				Lower limit	Upper limit			Lower limit	Upper limit
Thyroid gland (C73)									
	1995	39	1.9	2.5	2.5	78	3.4	4.2	4.2
	1996	34	1.6	2.1	2.1	82	3.5	4.3	4.3
	1997	52	2.4	3.1	3.1	116	5.1	6.0	6.0
	1998	33	1.5	2.0	2.0	114	5.0	5.9	5.9
	1999	35	1.6	2.1	2.1	137	6.2	7.2	7.2
	2000	45	2.0	2.6	2.6	116	5.0	5.9	5.9
	2001	31	1.4	1.9	1.9	112	4.5	5.4	5.4
	2002	36	1.5	2.0	2.0	116	4.7	5.6	5.6
	2003	56	2.4	3.0	3.0	128	5.1	6.0	6.0
	2004	55	2.3	2.9	2.9	136	5.3	6.2	6.2
Hodgkin lymphoma (C81)									
	1995	53	2.7	3.4	3.4	19	0.9	1.3	1.3
	1996	37	1.8	2.4	2.4	33	1.6	2.1	2.1
	1997	32	1.6	2.2	2.2	26	1.3	1.8	1.8
	1998	40	2.1	2.8	2.8	29	1.4	1.9	1.9
	1999	37	1.8	2.4	2.4	28	1.3	1.8	1.8
	2000	40	2.0	2.6	2.6	34	1.7	2.3	2.3
	2001	38	1.8	2.4	2.4	50	2.3	2.9	2.9
	2002	46	2.1	2.7	2.7	42	2.0	2.5	2.5
	2003	47	2.2	2.8	2.8	27	1.2	1.7	1.7
	2004	50	2.0	2.5	2.5	30	1.4	1.9	1.9
Non-Hodgkin lymphoma (C82–C85+C96)									
	1995	276	12.7	14.2	14.2	231	9.2	10.4	10.4
	1996	302	13.5	15.0	15.0	274	10.4	11.6	11.6
	1997	304	13.0	14.5	14.5	283	9.9	11.1	11.1
	1998	323	13.8	15.3	15.3	300	10.3	11.5	11.5
	1999	336	13.9	15.4	15.4	250	8.7	9.8	9.8
	2000	299	11.9	13.2	13.2	262	9.0	10.1	10.1
	2001	335	12.8	14.2	14.2	290	9.4	10.5	10.5
	2002	297	11.1	9.9	12.4	340	11.1	12.3	12.2
	2003	352	13.1	14.5	14.5	272	8.8	9.8	9.8
	2004	348	12.7	14.0	14.0	302	9.5	10.6	10.6
Multiple myeloma and immunoproliferative neoplasms (C88+C90)									
	1995	109	4.7	5.6	5.6	89	2.9	3.5	3.5
	1996	118	4.9	5.8	5.8	97	3.0	3.6	3.6
	1997	112	4.3	5.1	5.1	102	3.3	3.9	3.9
	1998	126	4.8	5.6	5.6	103	3.0	3.6	3.6
	1999	127	4.9	5.8	5.8	85	2.5	3.0	3.0
	2000	161	5.8	6.7	6.7	119	3.5	4.1	4.1
	2001	161	5.8	6.8	6.8	113	3.4	4.0	4.0
	2002	190	6.6	7.5	7.5	122	3.7	4.3	4.3
	2003	147	4.9	5.7	5.7	129	0.8	0.9	0.9
	2004	156	5.2	6.0	6.0	116	3.6	4.2	4.2

Table A-4: (continued) Cancer registrations: selected sites by sex, age-standardised rates and numbers for total population, 1995–2004

Cancer site (ICD)	Year	Male				Female			
		Number	Age-standardised rate*	95% confidence interval		Number	Age-standardised rate*	95% confidence interval	
				Lower limit	Upper limit			Lower limit	Upper limit
Lymphoid leukaemia (C91)									
	1995	126	6.2	7.3	7.3	75	2.9	3.6	3.6
	1996	121	5.6	6.6	6.6	104	4.0	4.8	4.8
	1997	178	8.0	9.2	9.2	126	4.7	5.5	5.5
	1998	182	7.6	8.7	8.7	114	3.7	4.4	4.4
	1999	161	7.2	8.3	8.3	101	3.8	4.5	4.5
	2000	227	10.2	11.5	11.5	128	4.7	5.5	5.5
	2001	229	9.9	11.2	11.2	145	5.2	6.1	6.1
	2002	259	10.3	11.6	11.6	181	6.2	7.1	7.1
	2003	282	10.8	12.1	12.1	195	6.8	7.8	7.8
	2004	230	8.3	9.4	9.4	163	5.9	6.8	6.8
Myeloid leukaemia (C92)									
	1995	108	4.8	5.7	5.7	88	3.5	4.2	4.2
	1996	117	5.0	5.9	5.9	104	3.9	4.6	4.6
	1997	100	4.2	5.0	5.0	94	3.6	4.3	4.3
	1998	130	5.3	6.2	6.2	103	3.6	4.3	4.3
	1999	115	4.8	5.7	5.7	82	2.9	3.5	3.5
	2000	123	5.0	5.9	5.9	99	3.6	4.3	4.3
	2001	121	4.7	5.6	5.6	107	3.8	4.5	4.5
	2002	119	4.6	5.5	5.5	111	3.7	4.4	4.4
	2003	96	3.4	4.1	4.1	85	3.0	3.7	3.7
	2004	95	3.6	4.3	4.3	103	3.5	4.2	4.2
All leukaemias (C91–C95)									
	1995	253	11.8	13.3	13.3	177	6.9	7.9	7.9
	1996	256	11.4	12.8	12.8	213	8.0	9.1	9.1
	1997	287	12.6	14.1	14.1	235	8.9	10.0	10.0
	1998	323	13.3	14.8	14.8	230	7.6	8.6	8.6
	1999	289	12.5	13.9	13.9	196	7.1	8.1	8.1
	2000	363	15.6	17.2	17.2	239	8.6	9.7	9.7
	2001	363	15.0	16.6	16.6	266	9.3	10.5	10.5
	2002	392	15.5	17.0	17.0	303	10.2	11.3	11.3
	2003	433	16.0	17.5	17.5	319	10.8	11.9	11.9
	2004	367	13.2	14.5	14.5	304	10.6	11.8	11.8

Notes:

* = rate per 100,000 age-standardised to Segi's world population

.. = data not available

... = not applicable

-- = amount too small to be calculated

Table A-5: Cancer registrations: site by ethnicity, total registrations, 2004

	Total					Male					Female				
	Māori	Pacific peoples	Other	Not stated	Total	Māori	Pacific peoples	Other	Not stated	Total	Māori	Pacific peoples	Other	Not stated	Total
C00 Lip	0	0	36	0	36	0	0	31	0	31	0	0	5	0	5
C01 Base of tongue	2	0	19	0	21	1	0	14	0	15	1	0	5	0	6
C02 Other and unspecified parts of tongue	4	1	34	2	41	1	1	23	1	26	3	0	11	1	15
C03 Gum	0	0	10	0	10	0	0	2	0	2	0	0	8	0	8
C04 Floor of mouth	6	0	18	0	24	5	0	13	0	18	1	0	5	0	6
C05 Palate	0	0	12	0	12	0	0	6	0	6	0	0	6	0	6
C06 Other and unspecified parts of mouth	1	0	14	1	16	0	0	8	1	9	1	0	6	0	7
C07 Parotid gland	5	1	22	1	29	4	0	10	0	14	1	1	12	1	15
C08 Other and unspecified major salivary glands	1	0	4	1	6	0	0	1	0	1	1	0	3	1	5
C09 Tonsil	6	1	37	0	44	6	0	25	0	31	0	1	12	0	13
C10 Oropharynx	0	0	9	0	9	0	0	5	0	5	0	0	4	0	4
C11 Nasopharynx	2	2	18	0	22	0	2	11	0	13	2	0	7	0	9
C12 Pyriform sinus	3	0	3	0	6	2	0	3	0	5	1	0	0	0	1
C13 Hypopharynx	1	0	6	0	7	1	0	5	0	6	0	0	1	0	1
C14 Other and ill-defined sites in the lip, oral cavity and pharynx	0	0	9	0	9	0	0	9	0	9	0	0	0	0	0
C15 Oesophagus	15	5	233	0	253	10	5	166	0	181	5	0	67	0	72
C16 Stomach	60	15	288	5	368	33	8	167	3	211	27	7	121	2	157
C17 Small intestine	8	2	60	0	70	8	1	32	0	41	0	1	28	0	29
C18 Colon	55	20	1726	11	1812	27	8	789	6	830	28	12	937	5	982
C19 Rectosigmoid junction	5	4	196	0	205	1	3	106	0	110	4	1	90	0	95
C20 Rectum	27	11	627	6	671	15	4	391	4	414	12	7	236	2	257
C21 Anus and anal canal	3	0	43	1	47	0	0	16	0	16	3	0	27	1	31
C22 Liver and intrahepatic bile ducts	25	23	116	0	164	21	19	81	0	121	4	4	35	0	43
C23 Gallbladder	9	3	46	0	58	0	2	14	0	16	9	1	32	0	42
C24 Other and unspecified parts of biliary tract	4	2	54	0	60	1	0	25	0	26	3	2	29	0	34
C25 Pancreas	35	7	318	0	360	20	3	153	0	176	15	4	165	0	184
C26 Other and ill-defined digestive organs	3	1	69	0	73	3	0	26	0	29	0	1	43	0	44
C30 Nasal cavity and middle ear	1	0	9	0	10	1	0	8	0	9	0	0	1	0	1
C31 Accessory sinuses	2	0	1	0	3	1	0	0	0	1	1	0	1	0	2
C32 Larynx	10	4	57	1	72	9	4	50	1	64	1	0	7	0	8
C33 Trachea	0	1	2	0	3	0	1	2	0	3	0	0	0	0	0
C34 Bronchus and lung	279	76	1450	11	1816	141	48	871	7	1067	138	28	579	4	749
C37 Thymus	0	1	5	0	6	0	0	3	0	3	0	1	2	0	3
C38 Heart, mediastinum and pleura	1	1	11	0	13	0	1	8	0	9	1	0	3	0	4
C39 Other and ill-defined sites in the respiratory system and intrathoracic organs	0	0	1	0	1	0	0	1	0	1	0	0	0	0	0

Table A-5: (continued) Cancer registrations: site by ethnicity, total registrations, 2004

	Total					Male					Female				
	Māori	Pacific peoples	Other	Not stated	Total	Māori	Pacific peoples	Other	Not stated	Total	Māori	Pacific peoples	Other	Not stated	Total
C40 Bone and articular cartilage of limbs	3	1	21	0	25	2	0	8	0	10	1	1	13	0	15
C41 Bone and articular cartilage of other and unspecified sites	5	1	14	1	21	2	0	11	1	14	3	1	3	0	7
C43 Malignant melanoma of skin	17	4	1661	214	1896	5	1	808	135	949	12	3	853	79	947
C44 Other malignant neoplasms of skin	5	2	89	9	105	1	1	50	7	59	4	1	39	2	46
C45 Mesothelioma	1	1	80	0	82	1	1	73	0	75	0	0	7	0	7
C46 Kaposi's sarcoma	0	0	6	0	6	0	0	6	0	6	0	0	0	0	0
C47 Peripheral nerves and autonomic nervous system	1	1	5	0	7	1	0	1	0	2	0	1	4	0	5
C48 Retroperitoneum and peritoneum	4	1	18	1	24	1	0	2	1	4	3	1	16	0	20
C49 Other connective and soft tissue	7	3	92	2	104	2	3	48	2	55	5	0	44	0	49
C50 Breast	196	69	2019	77	2361	0	1	20	1	22	196	68	1999	76	2339
C51 Vulva	2	0	51	0	53	2	0	51	0	53
C52 Vagina	0	1	9	0	10	0	1	9	0	10
C53 Cervix uteri	27	6	120	1	154	27	6	120	1	154
C54 Corpus uteri	30	33	264	3	330	30	33	264	3	330
C55 Uterus, part unspecified	0	0	11	0	11	0	0	11	0	11
C56 Ovary	26	10	240	1	277	26	10	240	1	277
C57 Other and unspecified female genital organs	0	1	18	0	19	0	1	18	0	19
C58 Placenta	1	1	5	0	7	1	1	5	0	7
C60 Penis	0	0	10	0	10	0	0	10	0	10
C61 Prostate	123	49	2244	277	2693	123	49	2244	277	2693
C62 Testis	25	2	103	8	138	25	2	103	8	138
C63 Other and unspecified male genital organs	0	0	2	0	2	0	0	2	0	2
C64 Kidney, except renal pelvis	28	6	355	12	401	21	4	220	11	256	7	2	135	1	145
C65 Renal pelvis	0	0	33	0	33	0	0	15	0	15	0	0	18	0	18
C66 Ureter	1	0	17	0	18	0	0	10	0	10	1	0	7	0	8
C67 Bladder	24	6	573	23	626	16	5	431	15	467	8	1	142	8	159
C68 Other and unspecified urinary organs	1	0	20	0	21	0	0	13	0	13	1	0	7	0	8
C69 Eye and adnexa	3	1	39	3	46	2	1	21	1	25	1	0	18	2	21
C70 Meninges	0	0	2	0	2	0	0	0	0	0	0	0	2	0	2
C71 Brain	13	6	239	2	260	6	3	135	2	146	7	3	104	0	114
C72 Spinal cord, cranial nerves and other parts of central nervous system	1	1	6	0	8	0	0	3	0	3	1	1	3	0	5
C73 Thyroid gland	23	11	150	7	191	7	2	44	2	55	16	9	106	5	136
C74 Adrenal gland	0	1	5	0	6	0	1	3	0	4	0	0	2	0	2
C75 Other endocrine glands and related structures	2	1	2	0	5	2	0	2	0	4	0	1	0	0	1
C76 Other and ill-defined sites	3	0	13	0	16	1	0	3	0	4	2	0	10	0	12

Table A-5: (continued) Cancer registrations: site by ethnicity, total registrations, 2004

	Total					Male					Female				
	Māori	Pacific peoples	Other	Not stated	Total	Māori	Pacific peoples	Other	Not stated	Total	Māori	Pacific peoples	Other	Not stated	Total
C77 Secondary and unspecified lymph nodes	4	2	50	1	57	1	2	35	0	38	3	0	15	1	19
C78 Secondary respiratory and digestive systems	29	10	239	2	280	17	5	113	1	136	12	5	126	1	144
C79 Secondary other sites	9	4	82	0	95	4	1	44	0	49	5	3	38	0	46
C80 Malignant neoplasm without specification of site	2	1	20	0	23	1	1	8	0	10	1	0	12	0	13
C81 Hodgkin's disease	7	3	69	1	80	4	2	43	1	50	3	1	26	0	30
C82 Follicular [nodular] non-Hodgkin lymphoma	1	0	118	5	124	0	0	68	2	70	1	0	50	3	54
C83 Diffuse non-Hodgkin lymphoma	18	12	298	8	336	12	7	160	5	184	6	5	138	3	152
C84 Peripheral and cutaneous T-cell lymphomas	4	3	46	3	56	3	1	28	2	34	1	2	18	1	22
C85 Other and unspecified types of non-Hodgkin's lymphoma	6	2	122	1	131	4	0	54	1	59	2	2	68	0	72
C88 Malignant immunoproliferative diseases	0	1	30	1	32	0	1	20	0	21	0	0	10	1	11
C90 Multiple myeloma and malignant plasma cell neoplasms	25	11	200	4	240	14	6	111	4	135	11	5	89	0	105
C91 Lymphoid leukaemia	22	6	333	32	393	15	4	195	16	230	7	2	138	16	163
C92 Myeloid leukaemia	16	5	175	2	198	3	1	89	2	95	13	4	86	0	103
C93 Monocytic leukaemia	3	0	7	0	10	0	0	5	0	5	3	0	2	0	5
C94 Other leukaemias of specified cell type	3	2	47	0	52	2	1	25	0	28	1	1	22	0	24
C95 Leukaemia of unspecified cell type	3	0	15	0	18	0	0	9	0	9	3	0	6	0	9
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	0	0	2	1	3	0	0	1	0	1	0	0	1	1	2
D45 Polycythaemia vera	40	12	152	3	207	24	10	77	2	113	16	2	75	1	94
D46 Myelodysplastic syndromes	9	8	359	8	384	5	2	218	6	231	4	6	141	2	153
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue	18	9	147	5	179	7	4	72	2	85	11	5	75	3	94
Total New Zealand	1364	491	16,610	758	19,223	645	232	8736	530	10,143	719	259	7874	228	9080

Notes:

... = not applicable

Table A-6: Selected cancer site: registrations and deaths of Pacific peoples by sex, 2004

Cancer site	Registrations				Deaths			
	Male No.	Rate*	Female No.	Rate*	Male No.	Rate*	Female No.	Rate*
Oesophagus (C15)	5	--	0	--	4	--	0	--
Stomach (C16)	8	10.2	7	7.7	6	9.0	3	--
Colorectum and anus (C18–C21)	15	21.2	20	21.2	7	10.9	9	9.1
Liver and intrahepatic bile ducts (C22)	19	25.4	4	--	22	30.3	5	--
Pancreas (C25)	3	--	4	--	7	8.7	2	--
Trachea, bronchus and lung (C33–C34)	49	69.1	28	29.5	44	65.6	15	19.2
Malignant melanoma of skin (C43)	1	--	3	--	0	--	1	--
Breast (C50)	1	--	68	64.8	0	--	28	31.1
Cervix uteri (C53)	6	5.4	4	--
Corpus uteri (C54)	33	37.5	6	7.4
Ovary (C56)	10	10.3	2	--
Prostate (C61)	49	73.8	11	19.9
Kidney, except renal pelvis (C64)	4	--	2	--	1	--	1	--
Bladder (C67)	5	--	1	--	2	--	1	--
Brain (C71)	3	--	3	--	3	--	1	--
Thyroid gland (C73)	2	--	9	7.7	0	--	2	--
Non-Hodgkin lymphoma (C82–C85, C96)	8	7.4	9	10.6	7	9.1	8	8.9
Multiple myeloma and malignant plasma cell neoplasms (C90)	6	8.3	5	--	4	--	2	--
Leukaemia (C91–C95)	6	6.6	7	6.9	6	8.0	6	5.9
Chronic myeloproliferative disorders and myelodysplastic syndromes (D45–D47)	16	20.0	13	14.5	2	--	1	--
All other sites	32	...	27
All sites	232	319.1	259	265.5	149	219.8	114	130.1

Notes:

No. = number

* = rate age-standardised to Segi's world population

... = not applicable

-- = number too small to be calculated

Table A-7: Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								Total 15-24
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	
All sites	296	13	39	33	39	124	65	107	172
C05 Palate									
Mucoepidermoid carcinoma									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
C06 Other and unspecified parts of mouth									
Embryonal rhabdomyosarcoma									
Total	1	0	0	1	0	1	0	0	0
Male	1	0	0	1	0	1	0	0	0
C07 Parotid gland									
Adenocarcinoma, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Acinar cell carcinoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
C11 Nasopharynx									
Lymphoepithelial carcinoma									
Total	2	0	0	0	1	1	1	0	1
Male	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	1	1	0	0	0
C16 Stomach									
Carcinoma, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Adenocarcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Signet ring cell carcinoma									
Total	3	0	0	0	0	0	0	3	3
Male	2	0	0	0	0	0	0	2	2
Female	1	0	0	0	0	0	0	1	1
C18 Colon									
Adenocarcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Adenocarcinoma in villous adenoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Mucinous adenocarcinoma									
Total	3	0	0	0	0	0	0	3	3
Female	3	0	0	0	0	0	0	3	3
C19 Rectosigmoid junction									
Adenocarcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1

Table A-7: (continued) Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
C22 Liver and intrahepatic bile ducts									
Cholangiocarcinoma									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Hepatoblastoma									
Total	1	0	1	0	0	1	0	0	0
Female	1	0	1	0	0	1	0	0	0
Epithelioid haemangioendothelioma, malignant									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
C25 Pancreas									
Adenocarcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
C34 Bronchus and lung									
Atypical carcinoid tumour									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
C37 Thymus									
Teratoma, malignant, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
C38 Heart, mediastinum and pleura									
Ewing sarcoma									
Total	1	0	0	0	1	1	0	0	0
Male	1	0	0	0	1	1	0	0	0
C40 Bone and articular cartilage of limbs									
Osteosarcoma, not otherwise specified									
Total	6	0	0	1	2	3	3	0	3
Male	3	0	0	0	1	1	2	0	2
Female	3	0	0	1	1	2	1	0	1
Chondroblastic osteosarcoma									
Total	2	0	0	0	1	1	0	1	1
Male	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	1	1	0	0	0
Parosteal osteosarcoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Chondrosarcoma, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
Ewing sarcoma									
Total	4	0	0	2	0	2	2	0	2
Male	1	0	0	0	0	0	1	0	1
Female	3	0	0	2	0	2	1	0	1

Table A-7: (continued) Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
Adamantinoma of long bones									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
C41 Bone and articular cartilage of other and unspecified sites									
Osteosarcoma, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
Chondroblastic osteosarcoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Ewing sarcoma									
Total	4	0	0	0	0	0	3	1	4
Male	2	0	0	0	0	0	1	1	2
Female	2	0	0	0	0	0	2	0	2
Chordoma, not otherwise specified									
Total	1	0	1	0	0	1	0	0	0
Male	1	0	1	0	0	1	0	0	0
Primitive neuroectodermal tumour, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
C43 Malignant melanoma of skin									
Malignant melanoma, not otherwise specified									
Total	7	0	0	0	0	0	2	5	7
Male	3	0	0	0	0	0	0	3	3
Female	4	0	0	0	0	0	2	2	4
Nodular melanoma									
Total	3	0	0	0	1	1	1	1	2
Male	2	0	0	0	0	0	1	1	2
Female	1	0	0	0	1	1	0	0	0
Superficial spreading melanoma									
Total	13	0	0	0	0	0	4	9	13
Male	5	0	0	0	0	0	1	4	5
Female	8	0	0	0	0	0	3	5	8
C44 Other malignant neoplasms of skin									
Dermatofibrosarcoma, not otherwise specified									
Total	2	0	0	0	0	0	1	1	2
Male	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	1	0	1
C45 Mesothelioma									
Epithelioid mesothelioma, malignant									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1

Table A-7: (continued) Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
C47 Peripheral nerves and autonomic nervous system									
Ganglioneuroblastoma									
Total	1	0	0	1	0	1	0	0	0
Female	1	0	0	1	0	1	0	0	0
Peripheral nerve sheath tumour with rhabdomyoblastic differentiation									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
C49 Other connective and soft tissue									
Neoplasm, malignant									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Myxoid liposarcoma									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
Leiomyosarcoma, not otherwise specified									
Total	2	0	0	0	0	0	0	2	2
Male	2	0	0	0	0	0	0	2	2
Embryonal rhabdomyosarcoma									
Total	2	0	1	1	0	2	0	0	0
Male	2	0	1	1	0	2	0	0	0
Synovial sarcoma, biphasic									
Total	1	0	0	0	1	1	0	0	0
Male	1	0	0	0	1	1	0	0	0
Ewing sarcoma									
Total	3	0	0	0	0	0	2	1	3
Male	2	0	0	0	0	0	1	1	2
Female	1	0	0	0	0	0	1	0	1
Primitive neuroectodermal tumour, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Alveolar soft part sarcoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
C50 Breast									
Infiltrating duct carcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
C51 Vulva									
Dermatofibrosarcoma, not otherwise specified									
Total	1	0	0	1	0	1	0	0	0
Female	1	0	0	1	0	1	0	0	0
C53 Cervix uteri									
Combined small cell carcinoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1

Table A-7: (continued) Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								Total 15-24
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	
Squamous cell carcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Squamous cell carcinoma, microinvasive									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
C56 Ovary									
Dysgerminoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Yolk sac tumour									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Mixed germ cell tumour									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
C58 Placenta									
Choriocarcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
C62 Testis									
Neoplasm, malignant									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Leydig cell tumour, malignant									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Embryonal rhabdomyosarcoma									
Total	2	0	0	1	0	1	1	0	1
Male	2	0	0	1	0	1	1	0	1
Seminoma, not otherwise specified									
Total	3	0	0	0	0	0	0	3	3
Male	3	0	0	0	0	0	0	3	3
Germ cell tumour, nonseminomatous									
Total	2	0	0	0	0	0	1	1	2
Male	2	0	0	0	0	0	1	1	2
Embryonal carcinoma, not otherwise specified									
Total	3	0	0	0	0	0	0	3	3
Male	3	0	0	0	0	0	0	3	3
Yolk sac tumour									
Total	1	1	0	0	0	1	0	0	0
Male	1	1	0	0	0	1	0	0	0
Teratocarcinoma									
Total	2	0	0	0	0	0	0	2	2
Male	2	0	0	0	0	0	0	2	2

Table A-7: (continued) Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
Mixed germ cell tumour									
Total	10	0	0	0	0	0	5	5	10
Male	10	0	0	0	0	0	5	5	10
Choriocarcinoma combined with other germ cell elements									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
C64 Kidney, except renal pelvis									
Renal cell carcinoma, not otherwise specified									
Total	2	0	0	0	1	1	0	1	1
Male	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	0	0	0	1	1
Renal cell carcinoma, chromophobe type									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Malignant cystic nephroma									
Total	1	0	1	0	0	1	0	0	0
Male	1	0	1	0	0	1	0	0	0
Nephroblastoma, not otherwise specified									
Total	8	1	5	2	0	8	0	0	0
Male	3	0	2	1	0	3	0	0	0
Female	5	1	3	1	0	5	0	0	0
Peripheral neuroectodermal tumour									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Neuroblastoma, not otherwise specified									
Total	1	0	1	0	0	1	0	0	0
Female	1	0	1	0	0	1	0	0	0
C69 Eye and adnexa									
Epithelioid cell melanoma									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
Embryonal rhabdomyosarcoma									
Total	1	0	1	0	0	1	0	0	0
Male	1	0	1	0	0	1	0	0	0
Retinoblastoma, not otherwise specified									
Total	5	1	3	1	0	5	0	0	0
Male	3	1	2	0	0	3	0	0	0
Female	2	0	1	1	0	2	0	0	0
C71 Brain									
Germinoma									
Total	1	0	0	1	0	1	0	0	0
Female	1	0	0	1	0	1	0	0	0
Haemangiopericytoma, malignant									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1

Table A-7: (continued) Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								Total 15-24
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	
Glioma, malignant									
Total	4	0	0	1	1	2	1	1	2
Male	1	0	0	0	0	0	1	0	1
Female	3	0	0	1	1	2	0	1	1
Ependymoma, not otherwise specified									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Ependymoma, anaplastic									
Total	2	1	0	0	0	1	0	1	1
Male	1	0	0	0	0	0	0	1	1
Female	1	1	0	0	0	1	0	0	0
Astrocytoma, anaplastic									
Total	2	0	0	0	0	0	0	2	2
Male	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Pleomorphic xanthoastrocytoma									
Total	1	0	0	1	0	1	0	0	0
Male	1	0	0	1	0	1	0	0	0
Glioblastoma, not otherwise specified									
Total	4	0	0	1	2	3	0	1	1
Male	2	0	0	1	0	1	0	1	1
Female	2	0	0	0	2	2	0	0	0
Medulloblastoma, not otherwise specified									
Total	4	0	1	1	2	4	0	0	0
Male	3	0	1	0	2	3	0	0	0
Female	1	0	0	1	0	1	0	0	0
Primitive neuroectodermal tumour, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Atypical teratoid/rhabdoid tumour									
Total	1	1	0	0	0	1	0	0	0
Male	1	1	0	0	0	1	0	0	0
C72 Spinal cord, cranial nerves and other parts of central nervous system									
Glioma, malignant									
Total	2	0	2	0	0	2	0	0	0
Male	1	0	1	0	0	1	0	0	0
Female	1	0	1	0	0	1	0	0	0
C73 Thyroid gland									
Papillary adenocarcinoma, not otherwise specified									
Total	9	0	1	0	0	1	1	7	8
Male	4	0	1	0	0	1	0	3	3
Female	5	0	0	0	0	0	1	4	5
Oxyphilic adenocarcinoma									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1

Table A-7: (continued) Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
Follicular adenocarcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Papillary carcinoma, follicular variant									
Total	4	0	0	0	0	0	2	2	4
Male	1	0	0	0	0	0	0	1	1
Female	3	0	0	0	0	0	2	1	3
Papillary microcarcinoma									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Papillary carcinoma, encapsulated									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
C74 Adrenal gland									
Adrenal cortical carcinoma									
Total	1	0	0	0	1	1	0	0	0
Male	1	0	0	0	1	1	0	0	0
Neuroblastoma, not otherwise specified									
Total	2	2	0	0	0	2	0	0	0
Male	2	2	0	0	0	2	0	0	0
C75 Other endocrine glands and related structures									
Germinoma									
Total	2	0	0	0	1	1	1	0	1
Male	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	1	1	0	0	0
Pineoblastoma									
Total	1	0	0	0	1	1	0	0	0
Male	1	0	0	0	1	1	0	0	0
C77 Secondary and unspecified lymph nodes									
Mucoepidermoid carcinoma									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
C78 Secondary respiratory and digestive organs									
Mucinous adenocarcinoma									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
C81 Hodgkin lymphoma									
Hodgkin lymphoma, mixed cellularity, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Hodgkin lymphoma, lymphocytic depletion, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Hodgkin lymphoma, nodular sclerosis, not otherwise specified									
Total	6	0	0	0	1	1	3	2	5
Male	3	0	0	0	0	0	2	1	3
Female	3	0	0	0	1	1	1	1	2

Table A-7: (continued) Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
C83 Diffuse non-Hodgkin lymphoma									
Malignant lymphoma, large B cell, diffuse, not otherwise specified									
Total	4	0	0	0	0	0	1	3	4
Male	2	0	0	0	0	0	0	2	2
Female	2	0	0	0	0	0	1	1	2
Burkitt lymphoma, not otherwise specified									
Total	5	0	1	1	0	2	3	0	3
Male	3	0	1	0	0	1	2	0	2
Female	2	0	0	1	0	1	1	0	1
Precursor cell lymphoblastic lymphoma, not otherwise specified									
Total	2	0	0	2	0	2	0	0	0
Male	1	0	0	1	0	1	0	0	0
Female	1	0	0	1	0	1	0	0	0
Precursor T-cell lymphoblastic lymphoma									
Total	2	0	0	0	2	2	0	0	0
Male	2	0	0	0	2	2	0	0	0
C84 Peripheral and cutaneous T-cell lymphomas									
Subcutaneous panniculitis-like T-cell lymphoma									
Total	1	0	0	0	1	1	0	0	0
Male	1	0	0	0	1	1	0	0	0
Cutaneous T-cell lymphoma, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Anaplastic large cell lymphoma, T-cell and Null cell type									
Total	2	0	0	0	2	2	0	0	0
Male	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Primary cutaneous CD30+ T-cell lymphoproliferative disorder									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
C85 Other and unspecified types of non-Hodgkin lymphoma									
Malignant lymphoma, non-Hodgkin, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
C91 Lymphoid leukaemia									
Precursor cell lymphoblastic leukaemia, not otherwise specified									
Total	13	0	2	5	2	9	3	1	4
Male	3	0	0	2	0	2	1	0	1
Female	10	0	2	3	2	7	2	1	3
Precursor B-cell lymphoblastic leukaemia									
Total	21	1	12	5	0	18	3	0	3
Male	8	1	4	2	0	7	1	0	1
Female	13	0	8	3	0	11	2	0	2
Precursor T-cell lymphoblastic leukaemia									
Total	2	0	1	0	1	2	0	0	0
Male	2	0	1	0	1	2	0	0	0

Table A-7: (continued) Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
C92 Myeloid leukaemia									
Acute myeloid leukaemia, not otherwise specified									
Total	10	0	3	1	2	6	2	2	4
Male	7	0	2	1	2	5	2	0	2
Female	3	0	1	0	0	1	0	2	2
Chronic myeloid leukaemia, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
Acute promyelocytic leukaemia, t(15;17) (q22;q11-12)									
Total	2	0	0	0	0	0	0	2	2
Female	2	0	0	0	0	0	0	2	2
Acute myelomonocytic leukaemia									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Acute myeloid leukaemia with maturation									
Total	2	0	0	0	0	0	2	0	2
Male	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Myeloid sarcoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
C93 Monocytic leukaemia									
Acute monocytic leukaemia									
Total	3	1	1	0	1	3	0	0	0
Female	3	1	1	0	1	3	0	0	0
C94 Other leukaemias of specified cell type									
Acute megakaryoblastic leukaemia									
Total	1	0	1	0	0	1	0	0	0
Female	1	0	1	0	0	1	0	0	0
Juvenile myelomonocytic leukaemia									
Total	2	2	0	0	0	2	0	0	0
Male	1	1	0	0	0	1	0	0	0
Female	1	1	0	0	0	1	0	0	0
C95 Leukaemia of unspecified cell type									
Leukaemia, not otherwise specified									
Total	1	1	0	0	0	1	0	0	0
Female	1	1	0	0	0	1	0	0	0
Acute biphenotypic leukaemia									
Total	1	0	0	1	0	1	0	0	0
Female	1	0	0	1	0	1	0	0	0
D45 Polycythaemia vera									
Polycythaemia vera									
Total	7	1	0	1	2	4	1	2	3
Male	4	1	0	0	1	2	1	1	2
Female	3	0	0	1	1	2	0	1	1

Table A-7: (continued) Child and youth cancer registrations: site and histology by sex and age, numbers, 2004

	Age in years at registration								Total 15-24
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	
D46 Myelodysplastic syndromes									
Refractory anaemia, not otherwise specified									
Total	2	0	0	0	0	0	1	1	2
Male	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	1	0	1
Refractory anaemia with excess of blasts									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Myelodysplastic syndrome, not otherwise specified									
Total	3	0	0	1	1	2	0	1	1
Male	2	0	0	1	1	2	0	0	0
Female	1	0	0	0	0	0	0	1	1
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue									
Chronic myeloproliferative disease									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Idiopathic thrombocythaemia									
Total	2	0	0	0	0	0	0	2	2
Female	2	0	0	0	0	0	0	2	2

Table A-8: Child and youth cancer registrations: histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
All histologies	296	13	39	33	39	124	65	107	172
Neoplasm, malignant									
Total	2	0	0	0	0	0	1	1	2
Male	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	1	0	1
Carcinoma, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Combined small cell carcinoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Squamous cell carcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Squamous cell carcinoma, microinvasive									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Lymphoepithelial carcinoma									
Total	2	0	0	0	1	1	1	0	1
Male	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	1	1	0	0	0
Adenocarcinoma, not otherwise specified									
Total	5	0	0	0	0	0	1	4	5
Male	3	0	0	0	0	0	0	3	3
Female	2	0	0	0	0	0	1	1	2
Cholangiocarcinoma									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Atypical carcinoid tumour									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Papillary adenocarcinoma, not otherwise specified									
Total	9	0	1	0	0	1	1	7	8
Male	4	0	1	0	0	1	0	3	3
Female	5	0	0	0	0	0	1	4	5
Adenocarcinoma in villous adenoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Oxyphilic adenocarcinoma									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Renal cell carcinoma, not otherwise specified									
Total	2	0	0	0	1	1	0	1	1
Male	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	0	0	0	1	1

Table A-8: (continued) Child and youth cancer registrations: histology by sex and age, numbers, 2004

	Age in years at registration								Total 15-24
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	
Renal cell carcinoma, chromophobe type									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Follicular adenocarcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Papillary carcinoma, follicular variant									
Total	4	0	0	0	0	0	2	2	4
Male	1	0	0	0	0	0	0	1	1
Female	3	0	0	0	0	0	2	1	3
Papillary microcarcinoma									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Papillary carcinoma, encapsulated									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Adrenal cortical carcinoma									
Total	1	0	0	0	1	1	0	0	0
Male	1	0	0	0	1	1	0	0	0
Mucoepidermoid carcinoma									
Total	2	0	0	0	0	0	1	1	2
Male	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	1	0	1
Mucinous adenocarcinoma									
Total	4	0	0	0	0	0	0	4	4
Male	1	0	0	0	0	0	0	1	1
Female	3	0	0	0	0	0	0	3	3
Signet ring cell carcinoma									
Total	3	0	0	0	0	0	0	3	3
Male	2	0	0	0	0	0	0	2	2
Female	1	0	0	0	0	0	0	1	1
Infiltrating duct carcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Acinar cell carcinoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Leydig cell tumour, malignant									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Malignant melanoma, not otherwise specified									
Total	7	0	0	0	0	0	2	5	7
Male	3	0	0	0	0	0	0	3	3
Female	4	0	0	0	0	0	2	2	4

Table A-8: (continued) Child and youth cancer registrations: histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
Nodular melanoma									
Total	3	0	0	0	1	1	1	1	2
Male	2	0	0	0	0	0	1	1	2
Female	1	0	0	0	1	1	0	0	0
Superficial spreading melanoma									
Total	13	0	0	0	0	0	4	9	13
Male	5	0	0	0	0	0	1	4	5
Female	8	0	0	0	0	0	3	5	8
Epithelioid cell melanoma									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
Dermatofibrosarcoma, not otherwise specified									
Total	3	0	0	1	0	1	1	1	2
Male	1	0	0	0	0	0	0	1	1
Female	2	0	0	1	0	1	1	0	1
Myxoid liposarcoma									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
Leiomyosarcoma, not otherwise specified									
Total	2	0	0	0	0	0	0	2	2
Male	2	0	0	0	0	0	0	2	2
Embryonal rhabdomyosarcoma									
Total	6	0	2	3	0	5	1	0	1
Male	6	0	2	3	0	5	1	0	1
Malignant cystic nephroma									
Total	1	0	1	0	0	1	0	0	0
Male	1	0	1	0	0	1	0	0	0
Nephroblastoma, not otherwise specified									
Total	8	1	5	2	0	8	0	0	0
Male	3	0	2	1	0	3	0	0	0
Female	5	1	3	1	0	5	0	0	0
Hepatoblastoma									
Total	1	0	1	0	0	1	0	0	0
Female	1	0	1	0	0	1	0	0	0
Synovial sarcoma, biphasic									
Total	1	0	0	0	1	1	0	0	0
Male	1	0	0	0	1	1	0	0	0
Epithelioid mesothelioma, malignant									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Dysgerminoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Seminoma, not otherwise specified									
Total	3	0	0	0	0	0	0	3	3
Male	3	0	0	0	0	0	0	3	3

Table A-8: (continued) Child and youth cancer registrations: histology by sex and age, numbers, 2004

	Age in years at registration								Total 15-24
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	
Germinoma									
Total	3	0	0	1	1	2	1	0	1
Male	1	0	0	0	0	0	1	0	1
Female	2	0	0	1	1	2	0	0	0
Germ cell tumour, nonseminomatous									
Total	2	0	0	0	0	0	1	1	2
Male	2	0	0	0	0	0	1	1	2
Embryonal carcinoma, not otherwise specified									
Total	3	0	0	0	0	0	0	3	3
Male	3	0	0	0	0	0	0	3	3
Yolk sac tumour									
Total	2	1	0	0	0	1	0	1	1
Male	1	1	0	0	0	1	0	0	0
Female	1	0	0	0	0	0	0	1	1
Teratoma, malignant, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Teratocarcinoma									
Total	2	0	0	0	0	0	0	2	2
Male	2	0	0	0	0	0	0	2	2
Mixed germ cell tumour									
Total	11	0	0	0	1	1	5	5	10
Male	10	0	0	0	0	0	5	5	10
Female	1	0	0	0	1	1	0	0	0
Choriocarcinoma, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Choriocarcinoma combined with other germ cell elements									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Epithelioid haemangioendothelioma, malignant									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Haemangiopericytoma, malignant									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Osteosarcoma, not otherwise specified									
Total	7	0	0	1	2	3	4	0	4
Male	4	0	0	0	1	1	3	0	3
Female	3	0	0	1	1	2	1	0	1
Chondroblastic osteosarcoma									
Total	3	0	0	0	1	1	0	2	2
Male	1	0	0	0	0	0	0	1	1
Female	2	0	0	0	1	1	0	1	1

Table A-8: (continued) Child and youth cancer registrations: histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
Parosteal osteosarcoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Chondrosarcoma, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
Ewing sarcoma									
Total	12	0	0	2	1	3	7	2	9
Male	6	0	0	0	1	1	3	2	5
Female	6	0	0	2	0	2	4	0	4
Adamantinoma of long bones									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Pineoblastoma									
Total	1	0	0	0	1	1	0	0	0
Male	1	0	0	0	1	1	0	0	0
Peripheral neuroectodermal tumour									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Chordoma, not otherwise specified									
Total	1	0	1	0	0	1	0	0	0
Male	1	0	1	0	0	1	0	0	0
Glioma, malignant									
Total	6	0	2	1	1	4	1	1	2
Male	2	0	1	0	0	1	1	0	1
Female	4	0	1	1	1	3	0	1	1
Ependymoma, not otherwise specified									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Ependymoma, anaplastic									
Total	2	1	0	0	0	1	0	1	1
Male	1	0	0	0	0	0	0	1	1
Female	1	1	0	0	0	1	0	0	0
Astrocytoma, anaplastic									
Total	2	0	0	0	0	0	0	2	2
Male	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Pleomorphic xanthoastrocytoma									
Total	1	0	0	1	0	1	0	0	0
Male	1	0	0	1	0	1	0	0	0
Glioblastoma, not otherwise specified									
Total	4	0	0	1	2	3	0	1	1
Male	2	0	0	1	0	1	0	1	1
Female	2	0	0	0	2	2	0	0	0

Table A-8: (continued) Child and youth cancer registrations: histology by sex and age, numbers, 2004

	Age in years at registration								Total 15-24
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	
Medulloblastoma, not otherwise specified									
Total	4	0	1	1	2	4	0	0	0
Male	3	0	1	0	2	3	0	0	0
Female	1	0	0	1	0	1	0	0	0
Primitive neuroectodermal tumour, not otherwise specified									
Total	3	0	0	0	0	0	1	2	3
Male	3	0	0	0	0	0	1	2	3
Ganglioneuroblastoma									
Total	1	0	0	1	0	1	0	0	0
Female	1	0	0	1	0	1	0	0	0
Neuroblastoma, not otherwise specified									
Total	3	2	1	0	0	3	0	0	0
Male	2	2	0	0	0	2	0	0	0
Female	1	0	1	0	0	1	0	0	0
Atypical teratoid/rhabdoid tumour									
Total	1	1	0	0	0	1	0	0	0
Male	1	1	0	0	0	1	0	0	0
Retinoblastoma, not otherwise specified									
Total	5	1	3	1	0	5	0	0	0
Male	3	1	2	0	0	3	0	0	0
Female	2	0	1	1	0	2	0	0	0
Peripheral nerve sheath tumour with rhabdomyoblastic differentiation									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Alveolar soft part sarcoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Malignant lymphoma, non-Hodgkin, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
Hodgkin lymphoma, mixed cellularity, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Hodgkin lymphoma, lymphocytic depletion, not otherwise specified									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Hodgkin lymphoma, nodular sclerosis, not otherwise specified									
Total	6	0	0	0	1	1	3	2	5
Male	3	0	0	0	0	0	2	1	3
Female	3	0	0	0	1	1	1	1	2
Malignant lymphoma, large B cell, diffuse, not otherwise specified									
Total	4	0	0	0	0	0	1	3	4
Male	2	0	0	0	0	0	0	2	2
Female	2	0	0	0	0	0	1	1	2

Table A-8: (continued) Child and youth cancer registrations: histology by sex and age, numbers, 2004

	Age in years at registration								
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	Total 15-24
Burkitt lymphoma, not otherwise specified									
Total	5	0	1	1	0	2	3	0	3
Male	3	0	1	0	0	1	2	0	2
Female	2	0	0	1	0	1	1	0	1
Subcutaneous panniculitis-like T-cell lymphoma									
Total	1	0	0	0	1	1	0	0	0
Male	1	0	0	0	1	1	0	0	0
Cutaneous T-cell lymphoma, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Anaplastic large cell lymphoma, T-cell and Null cell type									
Total	2	0	0	0	2	2	0	0	0
Male	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Primary cutaneous CD30+ T-cell lymphoproliferative disorder									
Total	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Precursor cell lymphoblastic lymphoma, not otherwise specified									
Total	2	0	0	2	0	2	0	0	0
Male	1	0	0	1	0	1	0	0	0
Female	1	0	0	1	0	1	0	0	0
Precursor T-cell lymphoblastic lymphoma									
Total	2	0	0	0	2	2	0	0	0
Male	2	0	0	0	2	2	0	0	0
Leukaemia, not otherwise specified									
Total	1	1	0	0	0	1	0	0	0
Female	1	1	0	0	0	1	0	0	0
Acute biphenotypic leukaemia									
Total	1	0	0	1	0	1	0	0	0
Female	1	0	0	1	0	1	0	0	0
Precursor cell lymphoblastic leukaemia, not otherwise specified									
Total	13	0	2	5	2	9	3	1	4
Male	3	0	0	2	0	2	1	0	1
Female	10	0	2	3	2	7	2	1	3
Precursor B-cell lymphoblastic leukaemia									
Total	21	1	12	5	0	18	3	0	3
Male	8	1	4	2	0	7	1	0	1
Female	13	0	8	3	0	11	2	0	2
Precursor T-cell lymphoblastic leukaemia									
Total	2	0	1	0	1	2	0	0	0
Male	2	0	1	0	1	2	0	0	0
Acute myeloid leukaemia, not otherwise specified									
Total	10	0	3	1	2	6	2	2	4
Male	7	0	2	1	2	5	2	0	2
Female	3	0	1	0	0	1	0	2	2

Table A-8: (continued) Child and youth cancer registrations: histology by sex and age, numbers, 2004

	Age in years at registration								Total 15-24
	Total 0-24	0-	1-4	5-9	10-14	Total 0-14	15-19	20-24	
Chronic myeloid leukaemia, not otherwise specified									
Total	1	0	0	0	0	0	1	0	1
Male	1	0	0	0	0	0	1	0	1
Acute promyelocytic leukaemia, t(15;17) (q22;q11-12)									
Total	2	0	0	0	0	0	0	2	2
Female	2	0	0	0	0	0	0	2	2
Acute myelomonocytic leukaemia									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Acute myeloid leukaemia with maturation									
Total	2	0	0	0	0	0	2	0	2
Male	1	0	0	0	0	0	1	0	1
Female	1	0	0	0	0	0	1	0	1
Acute monocytic leukaemia									
Total	3	1	1	0	1	3	0	0	0
Female	3	1	1	0	1	3	0	0	0
Acute megakaryoblastic leukaemia									
Total	1	0	1	0	0	1	0	0	0
Female	1	0	1	0	0	1	0	0	0
Myeloid sarcoma									
Total	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	0	1	1
Juvenile myelomonocytic leukaemia									
Total	2	2	0	0	0	2	0	0	0
Male	1	1	0	0	0	1	0	0	0
Female	1	1	0	0	0	1	0	0	0
Polycythaemia vera									
Total	7	1	0	1	2	4	1	2	3
Male	4	1	0	0	1	2	1	1	2
Female	3	0	0	1	1	2	0	1	1
Chronic myeloproliferative disease									
Total	1	0	0	0	0	0	0	1	1
Male	1	0	0	0	0	0	0	1	1
Idiopathic thrombocythaemia									
Total	2	0	0	0	0	0	0	2	2
Female	2	0	0	0	0	0	0	2	2
Refractory anaemia, not otherwise specified									
Total	2	0	0	0	0	0	1	1	2
Male	1	0	0	0	0	0	0	1	1
Female	1	0	0	0	0	0	1	0	1
Refractory anaemia with excess of blasts									
Total	1	0	0	0	1	1	0	0	0
Female	1	0	0	0	1	1	0	0	0
Myelodysplastic syndrome, not otherwise specified									
Total	3	0	0	1	1	2	0	1	1
Male	2	0	0	1	1	2	0	0	0
Female	1	0	0	0	0	0	0	1	1

Table A-9: Cancer mortality: site by age and sex, total population, 2004

	Age groups (years)																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
All sites (C00-C96, D45-D47)																			
Total	8145	3	5	12	10	12	25	50	93	162	245	441	539	785	942	1146	1277	1204	1194
Male	4246	2	3	4	4	7	12	19	36	59	110	197	274	411	525	681	743	642	517
Female	3899	1	2	8	6	5	13	31	57	103	135	244	265	374	417	465	534	562	677
C01 Base of tongue																			
Total	6	0	0	0	0	0	0	0	0	0	1	0	2	1	1	0	0	1	0
Male	4	0	0	0	0	0	0	0	0	0	1	0	2	1	0	0	0	0	0
Female	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
C02 Other and unspecified parts of tongue																			
Total	17	0	0	0	0	0	0	2	1	0	1	2	0	3	0	2	0	5	1
Male	9	0	0	0	0	0	0	0	1	0	1	2	0	3	0	1	0	1	0
Female	8	0	0	0	0	0	0	2	0	0	0	0	0	0	0	1	0	4	1
C03 Gum																			
Total	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Female	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C04 Floor of mouth																			
Total	10	0	0	0	0	0	0	0	0	0	0	2	2	0	2	2	0	1	1
Male	8	0	0	0	0	0	0	0	0	0	0	1	2	0	2	2	0	1	0
Female	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
C05 Palate																			
Total	8	0	0	0	0	0	1	0	0	0	2	0	2	1	0	0	1	1	0
Male	4	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0	1	0	0
Female	4	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	1	0
C06 Other and unspecified parts of mouth																			
Total	7	0	0	0	0	0	0	0	0	1	0	0	1	0	3	0	2	0	0
Male	7	0	0	0	0	0	0	0	0	1	0	0	1	0	3	0	2	0	0
C07 Parotid gland																			
Total	6	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	2	1
Male	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0
Female	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	1
C08 Other and unspecified major salivary glands																			
Total	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Female	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C09 Tonsil																			
Total	9	0	0	0	0	0	0	0	0	0	0	1	1	1	3	2	1	0	0
Male	5	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1	0	0	0
Female	4	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	0	0
C10 Oropharynx																			
Total	6	0	0	0	0	0	0	0	0	0	0	1	0	0	2	1	1	1	0
Male	5	0	0	0	0	0	0	0	0	0	0	1	0	0	2	1	1	0	0
Female	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C11 Nasopharynx																			
Total	11	0	0	0	0	0	0	0	1	0	1	1	1	2	1	2	1	1	0
Male	8	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	0
Female	3	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0	0

Table A-9: (continued) Cancer mortality: site by age and sex, total population, 2004

	Age groups (years)																		
	Total	0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80–	85+
C12 Pyriform sinus																			
Total	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0
Male	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0
C13 Hypopharynx																			
Total	9	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	1	2	1
Male	6	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2	1	1	0
Female	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1
C14 Other and ill-defined sites in the lip, oral cavity and pharynx																			
Total	7	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	3	1	0
Male	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2	0	0
Female	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0
C15 Oesophagus																			
Total	206	0	0	0	0	0	0	0	2	6	4	14	17	21	24	25	33	35	25
Male	132	0	0	0	0	0	0	0	2	5	4	9	12	17	19	15	20	18	11
Female	74	0	0	0	0	0	0	0	0	1	0	5	5	4	5	10	13	17	14
C16 Stomach																			
Total	301	0	0	0	0	1	1	5	4	9	13	23	21	29	36	37	54	28	40
Male	186	0	0	0	0	1	1	3	1	6	5	17	14	21	26	24	38	14	15
Female	115	0	0	0	0	0	0	2	3	3	8	6	7	8	10	13	16	14	25
C17 Small intestine																			
Total	30	0	0	0	0	0	0	0	1	2	1	0	2	2	5	3	3	2	9
Male	17	0	0	0	0	0	0	0	1	1	0	0	2	0	3	2	1	0	7
Female	13	0	0	0	0	0	0	0	0	1	1	0	0	2	2	1	2	2	2
C18 Colon																			
Total	783	0	0	0	0	1	0	0	4	7	26	30	42	68	77	129	130	138	131
Male	335	0	0	0	0	1	0	0	2	2	12	11	16	32	35	77	57	60	30
Female	448	0	0	0	0	0	0	0	2	5	14	19	26	36	42	52	73	78	101
C19 Rectosigmoid junction																			
Total	95	0	0	0	0	0	1	0	1	0	3	3	3	8	19	15	12	20	10
Male	56	0	0	0	0	0	1	0	0	0	1	2	2	4	12	10	5	13	6
Female	39	0	0	0	0	0	0	0	1	0	2	1	1	4	7	5	7	7	4
C20 Rectum																			
Total	273	0	0	0	0	0	1	1	3	6	8	10	15	35	29	34	43	47	41
Male	170	0	0	0	0	0	0	1	3	1	5	7	11	20	18	23	36	29	16
Female	103	0	0	0	0	0	1	0	0	5	3	3	4	15	11	11	7	18	25
C21 Anus and anal canal																			
Total	22	0	0	0	0	0	0	0	0	1	2	2	4	3	1	2	4	1	2
Male	9	0	0	0	0	0	0	0	0	0	1	1	2	2	0	1	1	1	0
Female	13	0	0	0	0	0	0	0	0	1	1	1	2	1	1	1	3	0	2
C22 Liver and intrahepatic bile ducts																			
Total	176	0	0	0	0	0	0	0	2	6	9	14	17	23	14	22	30	28	11
Male	119	0	0	0	0	0	0	0	2	5	6	9	12	18	11	16	20	15	5
Female	57	0	0	0	0	0	0	0	0	1	3	5	5	5	3	6	10	13	6
C23 Gallbladder																			
Total	47	0	0	0	0	0	0	0	0	0	1	4	3	5	6	4	9	8	7
Male	17	0	0	0	0	0	0	0	0	0	0	2	3	1	1	2	4	3	1
Female	30	0	0	0	0	0	0	0	0	0	1	2	0	4	5	2	5	5	6

Table A-9: (continued) Cancer mortality: site by age and sex, total population, 2004

	Age groups (years)																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C24 Other and unspecified parts of biliary tract																			
Total	46	0	0	0	0	0	0	0	1	1	0	2	3	4	2	8	10	8	7
Male	24	0	0	0	0	0	0	0	0	1	0	2	3	3	1	3	5	4	2
Female	22	0	0	0	0	0	0	0	1	0	0	0	0	1	1	5	5	4	5
C25 Pancreas																			
Total	355	0	0	0	0	0	0	1	0	3	11	13	27	35	37	58	63	46	61
Male	172	0	0	0	0	0	0	1	0	3	6	8	17	19	23	32	26	18	19
Female	183	0	0	0	0	0	0	0	0	0	5	5	10	16	14	26	37	28	42
C26 Other and ill-defined digestive organs																			
Total	84	0	0	0	0	0	0	0	0	0	2	1	2	3	8	8	13	12	35
Male	27	0	0	0	0	0	0	0	0	0	1	1	1	0	6	2	6	3	7
Female	57	0	0	0	0	0	0	0	0	0	1	0	1	3	2	6	7	9	28
C30 Nasal cavity and middle ear																			
Total	4	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	2	0
Male	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Female	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	2	0
C31 Accessory sinuses																			
Total	4	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	1	0	0
Male	3	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0
Female	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C32 Larynx																			
Total	35	0	0	0	0	0	0	0	0	0	0	2	1	3	4	6	6	7	6
Male	30	0	0	0	0	0	0	0	0	0	0	2	1	2	4	5	6	5	5
Female	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	1
C33 Trachea																			
Total	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Male	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C34 Bronchus and lung																			
Total	1554	0	0	0	0	0	0	5	8	18	37	88	123	190	241	277	279	190	98
Male	928	0	0	0	0	0	0	0	4	11	22	47	66	102	140	184	177	117	58
Female	626	0	0	0	0	0	0	5	4	7	15	41	57	88	101	93	102	73	40
C37 Thymus																			
Total	3	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0
Male	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
Female	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C38 Heart, mediastinum and pleura																			
Total	8	0	0	0	0	0	0	0	1	0	0	0	1	0	1	1	2	2	0
Male	3	0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0
Female	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	2	0
C40 Bone and articular cartilage of limbs																			
Total	10	0	0	3	2	3	1	0	0	0	0	0	0	0	0	0	1	0	0
Male	2	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0
Female	8	0	0	3	2	1	1	0	0	0	0	0	0	0	0	0	1	0	0
C41 Bone and articular cartilage of other and unspecified sites																			
Total	11	0	0	0	1	1	0	1	0	1	1	1	0	1	0	0	1	1	2
Male	6	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	1	2
Female	5	0	0	0	1	1	0	1	0	0	0	1	0	1	0	0	0	0	0

Table A-9: (continued) Cancer mortality: site by age and sex, total population, 2004

	Age groups (years)																		
	Total	0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80–	85+
C43 Malignant melanoma of skin																			
Total	249	0	0	0	0	0	2	7	13	7	10	14	20	18	26	29	31	34	38
Male	152	0	0	0	0	0	0	4	9	4	5	10	14	13	19	20	19	21	14
Female	97	0	0	0	0	0	2	3	4	3	5	4	6	5	7	9	12	13	24
C44 Other malignant neoplasms of skin																			
Total	85	0	0	0	0	0	0	0	0	0	2	1	1	4	9	11	10	15	32
Male	48	0	0	0	0	0	0	0	0	0	1	1	0	3	7	6	7	8	15
Female	37	0	0	0	0	0	0	0	0	0	1	0	1	1	2	5	3	7	17
C45 Mesothelioma																			
Total	77	0	0	0	0	0	0	0	0	0	1	2	5	14	10	11	18	11	5
Male	71	0	0	0	0	0	0	0	0	0	1	2	5	14	10	9	16	9	5
Female	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2	0
C47 Peripheral nerves and autonomic nervous system																			
Total	3	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0
Male	3	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0
C48 Retroperitoneum and peritoneum																			
Total	19	1	0	0	0	0	0	0	0	1	0	0	4	1	4	3	2	3	0
Male	5	1	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	1	0
Female	14	0	0	0	0	0	0	0	0	1	0	0	2	1	4	2	2	2	0
C49 Other connective and soft tissue																			
Total	29	1	0	0	0	1	1	0	0	0	3	0	0	5	4	4	4	3	3
Male	13	1	0	0	0	1	1	0	0	0	1	0	0	2	3	3	0	0	1
Female	16	0	0	0	0	0	0	0	0	0	2	0	0	3	1	1	4	3	2
C50 Breast																			
Total	646	0	0	0	0	1	3	8	22	43	40	70	60	66	69	69	49	68	78
Male	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	1
Female	642	0	0	0	0	1	3	8	22	43	40	70	59	66	69	69	49	66	77
C51 Vulva																			
Total	13	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2	5	4
Female	13	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2	5	4
C52 Vagina																			
Total	6	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	3
Female	6	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	3
C53 Cervix uteri																			
Total	71	0	0	0	0	0	2	0	4	8	8	10	7	6	6	4	7	3	6
Female	71	0	0	0	0	0	2	0	4	8	8	10	7	6	6	4	7	3	6
C54 Corpus uteri																			
Total	64	0	0	0	0	0	0	0	1	0	3	2	6	9	12	9	8	5	9
Female	64	0	0	0	0	0	0	0	1	0	3	2	6	9	12	9	8	5	9
C55 Uterus, part unspecified																			
Total	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	1	1
Female	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	1	1
C56 Ovary																			
Total	187	0	0	0	0	0	1	0	3	10	1	20	16	19	19	26	22	24	26
Female	187	0	0	0	0	0	1	0	3	10	1	20	16	19	19	26	22	24	26

Table A-9: (continued) Cancer mortality: site by age and sex, total population, 2004

	Age groups (years)																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C57 Other and unspecified female genital organs																			
Total	7	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	3	0
Female	7	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	3	0
C60 Penis																			
Total	3	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	1	0
Male	3	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	1	0
C61 Prostate																			
Total	583	0	0	0	0	0	0	0	0	0	0	3	9	23	52	85	125	134	152
Male	583	0	0	0	0	0	0	0	0	0	0	3	9	23	52	85	125	134	152
C62 Testis																			
Total	5	0	0	0	0	2	0	1	0	0	0	1	0	0	1	0	0	0	0
Male	5	0	0	0	0	2	0	1	0	0	0	1	0	0	1	0	0	0	0
C64 Kidney, except renal pelvis																			
Total	163	0	0	0	0	0	0	0	0	2	8	12	9	22	22	29	20	24	15
Male	108	0	0	0	0	0	0	0	0	1	5	7	7	15	15	23	13	15	7
Female	55	0	0	0	0	0	0	0	0	1	3	5	2	7	7	6	7	9	8
C65 Renal pelvis																			
Total	13	0	0	0	0	0	0	0	0	0	1	1	1	0	4	3	2	1	0
Male	8	0	0	0	0	0	0	0	0	0	0	0	1	0	2	3	1	1	0
Female	5	0	0	0	0	0	0	0	0	0	1	1	0	0	2	0	1	0	0
C66 Ureter																			
Total	6	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	1
Male	4	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	0
Female	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
C67 Bladder																			
Total	180	0	0	0	0	0	0	0	0	2	4	4	5	17	8	21	46	28	45
Male	124	0	0	0	0	0	0	0	0	0	3	2	5	15	6	18	28	20	27
Female	56	0	0	0	0	0	0	0	0	2	1	2	0	2	2	3	18	8	18
C68 Other and unspecified urinary organs																			
Total	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Male	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C69 Eye and adnexa																			
Total	9	0	0	0	0	0	0	0	0	0	0	1	2	1	1	1	0	1	2
Male	4	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	1	0
Female	5	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	2
C70 Meninges																			
Total	3	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0
Female	3	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0
C71 Brain																			
Total	222	0	1	3	0	0	4	4	9	15	12	22	30	20	26	26	27	14	9
Male	130	0	1	1	0	0	2	3	3	9	8	15	19	8	19	14	15	9	4
Female	92	0	0	2	0	0	2	1	6	6	4	7	11	12	7	12	12	5	5
C72 Spinal cord, cranial nerves and other parts of central nervous system																			
Total	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
Male	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Female	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1

Table A-9: (continued) Cancer mortality: site by age and sex, total population, 2004

	Age groups (years)																		
	Total	0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80–	85+
C73 Thyroid gland																			
Total	29	0	0	0	0	0	0	0	1	1	1	2	3	5	3	2	1	4	6
Male	10	0	0	0	0	0	0	0	0	1	1	1	1	2	1	1	0	1	1
Female	19	0	0	0	0	0	0	0	1	0	0	1	2	3	2	1	1	3	5
C74 Adrenal gland																			
Total	9	0	2	2	0	0	0	0	0	0	0	0	0	2	1	1	0	1	0
Male	4	0	1	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Female	5	0	1	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0
C76 Other and ill-defined sites																			
Total	21	0	0	0	0	0	0	0	0	0	0	2	0	2	2	3	2	1	9
Male	8	0	0	0	0	0	0	0	0	0	0	1	0	2	2	0	0	1	2
Female	13	0	0	0	0	0	0	0	0	0	0	1	0	0	0	3	2	0	7
C80 Malignant neoplasm without specification of site																			
Total	413	0	0	0	0	0	1	3	3	4	7	13	20	31	47	53	73	80	78
Male	207	0	0	0	0	0	1	1	1	3	6	6	9	20	23	31	40	40	26
Female	206	0	0	0	0	0	0	2	2	1	1	7	11	11	24	22	33	40	52
C81 Hodgkin lymphoma																			
Total	15	0	0	0	0	1	1	0	0	0	0	0	1	2	5	3	1	1	0
Male	9	0	0	0	0	0	1	0	0	0	0	0	1	1	4	1	0	1	0
Female	6	0	0	0	0	1	0	0	0	0	0	0	0	1	1	2	1	0	0
C82 Follicular [nodular] non-Hodgkin lymphoma																			
Total	52	0	0	0	0	0	0	1	0	1	3	3	5	4	6	9	5	7	8
Male	20	0	0	0	0	0	0	0	0	1	1	1	1	1	3	5	2	3	2
Female	32	0	0	0	0	0	0	1	0	0	2	2	4	3	3	4	3	4	6
C83 Diffuse non-Hodgkin lymphoma																			
Total	156	0	0	0	0	0	1	2	1	1	5	14	12	16	18	20	19	30	17
Male	79	0	0	0	0	0	1	1	1	1	2	7	9	8	9	10	11	13	6
Female	77	0	0	0	0	0	0	1	0	0	3	7	3	8	9	10	8	17	11
C84 Peripheral and cutaneous T-cell lymphomas																			
Total	17	0	0	0	1	0	1	1	0	1	0	1	1	0	3	2	2	1	3
Male	10	0	0	0	0	0	1	1	0	0	0	0	1	0	3	1	1	0	2
Female	7	0	0	0	1	0	0	0	0	1	0	1	0	0	0	1	1	1	1
Indeterminate																			
C85 Other and unspecified types of non-Hodgkin lymphoma																			
Total	63	0	0	0	0	0	0	0	0	0	1	1	3	6	4	10	10	16	12
Male	27	0	0	0	0	0	0	0	0	0	1	1	1	4	1	6	5	4	4
Female	36	0	0	0	0	0	0	0	0	0	0	0	2	2	3	4	5	12	8
C88 Malignant immunoproliferative diseases																			
Total	9	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	2	2	2
Male	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0
Female	5	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	2
C90 Multiple myeloma and malignant plasma cell neoplasms																			
Total	148	0	0	0	0	0	0	0	0	2	4	5	9	15	17	18	28	27	23
Male	76	0	0	0	0	0	0	0	0	2	2	3	6	9	9	7	16	10	12
Female	72	0	0	0	0	0	0	0	0	0	2	2	3	6	8	11	12	17	11

Table A-9: (continued) Cancer mortality: site by age and sex, total population, 2004

	Age groups (years)																		
	Total	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
C91 Lymphoid leukaemia																			
Total	98	1	2	4	2	1	1	1	3	2	2	3	1	13	6	9	10	13	24
Male	54	0	1	1	2	0	1	0	2	0	1	1	1	10	3	7	8	8	8
Female	44	1	1	3	0	1	0	1	1	2	1	2	0	3	3	2	2	5	16
C92 Myeloid leukaemia																			
Total	169	0	0	0	1	0	1	6	3	0	3	9	7	17	21	25	30	21	25
Male	77	0	0	0	1	0	1	2	2	0	1	6	2	6	9	10	14	12	11
Female	92	0	0	0	0	0	0	4	1	0	2	3	5	11	12	15	16	9	14
C93 Monocytic leukaemia																			
Total	6	0	0	0	2	0	0	0	0	0	0	0	0	0	2	0	0	1	1
Male	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0
Female	3	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C94 Other leukaemias of specified cell type																			
Total	8	0	0	0	0	0	0	1	0	0	1	2	3	0	1	0	0	0	0
Male	7	0	0	0	0	0	0	1	0	0	1	1	3	0	1	0	0	0	0
Female	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
C95 Leukaemia of unspecified cell type																			
Total	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	3	3
Male	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1
Female	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2
D45 Polycythaemia vera																			
Total	7	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	1	3
Male	5	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	1	1
Female	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
D46 Myelodysplastic syndromes																			
Total	79	0	0	0	0	0	0	0	0	0	0	0	0	3	5	1	8	17	45
Male	45	0	0	0	0	0	0	0	0	0	0	0	0	3	4	1	5	11	21
Female	34	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	6	24
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue																			
Total	36	0	0	0	0	0	0	0	0	0	0	1	1	1	1	9	3	7	13
Male	23	0	0	0	0	0	0	0	0	0	0	1	0	1	0	6	3	4	8
Female	13	0	0	0	0	0	0	0	0	0	0	0	1	0	1	3	0	3	5

Table A-10: Cancer mortality: site by ethnicity and sex, 2004

	Total				Male				Female			
	Māori	Pacific peoples	Other	Total	Māori	Pacific peoples	Other	Total	Māori	Pacific peoples	Other	Total
C00 Lip	0	0	0	0	0	0	0	0	0	0	0	0
C01 Base of tongue	1	0	5	6	1	0	3	4	0	0	2	2
C02 Other and unspecified parts of tongue	3	0	14	17	2	0	7	9	1	0	7	8
C03 Gum	0	0	1	1	0	0	0	0	0	0	1	1
C04 Floor of mouth	3	0	7	10	2	0	6	8	1	0	1	2
C05 Palate	1	1	6	8	1	1	2	4	0	0	4	4
C06 Other and unspecified parts of mouth	0	1	6	7	0	1	6	7	0	0	0	0
C07 Parotid gland	0	1	5	6	0	1	1	2	0	0	4	4
C08 Other and unspecified major salivary glands	0	0	1	1	0	0	0	0	0	0	1	1
C09 Tonsil	0	0	9	9	0	0	5	5	0	0	4	4
C10 Oropharynx	1	0	5	6	1	0	4	5	0	0	1	1
C11 Nasopharynx	2	3	6	11	2	2	4	8	0	1	2	3
C12 Pyriform sinus	1	0	2	3	1	0	2	3	0	0	0	0
C13 Hypopharynx	0	0	9	9	0	0	6	6	0	0	3	3
C14 Other and ill-defined sites in the lip, oral cavity and pharynx	0	0	7	7	0	0	5	5	0	0	2	2
C15 Oesophagus	17	4	185	206	10	4	118	132	7	0	67	74
C16 Stomach	53	9	239	301	32	6	148	186	21	3	91	115
C17 Small intestine	6	2	22	30	3	2	12	17	3	0	10	13
C18 Colon	32	9	742	783	12	5	318	335	20	4	424	448
C19 Rectosigmoid junction	2	1	92	95	1	0	55	56	1	1	37	39
C20 Rectum	17	6	250	273	11	2	157	170	6	4	93	103
C21 Anus and anal canal	3	0	19	22	1	0	8	9	2	0	11	13
C22 Liver and intrahepatic bile ducts	26	27	123	176	24	22	73	119	2	5	50	57
C23 Gallbladder	5	5	37	47	0	3	14	17	5	2	23	30
C24 Other and unspecified parts of biliary tract	4	1	41	46	2	1	21	24	2	0	20	22
C25 Pancreas	24	9	322	355	15	7	150	172	9	2	172	183
C26 Other and ill-defined digestive organs	3	2	79	84	3	1	23	27	0	1	56	57
C30 Nasal cavity and middle ear	1	0	3	4	0	0	1	1	1	0	2	3
C31 Accessory sinuses	1	0	3	4	1	0	2	3	0	0	1	1
C32 Larynx	5	0	30	35	5	0	25	30	0	0	5	5
C33 Trachea	0	1	0	1	0	1	0	1	0	0	0	0
C34 Bronchus and lung	237	58	1259	1554	117	43	768	928	120	15	491	626
C37 Thymus	1	0	2	3	0	0	2	2	1	0	0	1
C38 Heart, mediastinum and pleura	1	0	7	8	0	0	3	3	1	0	4	5
C40 Bone and articular cartilage of limbs	1	0	9	10	1	0	1	2	0	0	8	8
C41 Bone and articular cartilage of other and unspecified sites	0	0	11	11	0	0	6	6	0	0	5	5

Table A-10: (continued) Cancer mortality: site by ethnicity and sex, 2004

	Total				Male				Female			
	Māori	Pacific peoples	Other	Total	Māori	Pacific peoples	Other	Total	Māori	Pacific peoples	Other	Total
C43 Malignant melanoma of skin	6	1	242	249	4	0	148	152	2	1	94	97
C44 Other malignant neoplasms of skin	2	0	83	85	1	0	47	48	1	0	36	37
C45 Mesothelioma	3	1	73	77	2	1	68	71	1	0	5	6
C46 Kaposi's sarcoma	0	0	0	0	0	0	0	0	0	0	0	0
C47 Peripheral nerves and autonomic nervous system	0	0	3	3	0	0	3	3	0	0	0	0
C48 Retroperitoneum and peritoneum	4	1	14	19	2	0	3	5	2	1	11	14
C49 Other connective and soft tissue	2	0	27	29	1	0	12	13	1	0	15	16
C50 Breast	81	28	537	646	0	0	4	4	81	28	533	642
C51 Vulva	1	0	12	13	1	0	12	13
C52 Vagina	0	0	6	6	0	0	6	6
C53 Cervix uteri	15	4	52	71	15	4	52	71
C54 Corpus uteri	9	6	49	64	9	6	49	64
C55 Uterus, part unspecified	0	0	5	5	0	0	5	5
C56 Ovary	18	2	167	187	18	2	167	187
C57 Other and unspecified female genital organs	0	0	7	7	0	0	7	7
C58 Placenta	0	0	0	0	0	0	0	0
C60 Penis	0	0	3	3	0	0	3	3
C61 Prostate	37	11	535	583	37	11	535	583
C62 Testis	2	0	3	5	2	0	3	5
C64 Kidney, except renal pelvis	13	2	148	163	11	1	96	108	2	1	52	55
C65 Renal pelvis	0	0	13	13	0	0	8	8	0	0	5	5
C66 Ureter	0	0	6	6	0	0	4	4	0	0	2	2
C67 Bladder	7	3	170	180	3	2	119	124	4	1	51	56
C68 Other and unspecified urinary organs	0	0	1	1	0	0	1	1	0	0	0	0
C69 Eye and adnexa	1	0	8	9	1	0	3	4	0	0	5	5
C70 Meninges	2	0	1	3	0	0	0	0	2	0	1	3
C71 Brain	18	4	200	222	7	3	120	130	11	1	80	92
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	0	2	2	0	0	1	1	0	0	1	1
C73 Thyroid gland	4	2	23	29	2	0	8	10	2	2	15	19
C74 Adrenal gland	1	1	7	9	1	1	2	4	0	0	5	5
C75 Other endocrine glands and related structures	0	0	0	0	0	0	0	0	0	0	0	0
C76 Other and ill-defined sites	3	1	17	21	2	0	6	8	1	1	11	13
C77 Secondary and unspecified lymph nodes	0	0	0	0	0	0	0	0	0	0	0	0

Table A-10: (continued) Cancer mortality: site by ethnicity and sex, 2004

	Total				Male				Female			
	Māori	Pacific peoples	Other	Total	Māori	Pacific peoples	Other	Total	Māori	Pacific peoples	Other	Total
C78 Secondary respiratory and digestive organs	0	0	0	0	0	0	0	0	0	0	0	0
C79 Secondary other sites	0	0	0	0	0	0	0	0	0	0	0	0
C80 Malignant neoplasm without specification of site	38	20	355	413	22	9	176	207	16	11	179	206
C81 Hodgkin lymphoma	0	0	15	15	0	0	9	9	0	0	6	6
C82 Follicular [nodular] non-Hodgkin lymphoma	2	0	50	52	2	0	18	20	0	0	32	32
C83 Diffuse non-Hodgkin lymphoma	14	11	131	156	7	5	67	79	7	6	64	77
C84 Peripheral and cutaneous T-cell lymphomas	4	2	11	17	3	1	6	10	1	1	5	7
C85 Other and unspecified types of non-Hodgkin lymphoma	4	2	57	63	0	1	26	27	4	1	31	36
C88 Malignant immunoproliferative diseases	0	0	9	9	0	0	4	4	0	0	5	5
C90 Multiple myeloma and malignant plasma cell neoplasms	8	6	134	148	4	4	68	76	4	2	66	72
C91 Lymphoid leukaemia	7	3	88	98	4	2	48	54	3	1	40	44
C92 Myeloid leukaemia	5	8	156	169	2	3	72	77	3	5	84	92
C93 Monocytic leukaemia	1	0	5	6	0	0	3	3	1	0	2	3
C94 Other leukaemias of specified cell type	1	1	6	8	1	1	5	7	0	0	1	1
C95 Leukaemia of unspecified cell type	0	0	10	10	0	0	5	5	0	0	5	5
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	0	0	0	0	0	0	0	0	0	0	0	0
D45 Polycythaemia vera	1	1	5	7	1	0	4	5	0	1	1	2
D46 Myelodysplastic syndromes	0	1	78	79	0	1	44	45	0	0	34	34
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue	2	1	33	36	2	1	20	23	0	0	13	13
Total New Zealand	767	263	7115	8145	372	149	3725	4246	395	114	3390	3899

... = not applicable

Explanatory notes

Cancer registration data

Scope of the National Cancer Register

The National Cancer Register is a collection of data of malignant disease cases that have been diagnosed in New Zealand and reported to the New Zealand Cancer Registry. Registrations are based on discrete primary cancer cases that are distinguished by differences in topography or histology. Cancers are registered once, in the year of their first known diagnosis. (See also the 'Cancer Registry Act 1993', Appendix 1.)

To ensure a high standard of data, registry staff comprehensively screen all records before adding them to the register. Cancer deaths are reconciled with the cancer registrations on the register.

Skin cancers

Basal cell epithelioma and squamous cell carcinoma of the skin are not recorded by the Cancer Registry except when of the skin of genital organs. The registration of these cancers was discontinued in 1958 because of resource considerations.

A small number of non-melanoma cases (for example, dermatofibrosarcoma and Merkel cell tumours) have been registered and classified to site ICD C44. Before 1993, these cases were coded to ICD-9 code 171 Connective and other soft tissues.

In-situ cancers

In-situ cancers are localised lesions that have not invaded beyond the basement membrane. All in-situ cancers have been excluded from the main statistical tables.

Disease coding

The *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM) Second Edition* was used to classify the cancer site for the 2004 mortality data used in this report.

The *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM) Third Edition* was used to classify the site or topography for the 2004 cancer registration data used in this report. The *International Classification of Diseases for Oncology Third Edition (ICD-O)* was used to classify the morphology (histology type and behaviour) of tumours.

The third edition of ICD-O contains a revised morphology section. New classifications have been introduced and new codes assigned to accommodate them. This has resulted in changes to the coding of cancers diagnosed since 1 January 2003. For some tumour types, particularly haematological malignancies and ovarian cancer, these changes may affect incidence reporting. For particular cancer sites, registrations from 1 January 2003 onwards may not be comparable with 2002 and earlier registrations.

Ovarian tumours of borderline malignancy were considered malignant in the second edition of ICD-O, but are considered to be of uncertain behaviour in the third and have been excluded from incidence reporting since 2003. This has resulted in a slight reduction in the number of cases of ovarian cancer since 2003 compared with previous years.

Polycythaemia vera, myelodysplastic syndromes and chronic myeloproliferative disorders are considered to be malignant in the third edition of ICD-O, whereas in the second edition these diseases

were considered to be of uncertain behaviour. The ICD-10 codes for these new malignancies are in the range D45–D47 and were included for the first time in the 2003 data. In this publication, these are referred to as chronic myeloproliferative disorders and myelodysplastic syndromes.

For consistency within this publication, the total number of deaths from cancer includes deaths from the malignancies in the D45–47 code range. This produces a different total figure for cancer mortality than that reported in the Mortality and Demographic Data series (NZHIS 1994–2007), which did not include deaths coded to D45–47.

A diagnosis of leukaemia in a person already registered with one of the above malignancies will not be counted in incidence statistics because of the way the coding rules for multiple primary tumours are applied (see the next section).

Multiple primary tumours

Incidence counts and rates are based on the number of primary tumours rather than the number of individuals with cancer. The New Zealand Cancer Registry database records multiple primary cancers in the same person, of which only some are counted for incidence purposes, according to the rules of the International Agency for Research on Cancer and the International Association of Cancer Registries. In brief, these rules state that:

1. Recognition of the existence of two or more primary cancers does not depend on time.
2. A primary cancer is one that originates in a primary site or tissue and is thus neither an extension, a recurrence nor a metastasis (transfer of cancerous cells to other parts of the body) of a pre-existing tumour.
3. Only one tumour shall be recognised in an organ or pair of organs or tissue (as defined by a letter and a series of numerals of the ICD-10 topography) unless of different histology.

A cancer with a different histology in the same organ is counted as a new tumour. There are 12 defined groups of malignant neoplasms considered to be histologically different (Fritz et al. p 37). Incidence reporting of multiple tumours is based upon these groups.

Timeliness of data

The process of collecting, coding and collating national information on cancer registrations and deaths is complex. Data in the Cancer Registry come from laboratory reports, hospital information and mortality information, and data in the Mortality Collection come from the certificates of cause of death from doctors or coroners, post-mortem reports from private pathologists and hospitals, and death registration forms. Both sets of information cannot be finalised until completed from all sources. In particular, the timing of the publication is affected by manual processing of death data and the need to wait until almost all coroners' findings for any particular year have been received. In addition, there are a number of steps required to ensure the final information is of good quality.

Changes in legislation

On 1 July 1994 the Cancer Registry Act and Cancer Registry Regulations came into force, introducing fundamental changes to the collection of cancer data in New Zealand. The full text of the Cancer Registry Act 1993 and Cancer Registry Regulations 1994 are contained in the appendices to this publication. The effect of legislation on the statistics of cancer registration is discussed in the 1996 edition of *Cancer: New Registrations and Deaths*.

Ethnicity

Ethnicity data is required to be collected and classified according to the Ministry of Health ethnicity data protocols for the health and disability sector (see Ministry of Health 2004).

Under the protocols, ethnicity is collected through self-identification or, when this is not possible, by appropriate proxy using a standard question format. Individuals may select up to three ethnic groups they feel they belong to.

The ethnicity data in this publication is based on prioritised ethnicity. Each individual is allocated to a single ethnic group on the basis of the following priority: Māori, Pacific peoples, Asian, other groups except NZ European, NZ European. Thus, any person who selects Māori as one of their three ethnicities will be recorded as Māori. By using this method, it is estimated that the Māori group gains at the expense of Pacific peoples (by approximately 32,000) and Pacific peoples gain at the expense of other groups (by approximately 35,000) (Ministry of Health 2004, p 20).

Prior to 1994, ethnicity data were based on a single choice, sole ethnic origin.

The ethnicity recorded on the Cancer Register is taken from hospital discharge information, the National Health Index and the Mortality Collection. One result of the Cancer Registry Act 1993, is that, because increasing numbers of registrations are based on laboratory reports, there are a number of registrations where ethnicity has not been specified. Those registrations with unspecified ethnicity have been included in the non-Māori group in the comparison of Māori with non-Māori, so caution should be used when interpreting such comparisons.

Rate calculations

Age-specific rates show the number of events (for example, cancer registrations or deaths) per 100,000 of the population in each age group for each year.

Age-standardised rates adjust for differences in age distribution of the populations being compared. They are calculated by the direct standardisation method, which multiplies the age-specific rates by a standard population. The standard population used in this publication is Segi's world population.

In the next (2005) edition of this publication, NZHIS intends to move the population structure underlying the calculation of age-standardised rates from the Segi's World Population to the WHO population.

Deaths to registrations ratios are calculated by dividing the number of deaths by the number of registrations within a specific year. As such, these figures are indicative only and prone to error when numbers of either deaths or registrations are small.

Table N-1: Segi's world population

Age group	Population	Age group	Population
0-4	12,000	50-54	5000
5-9	10,000	55-59	4000
10-14	9000	60-64	4000
15-19	9000	65-69	3000
20-24	8000	70-74	2000
25-29	8000	75-79	1000
30-34	6000	80-84	500
35-39	6000	85+	500
40-44	6000	Total	100,000
45-49	6000		

Source: Segi (1960)

Estimated resident mean population of New Zealand by ethnicity, age and sex, for year ended 31 December 2004, and the estimated Pacific peoples population for 2004 are shown in the tables below.

Table N-2: Population data, 2004

Age	Total population			Māori		Māori			
	Total:	Male:	Female:	Total:	Male:	Female:	Total:	Male:	Female:
0-4	282,100	144,270	137,840	76,520	39,360	37,150	205,580	104,910	100,690
5-9	290,880	149,710	141,180	73,590	37,850	35,740	217,290	111,860	105,440
10-14	311,670	160,410	151,260	72,290	37,190	35,110	239,380	123,220	116,150
15-19	300,700	153,960	146,740	62,810	31,520	31,280	237,890	122,440	115,460
20-24	286,240	145,970	140,270	48,410	23,980	24,430	237,830	121,990	115,840
25-29	252,390	124,030	128,360	45,050	21,660	23,390	207,340	102,370	104,970
30-34	292,940	140,150	152,790	46,200	21,830	24,360	246,740	118,320	128,430
35-39	303,310	146,120	157,180	42,930	20,480	22,450	260,380	125,640	134,730
40-44	319,310	155,130	164,180	41,670	19,710	21,960	277,640	135,420	142,220
45-49	285,330	140,400	144,930	32,730	15,660	17,070	252,600	124,740	127,860
50-54	250,750	124,350	126,400	25,050	12,190	12,860	225,700	112,160	113,540
55-59	224,850	111,750	113,090	18,250	8840	9420	206,600	102,910	103,670
60-64	176,100	87,030	89,070	13,640	6620	7020	162,460	80,410	82,050
65-69	139,760	67,860	71,900	10,040	4750	5290	129,720	63,110	66,610
70-74	120,430	57,400	63,030	6600	3020	3580	113,830	54,380	59,450
75-79	101,100	45,640	55,460	3780	1640	2140	97,320	44,000	53,320
80-84	70,980	27,720	43,250	1760	680	1070	69,220	27,040	42,180
85+	53,600	16,380	37,210	1050	360	680	52,550	16,020	36,530
Total	4,062,500	1,998,300	2,064,200	622,400	307,400	315,000	3,440,100	1,690,900	1,749,200

Source: Statistics New Zealand

Note: because of rounding, individual figures in this table do not always sum to give stated totals.

Table N-3: Estimated Pacific peoples population data, 2004

Age	Estimated Pacific peoples population		
	Total:	Male:	Female:
0-4	26,445	13,550	12,895
5-9	26,365	13,425	12,940
10-14	26,145	13,490	12,655
15-19	22,340	11,440	10,900
20-24	20,205	10,045	10,160
25-29	18,540	8960	9580
30-34	18,805	9215	9590
35-39	18,630	8790	9840
40-44	15,565	7535	8030
45-49	12,420	6190	6230
50-54	10,035	5040	4995
55-59	7625	3760	3865
60-64	5570	2705	2865
65-69	4045	1815	2230
70-74	2870	1285	1585
75-79	1725	705	1020
80-84	775	265	510
85+	420	120	300
Total	238,525	118,335	120,190

Source: Population estimates based on 2001 Census

Note: because of rounding, individual figures in this table do not always sum to give stated totals.

Confidence intervals

Confidence intervals have been calculated for age-standardised rates for all sites for the years 1995 to 2004 at the 95 percent level (Table A-4). The confidence intervals have been calculated using the methods presented in Keyfitz (1966).

A confidence interval is a range of values used to describe the uncertainty around a single value (such as an age-standardised rate) used to estimate the true value in a population, such as the underlying or true rate. Confidence intervals describe how different the estimate could have been if chance had led to a different set of data. Confidence intervals are calculated with a stated probability, typically 95 percent (which would indicate that there is a 95 percent chance that the true value lies within the confidence intervals).

Confidence intervals may assist in comparing the rates over time for each cancer site and all sites combined. If two confidence intervals do not overlap, then it is reasonable to assume that the difference is not due to chance. However, if two confidence intervals overlap, it is not possible to make any conclusion about the significance of any difference between them.

Additional information available from the New Zealand Health Information Service

Should you require additional information, analysis or material not included in this report or material tabulated in different ways, please contact:

Business Intelligence Unit
New Zealand Health Information Service
PO Box 5013
Wellington
New Zealand

Phone (04) 496 2000

Fax (04) 816 2898

E-mail inquiries@nzhis.govt.nz

References

- Fritz A, Percy C, Jack A, et al. 2000. *International Classification of Diseases for Oncology (ICD-O), Third Edition*. Geneva: World Health Organization.
- Keyfitz N. 1966. Sampling Variance of Standardized Mortality Rates. *Human Biology*. 38: 309–317.
- Ministry of Health. 2004. *Ethnicity Data Protocols for the Health and Disability Sector*. Wellington: Ministry of Health.
- National Centre for Classification in Health. 1996. *Australian Version of the International Classification of Diseases, 9th Revision, Clinical Modification, Second edition (ICD-9-CM)*. Sydney: National Centre for Classification in Health.
- National Centre for Classification in Health. 2002. *The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Third Edition*. Sydney: National Centre for Classification in Health.
- New Zealand Health Information Service. 1995–2007. *Cancer: New Registrations and Deaths* (annual series). Wellington: Ministry of Health.
- New Zealand Health Information Service. 1994–2007. *Mortality and Demographic Data* (annual series). Wellington: Ministry of Health.
- Segi M. 1960. *Cancer mortality for selected sites in 24 countries (1950–1957)*. Sendai, Japan: Department of Public Health, Tohoku University School of Medicine.

Appendices

Appendix 1: Full text of the Cancer Registry Act 1993

1993

Cancer Registry

No. 102



ANALYSIS

Title

- | | |
|-----------------------------------|---|
| 1. Short Title and commencement | 6. Director General may require supply of further information |
| 2. Interpretation | 7. Protection against actions |
| 3. Act to bind the Crown | 8. Offences |
| 4. Maintenance of Cancer Registry | 9. Regulations |
| 5. Reporting of cancer | |

1993, No. 102

An Act to make better provision for the compilation of a statistical record of the incidence of cancer in its various forms, to provide a basis for the better direction of programmes for research and for cancer prevention

BE IT ENACTED by the Parliament of New Zealand as follows:

1. Short Title and commencement –

- (1) This Act may be cited as the Cancer Registry Act 1993.
- (2) This Act shall come into force on the 1st day of July 1994.

2. Interpretation – In this Act, unless the context otherwise requires, –

“Cancer” –

- (a) Means a malignant growth of human tissue that, if unchecked, –
 - (i) Is likely to spread to adjacent tissue or beyond its place of origin; and
 - (ii) May have the propensity to recur; and
- (b) Without limiting the generality of paragraph (a) of this definition, includes carcinoma-in-situ, carcinoma, sarcoma (including Kaposi’s sarcoma), any mixed tumour, leukaemia, any type of lymphoma, and melanoma; but
- (c) Does not include –
 - (i) Any secondary or metastatic cancer, except where the primary cancer is not identified:

- (ii) Any type of cancer that is declared by regulations made under this Act to be a cancer to which this Act does not apply:

“Cancer test” means any examination or test (including the examination of any blood, cytological or tissue biopsy specimen, or other material) that is carried out in any pathology laboratory to determine the presence or absence of cancer in any person (including a deceased person):

“Director-General” means the Director-General of Health.

3. Act to bind the Crown – This Act binds the Crown.

4. Maintenance of Cancer Registry –

- (1) The Director-General shall maintain or arrange for the maintenance of a Cancer Registry.
- (2) The purposes of the Cancer Registry are –
 - (a) To provide information on the incidence of, and mortality from, cancer; and
 - (b) To provide a basis for cancer survival studies and research programmes.

5. Reporting of cancer –

- (1) Where a cancer test indicates the presence of cancer in any person (including a deceased person), the person in charge of the laboratory where that test was carried out shall cause a report of that test to be made to the Director-General for the purposes of the Cancer Registry.
- (2) Where a post-mortem examination of any deceased person indicates the presence of cancer in that person, the person who carried out that examination shall cause a report of that examination to be made to the Director-General for the purposes of the Cancer Registry.
- (3) Every report under subsection (1) or subsection (2) of this section –
 - (a) Shall be made within the prescribed time; and
 - (b) Shall be made in the prescribed form and manner.
- (4) No person is required to make a report under this section with respect to –
 - (a) Any cancer test that indicates the presence of cancer in any person (including a deceased person); or
 - (b) Any post-mortem examination of any deceased person that indicates the presence of cancer in that person –

if the first-mentioned person has good reason to believe that the presence of that particular cancer in that other person has already been reported to the Director-General, whether in a report made under this section or pursuant to any arrangements that were in place before the commencement of this Act or otherwise.

6. Director-General may require supply of further information –

- (1) Where any report made under section 5 of this Act is incomplete in any respect by reason that the person making the report does not have available to that person certain information necessary to enable a complete report to be made, the Director-General may, for the purpose of obtaining that information, by notice in writing require any person (being a medical practitioner or the person in charge of any hospital) that the Director-General reasonably believes may have all or any of that information to provide to the Director-General such information as may be specified in the notice.
- (2) Every person to whom a notice is given under this section and who has any of the information specified in that notice shall provide that information within such time, and in such form and manner, as may be specified in the notice.

- [(3) In subsection (1), “medical practitioner” means a health practitioner who is, or is deemed to be, registered with the Medical Council of New Zealand continued by section 114(1)(a) of the Health Practitioners Competence Assurance Act 2003 as a practitioner of the profession of medicine.]

7. Protection against actions –

- (1) No proceedings, civil or criminal, shall lie against any person by reason of that person having made available any information for the purposes of complying with the requirements of section 5 or section 6(2) of this Act.
- (2) Nothing in subsection (1) of this section applies in respect of proceedings for an offence against section 8 of this Act.

8. Offences – Every person commits an offence and is liable on summary conviction to a fine not exceeding \$500 who –

- (a) Fails, without reasonable excuse, to comply with the requirements of section 5 or section 6(2) of this Act; or
- (b) Knowingly supplies information that is false or misleading in purported compliance with section 5 or section 6(2) of this Act.

9. Regulations – The Governor-General may from time to time, by Order in Council, make regulations for all or any of the following purposes:

- (a) Prescribing the form and manner in which reports are to be made to the Director-General under section 5 of this Act;
- (b) Prescribing the time within which reports are to be made to the Director-General under section 5 of this Act;
- (c) Declaring any type of cancer to be a cancer to which this Act does not apply;
- (d) Providing for such other matters as are contemplated by or necessary for giving full effect to this Act and for its due administration.

This Act is administered in the Ministry of Health.

Appendix 2: Full text of the Cancer Registry Regulations 1994

1994/89



THE CANCER REGISTRY REGULATIONS 1994

CATHERINE A TIZARD, Governor-General

ORDER IN COUNCIL

At Wellington this 30th day of May 1994

Present:

HER EXCELLENCY THE GOVERNOR-GENERAL IN COUNCIL

PURSUANT to section 9 of the Cancer Registry Act 1993, Her Excellency the Governor-General, acting by and with the advice and consent of the Executive Council, hereby makes the following regulations.

REGULATIONS

1. Title and commencement –

- (1) These regulations may be cited as the Cancer Registry Regulations 1994.
- (2) These regulations shall come into force on the 1st day of July 1994.

2. Interpretation –

- (1) In these regulations, unless the context otherwise requires, –
“the Act” means the Cancer Registry Act 1993;
“Report” means a report to the Director-General under section 5 of the Act.
- (2) Where any expression used in these regulations is not defined in these regulations but is defined in the Act, that expression shall, unless the context otherwise requires, have, in these regulations, the meaning given to it by the Act.

3. Time within which reports to be made –

Every report shall be made no later than 21 days after the end of the calendar month in which the cancer test to which the report relates was carried out.

4. Form of reports –

- (1) Every report shall contain the following information:
 - (a) The full name of the person who carried out the cancer test to which the report relates:
 - (b) In relation to the person who requested the carrying out of the cancer test to which the report relates, –
 - (i) The full name of that person; and
 - (ii) The name of the health care institution by which that person is employed or engaged or in which that person otherwise works (if any):
 - (c) In relation to the person in respect of whom the cancer test to which the report relates was carried out, –
 - (i) Either that person's National Health Index Identifier or that person's full name, maiden name (if any) and any known aliases:
 - (ii) That person's date of birth:
 - (iii) That person's sex:
 - (iv) Where available, that person's ethnicity:
 - (v) Where available, that person's full address:
 - (vi) Where available, that person's occupation:
 - (d) In relation to the cancer test to which the report relates, –
 - (i) The category into which the test falls, which shall be one of the categories set out in subclause (2) of this regulation:
 - (ii) A description of the anatomical site from which the sample in respect of which the test was carried out was obtained, as indicated with the request for the test:
 - (iii) Whether that site is the primary site or the secondary site of the cancer indicated by the test:
 - (e) In relation to the cancer indicated by the cancer test to which the report relates, –
 - (i) A full description of the pathological nature of the cancer:
 - (ii) In the case of malignant melanoma of the skin, –
 - (A) The thickness of the tumour, measured in accordance with Breslow's method:
 - (B) The extent of tumour invasion, expressed by reference to Clark's levels:
 - (iii) Where available, the stage of the cancer (other than for lymphoma, leukaemia, and malignant melanoma of the skin).
- (2) The categories referred to in subclause (1)(d)(i) of this regulation are as follows:
 - (a) The histology of the primary lesion or, in the absence of a known primary lesion, the metastases:
 - (b) Cytology or haematology, or both:
 - (c) Specific biochemical or immunological test, or both:
 - (d) Autopsy with concurrent or previous histology.
- (3) Where any information required to be included in any report is unavailable at the time the report is made, or is unobtainable, –
 - (a) The report shall indicate that the information is unavailable or, as the case may be, unobtainable; and
 - (b) If that information subsequently becomes available, the person required to make the report shall, as soon as practicable, transmit that information to the Director-General.

5. Manner in which reports to be made – A report shall be made –

- (a) In a written document; or
- (b) On computer tape, disk, or diskette; or
- (c) By directly inputting data into a database maintained in electronic form by the Director-General for the purposes of the Cancer Registry, such inputting being made by means of remote logon access to the database.

6. Act not to apply to certain cancers – It is hereby declared that the following types of cancer are cancers to which the Act does not apply:

- (a) Basal cell cancer arising in the skin:
- (b) Squamous cell cancer arising in the skin.

MARIE SHROFF,
Clerk of the Executive Council.

EXPLANATORY NOTE

This note is not part of the regulations, but is intended to indicate their general effect.

These regulations, which come into force on 1 July 1994, prescribe certain matters for the purposes of the Cancer Registry Act 1993. The regulations—

- (a) Prescribe the form and manner in which reports on cancer tests are to be made to the Director-General of Health under the Act, and
- (b) Prescribe the time within which such reports are to be made; and
- (c) Declare that certain types of cancer are cancers to which the Act does not apply.

Issued under the authority of the Acts and Regulations Publication Act 1989.
Date of notification in *Gazette*: 2 June 1994.
These regulations are administered in the Ministry of Health.